---
document_datetime: 2023-09-21 19:47:40
document_pages: 114
document_pathfilename: www.ema.europa.eu/en/documents/variation-report/tecentriq-h-c-004143-ii-0019-epar-assessment-report-variation_en.pdf
document_name: tecentriq-h-c-004143-ii-0019-epar-assessment-report-variation_en.pdf
version: success
processing_time: 255.1193685
conversion_datetime: 2025-12-25 04:46:30.366811
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
<!-- image -->

25 July 2019 EMA/CHMP/557479/2019 Committee for Medicinal Products for Human Use (CHMP)

## Assessment report

## Tecentriq

International non-proprietary name: atezolizumab

Procedure No. EMEA/H/C/004143/II/0019

## Note

Variation assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted.

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Table of contents

| 1. Background information on the procedure                                                                                 | ..............................................6                                                         |
|----------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------|
| 1.1. Type II variation ..................................................................................................6 |                                                                                                         |
| 1.2. Steps taken for the assessment of the product.........................................................6               |                                                                                                         |
| 2. Scientific discussion                                                                                                   | ................................................................................7                       |
| 2.1. Problem statement                                                                                                     | ...............................................................................................7        |
| 2.1.1. Disease or condition...........................................................................................7    |                                                                                                         |
| 2.1.2. Epidemiology                                                                                                        | ....................................................................................................7   |
| 2.1.3. Clinical presentation, diagnosis and stage/prognosis                                                                | ..............................................8                                                         |
| 2.1.4. Management.....................................................................................................8    |                                                                                                         |
| 2.2. Non-clinical aspects                                                                                                  | ..............................................................................................9         |
| 2.2.1. Ecotoxicity/environmental risk assessment ...........................................................9              |                                                                                                         |
| 2.2.2. Discussion and conclusion on non-clinical aspects..................................................9                |                                                                                                         |
| 2.3. Clinical aspects                                                                                                      | ....................................................................................................9   |
| 2.3.1. Introduction......................................................................................................9 |                                                                                                         |
| 2.3.2. Pharmacokinetics.............................................................................................10     |                                                                                                         |
| 2.3.3. PK/PD modelling..............................................................................................17     |                                                                                                         |
| 2.3.4. Pharmacodynamics..........................................................................................19        |                                                                                                         |
| 2.3.5. Discussion on clinical pharmacology...................................................................19            |                                                                                                         |
| 2.3.6. Conclusions on clinical pharmacology.................................................................20             |                                                                                                         |
| 2.4. Clinical efficacy                                                                                                     | ..................................................................................................21    |
| 2.4.1. Dose response study........................................................................................21       |                                                                                                         |
| 2.4.2. Main study......................................................................................................21  |                                                                                                         |
| 2.4.3. Discussion on clinical efficacy............................................................................67       |                                                                                                         |
| 2.4.4. Conclusions on the clinical efficacy.....................................................................69         |                                                                                                         |
| 2.5. Clinical safety                                                                                                       | ....................................................................................................70  |
| 2.5.1. Discussion on clinical safety                                                                                       | ..............................................................................98                        |
| 2.5.2. Conclusions on clinical safety ..........................................................................           | 100                                                                                                     |
| 2.5.3. PSUR cycle                                                                                                          | ................................................................................................... 100 |
| 2.6. Risk management plan......................................................................................            | 100                                                                                                     |
| 2.7. Update of the Product information ......................................................................              | 111                                                                                                     |
| 2.7.1. User consultation...........................................................................................        | 111                                                                                                     |
| 3. Benefit-Risk Balance............................................................................111                     |                                                                                                         |
| 3.1. Therapeutic Context .........................................................................................         | 111                                                                                                     |
| 3.1.1. Disease or condition.......................................................................................         | 111                                                                                                     |
| 3.1.2. Available therapies and unmet medical need.....................................................                     | 112                                                                                                     |
| 3.1.3. Main clinical studies                                                                                               | ....................................................................................... 112             |
| 3.2. Favourable effects ............................................................................................       | 112                                                                                                     |
| 3.3. Uncertainties and limitations about favourable effects...........................................                     | 112                                                                                                     |
| 3.4. Unfavourable effects.........................................................................................         | 112                                                                                                     |
| 3.5. Uncertainties and limitations about unfavourable effects                                                              | ....................................... 113                                                             |
| 3.6. Effects Table....................................................................................................     | 113                                                                                                     |
| 3.7. Benefit-risk assessment and discussion...............................................................                 | 113                                                                                                     |
| 3.7.1. Importance of favourable and unfavourable effects............................................                       | 113                                                                                                     |

<div style=\"page-break-after: always\"></div>

3.7.2. Balance of benefits and risks  ...........................................................................  114

3.7.3. Additional considerations on the benefit-risk balance ......................................... 114

3.8. Conclusions .....................................................................................................  114

4. Recommendations ...............................................................................  114

5. EPAR changes  ......................................................................................  114

<div style=\"page-break-after: always\"></div>

## List of abbreviations

| ADA            | anti-drug antibody, also called anti-therapeutic antibody                                                       |
|----------------|-----------------------------------------------------------------------------------------------------------------|
| ADR            | adverse drug reaction                                                                                           |
| AE             | adverse event                                                                                                   |
| AESI           | adverse event of special interest                                                                               |
| Atezo          | Atezolizumab                                                                                                    |
| CCOD           | clinical cut-off date                                                                                           |
| CD47           | Cluster of Differentiation 47                                                                                   |
| CE             | Carboplatin + Etoposide                                                                                         |
| CI             | confidence interval                                                                                             |
| CMC            | chemistry, manufacturing, and control                                                                           |
| Cmin           | minimum serum or plasma concentration                                                                           |
| CNS            | central nervous system                                                                                          |
| CR             | complete response                                                                                               |
| CSR            | Clinical Study Report                                                                                           |
| DOR            | Duration of response                                                                                            |
| ECOG PS        | Eastern Cooperative Oncology Group Performance status                                                           |
| eCRF           | electronic Case Report Form                                                                                     |
| EMA            | European Medicines Agency                                                                                       |
| EORTC QLQ-C30  | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30            |
| EORTC QLQ-LC13 | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Lung Cancer Module |
| ES-SCLC        | extensive-stage small cell lung cancer                                                                          |
| EU             | European Union                                                                                                  |
| FNA            | fine needle aspiration                                                                                          |
| HR             | hazard ratio                                                                                                    |
| HRQoL          | Health-Related Quality of Life                                                                                  |
| iDMC           | Independent Data Monitoring Committee                                                                           |
| IgG1           | immunoglobulin G1                                                                                               |
| IHC            | immunohistochemistry                                                                                            |
| IL-10          | Interleukin 10                                                                                                  |
| ITT            | intent-to-treat                                                                                                 |

<div style=\"page-break-after: always\"></div>

| IV     | intravenous                                   |
|--------|-----------------------------------------------|
| IxRS   | Interactive Voice/Web Response System         |
| KM     | Kaplan-Meier                                  |
| MAA    | Marketing Authorisation Application           |
| mAb    | monoclonal antibody                           |
| NSCLC  | non-small cell lung cancer                    |
| ORR    | objective response rate                       |
| OS     | overall survival                              |
| PBO    | placebo                                       |
| PCI    | prophylactic cranial irradiation              |
| PD     | progressive disease                           |
| PD-1   | programmed death-1                            |
| PD-L1  | programmed death-ligand 1                     |
| PFS    | progression-free survival                     |
| PK     | Pharmacokinetic                               |
| PopPK  | population pharmacokinetics                   |
| PR     | partial response                              |
| PRO    | patient-reported outcome                      |
| q3w    | every three weeks                             |
| RECIST | Response Evaluation Criteria for Solid Tumors |
| RMP    | Risk Management Plan                          |
| SAE    | serious adverse event                         |
| SAP    | Statistical Analysis Plan                     |
| SBP    | Summary of Biopharmaceutics                   |
| SCE    | Summary of Clinical Efficacy                  |
| SCP    | Summary of Clinical Pharmacology              |
| SCS    | Summary of Clinical Safety                    |
| SmPC   | Summary of Product Characteristics            |
| TGF-β  | transforming growth factor beta               |
| Ttd    | time to deterioration                         |
| UC     | urothelial carcinoma                          |

<div style=\"page-break-after: always\"></div>

## 1. Background information on the procedure

## 1.1. Type II variation

Pursuant to Article 16 of Commission Regulation (EC) No 1234/2008, Roche Registration GmbH submitted to the European Medicines Agency on 15 October 2018 an application for a variation.

The following variation was requested:

| Variation requested   | Variation requested                                                                                                            | Type    | Annexes affected   |
|-----------------------|--------------------------------------------------------------------------------------------------------------------------------|---------|--------------------|
| C.I.6.a               | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | Type II | I and IIIB         |

Extension of Indication to include Tecentriq, in combination with nab-paclitaxel and carboplatin, indicated for the first-line treatment of adult patients with metastatic non-squamous non-small cell lung cancer (NSCLC) who do not have EGFR mutant or ALK-positive NSCLC; as a consequence, sections 4.1, 4.2, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. RMP version 9.0 has been submitted.

The requested variation proposed amendments to the Summary of Product Characteristics and Package Leaflet and to the Risk Management Plan (RMP).

## Information on paediatric requirements

Pursuant to Article 8 of Regulation (EC) No 1901/2006, the application included an EMA Decision P/0220/2015 on the agreement of a paediatric investigation plan (PIP).

At the time of submission of the application, the PIP P/0220/2015 was not yet completed as some measures were deferred.

## Information relating to orphan market exclusivity

## Similarity

Pursuant to Article 8 of Regulation (EC) No. 141/2000 and Article 3 of Commission Regulation (EC) No 847/2000, the applicant did not submit a critical report addressing the possible similarity with authorised orphan medicinal products because there is no authorised orphan medicinal product for a condition related to the proposed indication.

## Scientific advice

The applicant did not seek Scientific Advice at the CHMP.

## 1.2. Steps taken for the assessment of the product

The Rapporteur and Co-Rapporteur appointed by the CHMP were:

Rapporteur:

Sinan B. Sarac

Co-Rapporteur:

Jan Mueller-Berghaus

<div style=\"page-break-after: always\"></div>

| Timetable                                            | Actual dates     |
|------------------------------------------------------|------------------|
| Submission date                                      | 15 October 2018  |
| Start of procedure:                                  | 3 November 2018  |
| CHMP Co-Rapporteur Assessment Report                 | 20 December 2018 |
| CHMP Rapporteur Assessment Report                    | 17 December 2018 |
| PRAC Rapporteur Assessment Report                    | 4 January 2019   |
| PRAC members comments                                | 9 January 2019   |
| Updated PRAC Rapporteur Assessment Report            | 10 January 2019  |
| PRAC Outcome                                         | 17 January 2019  |
| CHMP members comments                                | 21 January 2019  |
| Updated CHMP Rapporteur(s) (Joint) Assessment Report | 24 January 2019  |
| Request for supplementary information (RSI)          | 31 January 2019  |
| CHMP Rapporteur Assessment Report                    | 6 May 2019       |
| CHMP members comments                                | 20 May 2019      |
| Updated CHMP Rapporteur Assessment Report            | 23 May 2019      |
| Request for supplementary information (RSI)          | 29 May 2019      |
| Restart of procedure                                 | 26 June 2019     |
| CHMP Rapporteur Assessment Report                    | 9 July 2019      |
| CHMP members comments                                | 15 July 2019     |
| Updated CHMP Rapporteur Assessment Report            | 18 July 2019     |
| Opinion                                              | 25 July 2019     |

## 2. Scientific discussion

## 2.1. Problem statement

## 2.1.1. Disease or condition

The claimed indication is for Tecentriq in combination with nab paclitaxel and carboplatin, for the first line treatment of adult patients with metastatic non-squamous non-small cell lung cancer (NSCLC) who do not have EGFR mutant or ALK positive NSCLC.

## 2.1.2. Epidemiology

Lung cancer remains the leading cause of cancer death worldwide, estimated to be responsible for nearly one in five cancer deaths globally (1.76 million deaths, 18.4% of the total; Globocan 2018). There were estimated to be 2.1 million new cases in 2018 (11.6% of the total), 58% of which occurred in less developed regions. This disease is the most common cancer in men worldwide (1.4 million, 15% of the total cancers in men) and accounts for the highest absolute number of cancer deaths globally (1.2 million deaths, 24% of cancer deaths in men). Non-small cell lung cancer (NSCLC) is the predominant subtype, accounting for approximately 85% of all cases. NSCLC can be divided into two major histologic types: non-squamous and squamous cell carcinoma. Non-squamous histology accounts for more than half of all

<div style=\"page-break-after: always\"></div>

NSCLC, whereas squamous histology accounts for approximately 30% (Brambilla et al, 2014 and Schrump DS et al. NSCLC; Principles and Practice of Oncology. 9th Edition. 2011).

## 2.1.3. Clinical presentation, diagnosis and stage/prognosis

More than half of the patients are diagnosed at an advanced stage of disease, which directly contributes to poor survival, as expressed by an untreated median OS of 4 months and a metastatic 5-year survival rate of &lt;5% (Lindsey A. et al, 2016). Poor prognostic factors for survival in patients with NSCLC include advanced stage of disease at the time of initial diagnosis, poor performance status (PS), and a history of unintentional weight loss. More than half of the patients with NSCLC are diagnosed with distant metastatic disease, which directly contributes to poor survival prospects.

## 2.1.4. Management

For patients who have metastatic NSCLC without an oncogenic driver mutation (such as EGFR mutations or ALK translocation), the standard of care is platinum-based chemotherapy, partnered with agents such as taxanes (paclitaxel, docetaxel), vinorelbine, gemcitabine, and pemetrexed, with or without bevacizumab.

Over the past 4 years, immune checkpoint inhibitors, such as PD-1/PD-L1 blocking antibodies, have emerged as effective alternatives to chemotherapy for many tumour types. In 2L+ NSCLC, PD-1 inhibitors (nivolumab, pembrolizumab) and PD-L1 inhibitors (atezolizumab) demonstrated superiority over docetaxel as monotherapy. Subsequently, it was also shown that pembrolizumab monotherapy is effective in the first line setting for patients who express high levels of PD-L1. Pembrolizumab is currently approved for 1L treatment of NSCLC patients whose tumours express high levels of PD-L1 (≥ 50% tumour proportion score). Atezolizumab has also been authorised for the treatment of 1L metastatic non-squamous NSCLC when used in combination with bevacizumab, paclitaxel and carboplatin. In the authorised indications, patients with EGFR or ALK positive tumour mutations should also have received targeted therapy before treatment with PD-1/PD-L1 inhibitors in combination with chemotherapy.

## About the product

Atezolizumab  is  an  Fc-engineered  humanized  immunoglobulin  (IgG1)  monoclonal  antibody  (MAb) targeting  the  programmed  death-ligand  1  (PD-L1).  Binding  of  atezolizumab  to  PD-L1  inhibits  the interaction of the PD-1 and B7.1 receptors. Both of these interactions are reported to provide inhibitory signals to T cells.

Tecentriq is currently authorised in the following indications:

- as monotherapy for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (UC):

- after prior platinum-containing chemotherapy, or
- who are considered cisplatin ineligible, and whose tumours have a PD-L1 expression ≥ 5%.

- in combination with bevacizumab, paclitaxel and carboplatin, for the first-line treatment of adult patients with metastatic non-squamous non-small cell lung cancer (NSCLC). In patients with EGFR mutant or ALK-positive NSCLC, Tecentriq, in combination with bevacizumab, paclitaxel and carboplatin, is indicated only after failure of appropriate targeted therapies.

- as monotherapy for the treatment of adult patients with locally advanced or metastatic NSCLC after prior chemotherapy. Patients with EGFR mutant or ALK-positive NSCLC should also have received targeted therapies before receiving Tecentriq.

<div style=\"page-break-after: always\"></div>

The current application is supported by the results from the primary analysis of IMpower130 (Study GO29537; n = 723), a Phase III trial designed to evaluate the safety and efficacy of atezolizumab-carboplatin-nab-paclitaxel (Atezo-CnP) versus treatment with carboplatin-nab-paclitaxel (CnP) in chemotherapy-naïve patients with Stage IV non-squamous NSCLC.

The following new indication is recommended:

Tecentriq, in combination with nab paclitaxel and carboplatin, is indicated for the first line treatment of adult patients with metastatic non-squamous NSCLC who do not have EGFR mutant or ALK positive NSCLC.

During  the  induction  phase,  the  recommended  dose  of  Tecentriq  is  1,200 mg  administered  by intravenous infusion, followed by nab-paclitaxel and carboplatin every three weeks for four or six cycles. For each 21-day cycle, Tecentriq, nab-paclitaxel, and carboplatin are administered on day 1. In addition, nab-paclitaxel is administered on days 8 and 15.

The  induction  phase  is  followed  by  a  maintenance  phase  without  chemotherapy  in  which  1,200 mg Tecentriq is administered by intravenous infusion every three weeks.

For first line NSCLC, in patients given Tecentriq in combination with carboplatin and nab-paclitaxel, it is recommended  that  patients  are  treated  with  Tecentriq  until  disease  progression  or  unmanageable toxicity. Treatment beyond disease progression may be considered at the discretion of the physician (see section 5.1).

## 2.2. Non-clinical aspects

No new non-clinical data have been submitted in this application, which was considered acceptable by the CHMP.

## 2.2.1. Ecotoxicity/environmental risk assessment

Atezolizumab is an IgG1 monoclonal antibody produced by recombinant DNA technology, a protein with a molecular mass of ~150 kDa. As an unaltered protein, being extensively degraded in the patient's body by regular proteolytic mechanisms before excretion, atezolizumab is unlikely to result in a significant environmental exposure. Atezolizumab is expected to biodegrade in the environment and does not pose a  significant  risk  to  the  environment.  Thus,  according  to  the  'Guideline  on  the  Environmental  Risk Assessment of Medicinal Products for Human Use' (EMEA/CHMP/SWP/4447/00), atezolizumab is exempt from the submission of Environmental Risk Assessment studies as the product and excipients do not pose a significant risk to the environment.

## 2.2.2. Discussion and conclusion on non-clinical aspects

No new nonclinical data has been provided to support this application. The applicant did not submit studies for the ERA. According to the relevant guideline, in the case of products containing proteins as active pharmaceutical ingredient(s), this is acceptable.

## 2.3. Clinical aspects

## 2.3.1. Introduction

## GCP

The Clinical trials were performed in accordance with GCP as claimed by the applicant&gt;

<div style=\"page-break-after: always\"></div>

The applicant has provided a statement to the effect that clinical trials conducted outside the community were carried out in accordance with the ethical standards of Directive 2001/20/EC.

- Tabular overview of clinical studies

Table 1: Summary of studies contributing to efficacy evaluation

| Study No.                    | Study Design                                         | Population                                                                                                                                                                                                                                                 | No. of Patients Enrolled                                   | Dose, Route, and Regimen                                                                  | Primary Efficacy Endpoint                          | Analysis Timing (DataCutoff Date)                                                          |
|------------------------------|------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------|-------------------------------------------------------------------------------------------|----------------------------------------------------|--------------------------------------------------------------------------------------------|
| Pivotal Study                |                                                      |                                                                                                                                                                                                                                                            |                                                            |                                                                                           |                                                    |                                                                                            |
| GO29537 (IMpower130) global, | Phase Ill, open-label, multicenter, randomized study | Patients with 1L chemotherapy-naive non-squamous NSCLC Patientswerestratifiedby sex (male vs. female), presenceof liver metastases atbaseline (yes vs.no), and PD-L1 tumor expression by IHC (TC3 and any IC vs. TC0/1/2 and IC2/3 vs. TCO/1/2 and IC0/1). | Total: n=723 a Arm A (Atezo+CnP): n=483 Arm B (CnP): n=240 | Atezolizumab1200mgIVq3w Carboplatin AUC of 6 mg/mL/min IV q3w Nab-paclitaxel 100mg/m2IVqw | OS and yinvestigator- assessed PFS per RECIST v1.1 | Primary analysis After357OS events in the ITT-WT population across both arms (15 Mar 2018) |

1L=first-line; Atezo=atezolizumab; AUC=area underthe concentration-time curve; CnP=carboplatin+nab-paclitaxel; IC=tumor-infiltrating immune cell;IHC=immunohistochemistry;ITT=intent-to-treat;IV=intravenous;NSCLC=non-smallcell lung cancer;OS=overallsurvival; PD-L1=programmed death-ligand 1; PFS=progression-free survival; q3w=every 3 weeks; qw=once a week; RECIST=Response Evaluation Criteria inSolid Tumors; TC=tumor cell; WT=wild type.

Reflects the ITT population included in this summary. A total of 724 patients were randomized; however, 1 patient was excluded from the ITTpopulationbecausethedeathdatewaspriortotherandomizationdate.

Source: IMpower130 Primary CSR(Figure 3 and Table 17).

## 2.3.2. Pharmacokinetics

The application includes key results of the atezolizumab clinical pharmacology program and new data from Study IMpower130 (Study GO29537).  The clinical pharmacology properties of atezolizumab has been characterized in previous studies when atezolizumab was administered as monotherapy in patients predominantly with mUC and NSCLC (see Tecentriq EPAR). The new data investigates Atezolizumab when administered in combination with carboplatin and nab-paclitaxel in stage IV non-squamous NSCLC.

## Phase III Study GO29537; IMpower130

Pharmacokinetics of atezolizumab, carboplatin and nab-paclitaxel and immunogenicity were investigated in IMpower130, a randomized, Phase III, multicenter, open-label study designed to evaluate the safety and efficacy of atezolizumab in combination with carboplatin + nab-paclitaxel (atezo+CnP) compared with carboplatin + nab-paclitaxel in chemotherapy naive patients with Stage IV non squamous NSCLC.

Patients were randomized (2:1) to one of the following treatment regimens:

- Arm A:  atezolizumab+carboplatin+nab paclitaxel (atezo+CnP) for four or six 21 day cycles during induction; followed by atezolizumab maintenance
- Arm B:  carboplatin+nab paclitaxel (CnP) for four or six 21 day cycles during induction; followed by best supportive care or pemetrexed maintenance

Atezolizumab was administered at 1200 mg IV every three weeks (q3w), carboplatin at AUC 6 mg/mL/min IV q3w on Day 1 and nab-paclitaxel (100 mg/m2) IV was administered on Days 1, 8 and 15.

The PK objectives included in study IMpower130 were:

- To evaluate the maximum observed serum concentration (Cmax) of atezolizumab after infusion on Cycle 1 Day 1 (C1D1) and minimum observed serum concentration

<div style=\"page-break-after: always\"></div>

- (Cmin) of atezolizumab prior to infusion at selected cycles, at treatment discontinuation, and at 120 days (±30 days) after the last dose of atezolizumab for patients randomized to Atezo+CnP
- To evaluate the plasma concentrations of carboplatin (Atezo+CnP and CnP arms)
- To evaluate the plasma concentrations of nab-paclitaxel reported as total paclitaxel (Atezo+CnP and CnP arms)

The immunogenicity objective was:

- To evaluate the incidence and titers of anti-drug antibody (ADAs) response to atezolizumab and potential correlation with pharmacokinetic (PK), pharmacodynamic, safety, and efficacy parameters

## Pharmacokinetic Analysis Population

The PK-evaluable population was defined as all patients who received any dose of atezolizumab, carboplatin, or nab-paclitaxel and who had evaluable PK samples.

## Pharmacokinetic Analysis

A total of 465 patients had evaluable atezolizumab PK data. Atezolizumab PK + immunogenicity samples were collected according to table below:

<div style=\"page-break-after: always\"></div>

Table 2: Schedule of PK, biomarker, and anti-therapeutic antibody assessments

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

Atezolizumab serum concentration data (Cmin and Cmax) were tabulated and summarized.

A validated ELISA with a lower limit of quantification (LLOQ) of 0.06 µg/mL was used to quantify atezolizumab in human serum. A validated inductively coupled plasma mass spectrometry with a LLOQ of 100 ng/mL and a validated liquid chromatography tandem mass spectrometry with a LLOQ of 2 ng/mL were used to determine carboplatin and paclitaxel concentrations, respectively, in the plasma. The concentrations of atezolizumab, carboplatin and paclitaxel were summarized using descriptive statistics including means, medians, ranges, and SD.

## Immunogenicity Analysis

Baseline prevalence and post-baseline incidence of ADA against atezolizumab were summarized. Analyses of pharmacokinetics, efficacy, and safety by atezolizumab ADA status were conducted to explore the potential impact of immunogenicity, as appropriate.

## PK results from IMpower130

## Atezolizumab pharmacokinetics:

Descriptive statistics of serum concentrations of atezolizumab, Cmax (30 minutes following the end of the atezolizumab infusion) and Cmin (pre-dose) following the administration of Atezolizumab 1200 mg every 3 weeks (q3w) IV in combination with carboplatin and nab-Paclitaxel are summarized in Table 3.

<div style=\"page-break-after: always\"></div>

Table 3: Summary Statistics for Atezolizumab Cmax and Cmin Following Multiple IV Doses of Atezolizumab 1200 mg, Administered Every 3 Weeks in Combination with Carboplatin and nab-Paclitaxel

| Treatment   | Visit 1   |   Nominal Time from First Dose (day) |   N | AM (μg/mL)   | AM SD (μg/mL)   | GM (μg/mL)   | GM %CV   | Min (μg/mL)   |   Median (μg/mL) |   Max (μg/mL) |
|-------------|-----------|--------------------------------------|-----|--------------|-----------------|--------------|----------|---------------|------------------|---------------|
| Atezo + CnP | C1D1      |                               0      | 446 | NR           | NR              | NE           | NR       | NR            |                0 |             0 |
| Atezo + CnP | C1D1      |                               0.0625 | 437 | 392          | 114             | 344          | 136      | 0.03          |              377 |           943 |
| Atezo + CnP | C1D21     |                              21      | 416 | 70.9         | 35.1            | 61.7         | 84.5     | 0.03          |               67 |           380 |
| Atezo + CnP | C2D21     |                              42      | 384 | 111          | 52.2            | 97.1         | 76.5     | 0.03          |              106 |           610 |
| Atezo + CnP | C3D1      |                              42.04   | 356 | 454          | 170             | 422          | 50.4     | 1.41          |              441 |          2340 |
| Atezo + CnP | C3D21     |                              63      | 352 | 134          | 57.8            | 122          | 47.5     | 23.7          |              129 |           460 |
| Atezo + CnP | C7D21     |                             147      | 257 | 218          | 93.7            | 199          | 45.3     | 24.3          |              204 |           596 |

AM = Arithmetic Mean; Atezo + CnP = atezolizumab in combination with carboplatin and nab-paclitaxel; Cmax = maximum serum concentration; Cmin = minimum serum concentration; CV = coefficient of variation; GM = Geometric Mean; Max = maximum; Min = minimum; SD = standard deviation; NE = Not Evaluable; NR = Not Reportable.

1 Visit is denoted by Cycle abbreviated by 'C' and Day abbreviated by 'D'.  For example, C1D1 corresponds to Cycle 1, Day 1.  Predose Cycle 1 is C1D1, 0 days. Cmax is C1D1 30 minutes post end of infusion. Predose Cycle 2 is C1D21, predose Cycle 3 is C2D21, Cmax is C3D1 30 minutes post end of infusion etc.

Data source: CSR IMpower130, Table 30

A total of 465 patients (out of 483 total enrolled patients) had evaluable atezolizumab PK.  Mean ± standard deviation (SD) serum atezolizumab concentrations over time are shown in Figure 1. The steady state based on atezolizumab Cmin was reached by approximately Cycle 4-8.  The geometric mean Cmin of atezolizumab was 61.7 µg/mL at the end of Cycle1 and 199 µg/mL at the end of Cycle 7, respectively.

Atezo + Carb + nPac = atezolizumab in combination with carboplatin and nab-Paclitaxel. Data source: CSR IMpower130, Figure 17 Figure 1: Mean ( ± SD) Plot of Atezolizumab Serum Concentrations versus Time Following Multiple IV Doses of Atezolizumab 1200 mg, Administered Every 3 Weeks in Combination with Carboplatin and nab-Paclitaxel

<!-- image -->

Carboplatin Pharmacokinetics

<div style=\"page-break-after: always\"></div>

A total of 49 patients had evaluable carboplatin PK (29 from the Atezo + CnP arm and 20 from the CnP arm).  The mean plasma carboplatin concentrations over time are presented in Figure 2.

<!-- image -->

Data source: CSR IMpower130, Figure 18

Figure 2: Mean (±SD) Plot of Carboplatin Concentrations versus Time Following Multiple IV Doses of Carboplatin AUC6 mg/mL/min, Administered Every 3 Weeks in Combination With nab-Paclitaxel, With or Without Atezolizumab (PK-Evaluable Population)

## Nab-Paclitaxel Pharmacokinetics

A total of 50 patients had evaluable paclitaxel PK (30 from the Atezo+CnP arm and 20 from the CnP arm). The mean plasma paclitaxel concentrations over time are presented in Figure 3.

<!-- image -->

Data source: CSR IMpower130, Figure 19

Figure 3: Mean (±SD) Plot of Paclitaxel Concentrations versus Time Following Multiple IV Doses of nab-Paclitaxel 100 mg/m 2 ,    Administered on Day 1, 8, and 15 of a 3 Week Cycle, in Combination With Carboplatin, With or Without Atezolizumab (PK Evaluable Population)

## Pharmacokinetics by Treatment-Emergent ADA Status

The baseline prevalence of atezolizumab ADA was 3.1% in the Atezo+CnP arm and 4.8% in the CnP arm (cross-over patients). The incidence of post-baseline treatment-emergent ADA was 22.4% for the

<div style=\"page-break-after: always\"></div>

Atezo+CnP arm and 23.5% for the CnP arm (crossover patients). These atezolizumab ADA-positive rates were within the ADA-positive rate ranges (16.7%-54.5%) observed in atezolizumab monotherapy studies.

Atezolizumab concentrations up to Cycle 7 by treatment emergent ADA status for Atezo + CnP arm are summarized in Figure 4 and shown in Table 4.  The geometric mean Cmin for Cycle 7 Day 21 was 194 μg/mL (48.2% CV) and 201 μg/mL (44.6% CV) for ADA-positive (n = 54) and ADA-negative (n = 203) patients, respectively.

Table 4: Summary Statistics for Atezolizumab Cmax and Cmin Following Multiple IV Doses of Atezolizumab 1200 mg Given Every 3 Weeks in Combination with Carboplatin and nab-Paclitaxel by Atezolizumab Anti-Drug Antibody Status (PK-Evaluable Population)

| ADA Status   | Visit 1   |   Nominal Time From First Dose (day) |   N |   AM (μg/mL) |   AM SD (μg/mL) | GM (μg/mL)   | GM %CV   |   Min (μg/mL) |   Median (μg/mL) |   Max (μg/mL) |
|--------------|-----------|--------------------------------------|-----|--------------|-----------------|--------------|----------|---------------|------------------|---------------|
| Negative     | C1D1      |                               0      | 330 |          0   |             0   | NE           | NE       |          0    |              0   |             0 |
| Negative     | C1D1      |                               0.0625 | 326 |        391   |           121   | 330          | 172      |          0.03 |            378   |           943 |
| Negative     | C1D21     |                              21      | 322 |         74   |            36.4 | 67.2         | 48.4     |          3.43 |             69.6 |           380 |
| Negative     | C2D21     |                              42      | 297 |        116   |            53.1 | 105          | 48.9     |          5.72 |            110   |           610 |
| Negative     | C3D1      |                              42.04   | 276 |        460   |           174   | 432          | 38.8     |         61.8  |            448   |          2340 |
| Negative     | C3D21     |                              63      | 273 |        141   |            58.3 | 130          | 43.5     |         34.6  |            133   |           460 |
| Negative     | C7D21     |                             147      | 203 |        218   |            91.5 | 201          | 44.6     |         24.3  |            206   |           596 |
| Positive     | C1D1      |                               0      |  97 |          0   |             0   | NE           | NE       |          0    |              0   |             0 |
| Positive     | C1D1      |                               0.0625 |  92 |        395   |            96.8 | 384          | 24.5     |        218    |            375   |           641 |
| Positive     | C1D21     |                              21      |  94 |         60.2 |            27.9 | 45.9         | 195      |          0.03 |             57.9 |           124 |
| Positive     | C2D21     |                              42      |  87 |         93.4 |            45   | 73.5         | 153      |          0.03 |             93.5 |           212 |
| Positive     | C3D1      |                              42.04   |  80 |        435   |           153   | 389          | 82.7     |          1.41 |            432   |           997 |
| Positive     | C3D21     |                              63      |  79 |        112   |            50.4 | 99.9         | 53.9     |         23.7  |            105   |           268 |
| Positive     | C7D21     |                             147      |  54 |        215   |           102   | 194          | 48.2     |         73.5  |            195   |           508 |

ADA = anti-drug antibodies, AM = arithmetic mean, SD = standard deviation, CV = coefficient of variation, GM = geometric mean, NE = not evaluable, BLQ = below the limit of quantification

1 Visit is denoted by Cycle abbreviated by 'C' and Day abbreviated by 'D'.  For example, C1D1 corresponds to Cycle 1, Day 1.  Predose Cycle 1 is C1D1, 0 days. Cmax is C1D1 30 minutes post end of infusion. Predose Cycle 2 is C1D21, predose Cycle 3 is C2D21, Cmax is C3D1 30 minutes post end of infusion etc.

Figure 4: Mean (±SD) Plot of Atezolizumab Concentrations versus Time Following Multiple IV Doses of Atezolizumab 1200mg Given Every 3 Weeks in Combination with Carboplatin and nab-Paclitaxel by ADA Status (PK-Evaluable Population)

<!-- image -->

<div style=\"page-break-after: always\"></div>

## 2.3.3. PK/PD modelling

## Base Population Pharmacokinetic Model

The popPK of atezolizumab was first assessed based on Phase I data from two clinical studies (the 'Phase I popPK Model'):  Study PCD4989g and Study JO28944 (see Tecentriq EPAR).

For the Phase I popPK Model, serum PK of atezolizumab across the two studies PCD4989g and JO28944 (dose range: 1-20 mg/kg q3w, including the fixed 1200 mg dose of atezolizumab q3w) was described by a linear two compartment disposition model with first-order elimination.  The estimated typical population CL was 0.200 L/day and typical V1 was 3.28 L for a male patient, 77 kg with 40 g/L of albumin, tumor burden of 63 mm and no ADA. The typical Vss was 6.9 L and terminal t1/2 was 27 days.

## Final Population Pharmacokinetic Model

In the final popPK model, body weight, albumin, tumor burden, and ADA were statistically significant covariates for CL; body weight, and albumin were statistically significant covariates for V1, and body weight, albumin and gender were statistically significant covariates for V1, and gender was statistically significant for V2.  The results from the popPK analysis suggest the unexplained IIV is moderate for CL (i.e., 29%), V1 (i.e., 18%), and V2 (i.e., 34%).

In treatment-emergent ADA positive patients, CL is estimated to be 16% higher than in ADA negative patients.  In females, volume of distribution would be 13% and 27% lower than in males for V1 and V2, respectively.  No covariate induced more than 27% change from the typical PK model parameter for extreme values.

The Phase I popPK Model was subjected to an external validation by prediction-corrected visual predictive check (pcVPC) for UC, NSCLC, and ES-SCLC separately, using PK data collected in IMvigor210 and IMvigor211 for UC, data collected in BIRCH, POPLAR, FIR, OAK, IMpower150 and IMpower130 for NSCLC and data collected in IMpower133 for ES-SCLC.  The results of pcVPC by study indicated that Phase I popPK Model was adequate to describe atezolizumab PK data in studies mentioned above and suggested a consistent atezolizumab PK in patients with NSCLC, SCLC and UC.

## External Validation- IMpower130

The Phase I popPK Model was used to derive the individual PK estimates based on atezolizumab observed concentration-time profiles in IMpower130.

The prediction-corrected visual predictive check suggested that the median, 95th, and 5th percentiles of observed Cmax and Cmin were generally well within the prediction intervals of the Phase I popPK Model. Covariate effects (i.e., BWT, gender, ADA status, baseline albumin levels and tumor burden) in the IMpower130 data were generally consistent with those identified in the popPK Model.  Both cycle 1 and steady-state exposure metrics were similar to those estimated in other NSCLC studies (RDR 1067735 and 1074540) for atezolizumab in monotherapy or in combination with carboplatin + paclitaxel ± bevacizumab (IMpower150), which suggested that the atezolizumab PK was not impacted by the co-administration chemotherapy (carboplatin + nab-paclitaxel).

<div style=\"page-break-after: always\"></div>

There appeared to be a trend toward under-prediction of atezolizumab exposure data (troughs) after long-term administration (7th, 15th, 23rd+ dose), with observations above the prediction intervals by the Phase I popPK Model.  This observation is consistent with the results of a post-hoc analysis reported in the USPI, where atezolizumab clearance was found to decrease over time, with a mean maximal reduction % (coefficient of variation [CV%]) from the baseline CL value of approximately 17.1% (40.6%).

The geometric mean accumulation ratio based on AUC was 1.81-fold.  Cmin and Cmax accumulated 2.04and 1.41-fold (geometric means), respectively.

Table 5: Summary Statistics (Geometric Mean [Geometric Mean CV%]) of Atezolizumab Exposure Metrics at Cycle 1 and Steady-State in Study IMpower130 Predicted using popPK Model

| IMpower130 (N = 465)   | IMpower130 (N = 465)   | IMpower130 (N = 465)   | IMpower130 (N = 465)   |
|------------------------|------------------------|------------------------|------------------------|
| Cmax (µg/mL)           | Cmin (µg/mL)           | AUC (µg.day/mL)        | t 1/2 beta (day)       |
| 382 [19.2]             | 72.6 [30.6]            | 2862 [19.9]            | 20.2 [5.1]             |
| Cmax ,ss (µg/mL)       | Cmin ,ss (µg/mL)       | AUC ,ss (µg.day/mL)    | Accumulation ratio     |
| 537 [22.8]             | 148 [45.9]             | 5171 [31.5]            | 1.81 [15.0]            |

N = Number of patients; Cmax,ss = Cmax at steady-state; Cmin,ss = Cmin at steady-state; AUC,ss = AUC at steady-state; Accumulation ratio is derived as the ratio between AUC at cycle 1 and AUC,ss; CV% = coefficient of variation. Source: IMpower130 PopPK report Tables 6 and 7.

<!-- image -->

CI = confidence interval; popPK = population pharmacokinetics; VPC = visual predictive check. Source:  IMpower130 PopPK report 1089066, Figure 2

Figure 5: Pred-Corrected Visual Predictive Check Atezolizumab Concentration

Exploratory analyses of the relationships between individual CL, V1 and V2 patient-level random effects and covariates (continuous, categorical, and including body weight, albumin, tumor burden, gender, and ADA) indicated that covariate effects in IMpower130 data were generally consistent with those identified in the Phase 1 popPK Model. In addition, these exploratory analyses did not reveal any unexpected covariate effect not identified in the Phase 1 popPK Model. Finally, random effects of parameters were not influenced by PD-L1 expression (IC/TC status).

<div style=\"page-break-after: always\"></div>

ADA = Anti-drug antibodies; Eta.CL = random effect on clearance; Eta.V1 = random effect on central volume of distribution; Eta.V2 = random effect on peripheral vblume of distribution; N = number of patients

<!-- image -->

Figure 6: Exploratory analyses of the relationship between random effects and ADA on IMpower130 data

Negative eta CL in positive ADA patients compared to negative ADA (p&lt;0.001) indicates less effect in IMpower130 compared to Phase 1 popPK Model (Figure 6).

## 2.3.4. Pharmacodynamics

## Exposure - response (ER) analyses

No new ER analyses have been submitted with this application.

## Immunogenicity in IMpower130

Demographic and baseline characteristics were generally balanced between post baseline treatment emergent atezolizumab ADA-positive and ADA negative patients in the Atezo+CnP arm of ADA-evaluable WT  population. Some imbalance for Atezo + CnP patients was seen in baseline SLD (sum of longest diameters) between ADA positive and ADA negative patients, with medians of 87 mm and 71 mm respectively.

Further information on the impact of ADA on efficacy and safety is further described in the clinical efficacy and safety sections respectively.

## Dose rationale

## 2.3.5. Discussion on clinical pharmacology

The clinical pharmacology of atezolizumab has been characterized in previously submitted studies with atezolizumab administered as monotherapy. The PK of atezolizumab is linear over a dose range of 1 to 20 mg/kg of atezolizumab, including the fixed 1200 mg dose of atezolizumab used in the IMPower130 study in patients with metastatic NSCLC in combination with carboplatin and nab-paclitaxel.

The pharmacokinetics of atezolizumab, carboplatin and nab-paclitaxel were investigated in IMPower130 and an external validation of the Phase 1 Pop PK model was conducted with the PK data from IMpower130. The PK of atezolizumab in combination with carboplatin and nab-paclitaxel was similar the PK of atezolizumab when given as monotherapy and there was no evidence of drug-drug interactions. Covariates were investigated in the Pop PK model and found to be comparable to previous findings. Significant covariates were body weight, gender, ADA status, albumin level and tumour burden.

<div style=\"page-break-after: always\"></div>

The recommended dose of atezolizumab is 1200 mg q3w via intravenous infusion.  IMpower130 evaluated atezolizumab at this dose level and schedule in combination with carboplatin and nab paclitaxel in chemotherapy-naïve patients with Stage IV non-squamous NSCLC.

The original rationale for the recommended dose was based on data from nonclinical studies and clinical data from Phase I Study GO27831 (PCD4989g). Atezolizumab 1200 mg q3w as a single agent showed clinical efficacy in NSCLC and mUC and patients receiving atezolizumab 1200 mg q3w had a safety profile that was well tolerated. In IMpower130, the PK of atezolizumab 1200 mg q3w in combination with carboplatin and nab paclitaxel were similar to atezolizumab 1200 mg q3w as monotherapy.  There is no evidence of a PK drug-drug interaction with the co administration of atezolizumab with carboplatin and/or nab paclitaxel.  Treatment-emergent ADA did not appear to have a clinically relevant impact on pharmacokinetics, efficacy, or safety.

Collectively, atezolizumab 1200 mg q3w administered with carboplatin and nab paclitaxel provided a favorable benefit-risk profile which supports the recommended dosing regimen of atezolizumab in combination with carboplatin and nab-paclitaxel for treatment of chemotherapy-naïve patients with Stage IV non-squamous NSCLC.

The proportion of patients who developed treatment-emergent ADAs for atezolizumab in IMpower130 were 22.4%, which is comparable to historical data for atezolizumab (ranges from 16.7% to 54.5%). Even though the MAH has submitted data to support a valid and sensitive NAb assay, no data regarding NAbs have been included. Treatment emergent ADAs did not appear to have a clinically meaningful impact on PK, efficacy, and safety, however, the number of ADA positive subjects is limited and the MAH is recommended to propose how an assessment of the effect of atezolizumab ADAs and NAbs on PK parameters and efficacy endpoints including OS, PFS and ORR in NSCLC studies could be conducted. These will be investigated as part of a post-authorisation commitment.

ADAs have previously in the Pop PK model been found to increase atezolizumab clearance with 16 %, but no impact of ADAs on clearance was identified in IMPower130. However, the numerical differences in clearance estimated between the IMpower130 study and the PCD4989g+JO28944 studies are small.  In the IMpower130, clearance is higher in ADA+ positive as also previously identified in other atezolizumab studies. The difference in clearance between ADA+ and ADA- is slightly smaller compared to the difference identified in the final Pop PK model (11.2 % vs 15.9% respectively). The Applicant has not identified any apparent cause of this small difference. This is acceptable as clinical consequences are unlikely. The impact of ADA on PK - presumably predominately clearance - will be investigated further as part of a post-approval commitment.

Exposure-efficacy (ORR, OS) and exposure-safety (adverse events of special interest [AESI], adverse events of Grade 3 to 5 [AEG35]) analyses were performed using Phase I, II, and III trials in mixed solid tumour, NSCLC, and mUC patients when atezolizumab was administered as monotherapy. No clinically meaningful ER relationships were identified when patient prognostic factors were considered in the analysis.  Since combination administration poses additional confounding factors, the Sponsor obtained agreement (meeting minutes with EMA) with regulatory agencies that no further ER analysis are required for atezolizumab administered in combination settings.

## 2.3.6. Conclusions on clinical pharmacology

The clinical pharmacology of atezolizumab has previously been characterized and the PK investigations in IMPower130 overall confirm previous findings. The PK of atezolizumab is similar when administered in combination with carboplatin and nab-paclitaxel without evidence of drug-drug interactions. No unexpected covariates have been identified and the proposed dose of 1200 mg q3w seems to be appropriate and is endorsed.

<div style=\"page-break-after: always\"></div>

The number of patients with ADAs is about 22 %, which is consistent with previous findings and ADAs do not appear to impact PK. However, data regarding neutralising antibodies (NAbs) are lacking, the MAH is recommended to further investigate it post authorisation.

## 2.4. Clinical efficacy

## 2.4.1. Dose response study

No dose response study was submitted. Please refer to the clinical pharmacology assessment.

## 2.4.2. Main study

IMpower 130 (GO29537): Randomised phase III trial in chemotherapy-naïve patients with metastatic non-squamous NSCLC, in combination with nab paclitaxel and carboplatin

Table 6: Study design features of IMpower130

| Study Design Feature                 | Arm A: Atezo+CnP                                                                                                                                                                                                 | Arm B: CnP                                                                                                                                                                                                       |
|--------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Line of therapy                      | First-line                                                                                                                                                                                                       | First-line                                                                                                                                                                                                       |
| Sample size                          | 2:1 based on 715 total patients planned                                                                                                                                                                          | 2:1 based on 715 total patients planned                                                                                                                                                                          |
| PD-L1 status                         | All-comers population stratified by PD-L1 expression by IHC (TC3 and any IC vs. TC0/1/2 and IC2/3 vs. TC0/1/2 and IC0/1)                                                                                         | All-comers population stratified by PD-L1 expression by IHC (TC3 and any IC vs. TC0/1/2 and IC2/3 vs. TC0/1/2 and IC0/1)                                                                                         |
| Dose/regimen (as applicable per arm) | Atezolizumab 1200 mg IV q3w Carboplatin AUC of 6 mg/mL/min IV q3wa Nab-paclitaxel 100 mg/m2 IV on Days 1, 8, and 15 of each 21-day cycle                                                                         | Atezolizumab 1200 mg IV q3w Carboplatin AUC of 6 mg/mL/min IV q3wa Nab-paclitaxel 100 mg/m2 IV on Days 1, 8, and 15 of each 21-day cycle                                                                         |
| Treatment duration                   | Induction Atezo+CnP for four or six cycles b or until loss of clinical benefit Maintenance Atezolizumab until loss of clinical benefit                                                                           | Induction CnP for four or six cycles b or until PD per RECIST v1.1 Maintenance BSCorpemetrexed until PDper RECIST v1.1                                                                                           |
| Response assessment                  | Response assessed by investigator using RECIST v1.1 and modified RECISTc Tumor assessments every 6 weeks up to Week 48, then every 9 weeks until PD or loss of clinical benefit, withdrawal, death, or study end | Response assessed by investigator using RECIST v1.1 and modified RECISTc Tumor assessments every 6 weeks up to Week 48, then every 9 weeks until PD or loss of clinical benefit, withdrawal, death, or study end |
| Follow-up assessment                 | Survival follow-up every 3 months until death, loss to follow-up, or study end                                                                                                                                   | Survival follow-up every 3 months until death, loss to follow-up, or study end                                                                                                                                   |

Atezo=atezolizumab; AUC=area under the concentration-time curve; BSC=best supportive care; CnP=carboplatin+nab-paclitaxel; IC=tumor-infiltrating immune cell; IHC=immunohistochemistry; IV=intravenous; PD=progressive disease; PD-L1=programmed death-ligand 1; q3w=every 3 weeks; RECIST=Response Evaluation Criteria in Solid Tumors; TC=tumor cell.

aRefer toProtocol v7Section 4.3.2.2for details on dose calculations of carboplatin.

b One cycle was 21 days. The number of planned cycles of induction treatment (four or six) was at the discretion of the investigator and was determined and documented prior to randomization.

c Tumor assessments using modified RECIST were performed only for patients in Arm A (Atezo+CnP).

## Methods

## Study participants

IMpower130 recruited patients with histologically or cytologically  confirmed  Stage  IV  non-squamous NSCLC according to the American Joint Committee on Cancer (AJCC) 7th edition, regardless of the PD-L1

<div style=\"page-break-after: always\"></div>

expression level in tumour tissue.  No prior treatment for Stage IV non-squamous NSCLC was allowed, except targeted therapy for EGFR -mutant and/or ALK -positive patients (see below for details).

IMpower130 included standard eligibility criteria for Stage IV NSCLC studies.

Key efficacy-related inclusion criteria were as follows:

- Male or female, 18 years of age or older
- ECOG performance status of 0 or 1
- Histologically or cytologically confirmed, Stage IV non-squamous NSCLC

Patients with tumors of mixed histology (i.e., squamous and non-squamous) were eligible if the major histological component appeared to be non-squamous.

- No prior treatment for Stage IV non-squamous NSCLC

Patients  with  a  sensitizing  mutation  in  the EGFR gene  had  to  have  experienced  disease progression (during or after) or intolerance to treatment with one or more EGFR tyrosine kinase inhibitors for the treatment of EGFR -mutant NSCLC.

Patients with an ALK fusion oncogene must have experienced disease progression (during or after) or intolerance to treatment with one or more ALK inhibitors for the treatment of NSCLC in patients having an ALK fusion oncogene.

Patients with unknown EGFR and ALK status were required to have test results at screening. ALK and/or EGFR could be assessed locally or at a central laboratory.

Patients who received prior neo-adjuvant, adjuvant chemotherapy, radiotherapy, or chemoradiotherapy with curative intent for non-metastatic disease had to have experienced a treatment-free interval of at least 6 months from randomization since the last chemotherapy, radiotherapy, or chemoradiotherapy cycle.

- Known PD-L1 tumor status as determined by an IHC assay performed by a central laboratory on previously obtained archival tumor tissue or tissue obtained from a biopsy at screening
- Measurable disease, as defined by RECIST v1.1
- Previously irradiated lesions could only be considered as measurable disease if disease progression had been unequivocally documented at that site since radiation and the previously irradiated lesion was not the only site of disease.

Key efficacy-related exclusion criteria included the following:

- Active or untreated CNS metastases as determined by computed tomography (CT) or magnetic resonance imaging during screening and prior radiographic assessments
- Spinal  cord  compression  not  definitively  treated  with  surgery  and/or  radiation  or  previously diagnosed and treated spinal cord compression without evidence that the disease had been clinically stable for &gt; 2 weeks prior to randomization
- History  of  autoimmune  disease,  including,  but  not  limited  to,  myasthenia  gravis,  myositis, autoimmune hepatitis,  systemic lupus  erythematosus,  rheumatoid  arthritis,  inflammatory  bowel disease, vascular thrombosis associated with anti-phospholipidsyndrome, Wegener's granulomatosis,  Sjögren's  syndrome,  Guillain-Barré  syndrome,  multiple  sclerosis,  vasculitis,  or glomerulonephritis
- Leptomeningeal disease

<div style=\"page-break-after: always\"></div>

- Malignancies other than NSCLC within 5 years prior to randomization, with the exception of those with a negligible risk of metastasis or death treated with expected curative outcome
- Known tumor PD-L1 expression status as determined by an IHC assay from other clinical studies
- Any approved anti-cancer therapy within 21 days prior to initiation of study treatment
- Treatment  with  any  other  investigational  agent  with  therapeutic  intent  within  28 days  prior  to randomization
- Administration of a live, attenuated vaccine within 4 weeks before randomization or anticipation that such a live attenuated vaccine would be required during the study
- Prior  treatment  with  CD137  agonists  or  immune  checkpoint  blockade  therapies,  anti-PD-1,  and anti-PD-L1 therapeutic antibodies
- Prior anti-cytotoxic T-lymphocyte-associated protein (CTLA)-4 treatment was permitted, provided the last dose was at least 6 weeks prior to randomization and the patient had no history of severe immune-mediated adverse effects from anti-CTLA-4.
- Treatment with systemic immunostimulatory agents within 4 weeks or five half-lives of the drug, whichever was longer, prior to randomization
- Treatment with systemic immunosuppressive medications within 2 weeks prior to randomization

## Treatments

Table 7: Treatment regimens

|                                      |                                                                                                  | Atezolizumab                 | Nab-Paclitaxel               | Carboplatin                      |
|--------------------------------------|--------------------------------------------------------------------------------------------------|------------------------------|------------------------------|----------------------------------|
| Dose and administration route        | 1200 mg IV                                                                                       |                              | 100 mg/m2 IV                 | AUC 6 mg/mL/min IV               |
| Infusion rate                        | 60 (±15) minutes for the first infusion, shortening to 30 (±10) minutes for subsequent infusions |                              | Over 30 minutes              | Over approximately 15-30 minutes |
| Frequency                            | Day 1 of every 21-day cyclea                                                                     | Day 1 of every 21-day cyclea | Day 1 of every 21-day cyclea | Day 1 of every 21-day cyclea     |
| TreatmenttobeAdministered            | TreatmenttobeAdministered                                                                        | TreatmenttobeAdministered    | TreatmenttobeAdministered    | TreatmenttobeAdministered        |
| Induction phase (four or six cycles) | Arm A                                                                                            | X                            | X                            | X                                |
| Induction phase (four or six cycles) | Arm B                                                                                            |                              | X                            | X                                |
| Maintenance phase                    | Arm A                                                                                            | X                            | 一                            | 一                                |
| Maintenance phase                    | Arm Bb                                                                                           |                              |                              | 一                                |

Arm A=atezolizumab+carboplatin+nab-paclitaxel; Arm B=carboplatin+nab-paclitaxel; AUC=area under the concentration-time curve; IV=intravenous.

Nab-paclitaxel was also administered on Days 8 and 15 using the same dose and infusion time.Guidelines for dose modification and treatment interruption or discontinuation for carboplatin and nab-paclitaxel are provided in Protocol v7 Section 5.1.7 and Section 5.1.9.

Switch maintenance to erlotinib (for patients treated under v1-v4 of the protocol) or pemetrexed was permitted for patients randomized to Arm B. For patients remaining on Arm B, best supportive care was administered.

Switch maintenance to pemetrexed was permitted for patients randomized to the CnP arm. Switch maintenance to erlotinib was no longer permitted in Protocol v5 and after. However, patients randomized to the CnP arm who had already started switch maintenance treatment with erlotinib under v1-v4 of the protocol were allowed to continue treatment with erlotinib upon discussion of the risks, potential benefits, and alternative treatment options with the investigator. Because erlotinib was considered an

<div style=\"page-break-after: always\"></div>

investigational medicinal product (IMP), erlotinib was provided by the Sponsor if required by local health authority regulations. Pemetrexed was used in a commercially available formulation at each participating site.

Following PD, patients consented under Protocol v1-v4 and randomized to the CnP arm were given the option to receive atezolizumab monotherapy provided they met crossover eligibility criteria (with the exception of no prior treatment for Stage IV non-squamous NSCLC and no prior treatment with immune checkpoint blockade therapy).

## Objectives

## Efficacy objectives

In  regard  to  the  objectives  below,  the  intent-to-treat  (ITT)-wild  type  (WT)  population  refers  to randomized  patients  who  did  not  have  an  activating EGFR mutation  or ALK translocation.  The  ITT population refers to all randomized patients. Some efficacy endpoints were analyzed in a population of randomized patients with a defined level of PD-L1 expression. Tumour specimens were evaluated for PD-L1 expression on tumour cells (TC) and tumour infiltrating immune cells (IC) as assayed by a centrally performed immunohistochemistry (IHC) test. The results  were  used  to  define  the  PD-L1  expression subgroups for the analyses described under statistical methods.

## Co-Primary Efficacy Objectives

The co-primary objectives for this study were as follows:

- To evaluate the efficacy of Atezo-CnP compared with CnP as measured by investigator-assessed PFS according to Response Evaluation Criteria in Solid Tumours (RECIST) Version 1.1 in the ITT-WT population
- To evaluate the efficacy of Atezo-CnP compared with CnP as measured by OS in the ITT-WT population

## Secondary Efficacy Objectives

The secondary efficacy objectives for this study were as follows:

- To evaluate the efficacy of atezolizumab as measured by investigator-assessed PFS according to RECIST v1.1 and OS in the ITT population
- To evaluate the efficacy of atezolizumab as measured by investigator-assessed PFS according to RECIST v1.1 and OS in the PD-L1 expression population and PD-L1 expression WT population
- To  evaluate  the  efficacy  of  atezolizumab  as  measured  by  investigator-assessed  objective response rate (ORR) according to RECIST v1.1 in the ITT-WT population
- To  evaluate  the  efficacy  of  atezolizumab  as  measured  by  investigator-assessed  duration  of response (DOR) according to RECIST v1.1 in the ITT-WT population
- To evaluate the OS rates at 1 and 2 years after randomization in each treatment arm in the ITT-WT population
- To  determine  the  impact  of  atezolizumab  as  measured  by  time  to  deterioration  (TTD)  in patient-reported  lung  cancer  symptoms,  using  the  European  Organisation  for  Research  and Treatment  of  Cancer  (EORTC)  Quality  of  Life  Questionnaire-Core  30  (QLQ-C30)  and  the supplemental 13-Item Lung Cancer Module (LC13) in the ITT-WT population
- To  determine  the  impact  of  atezolizumab  as  measured  by  change  from  baseline  (i.e., improvement or deterioration based on presenting symptomatology) in patient-reported lung

<div style=\"page-break-after: always\"></div>

cancer symptoms (chest pain, dyspnoea, and cough) using the Symptoms in Lung Cancer (SILC) scale symptom severity score in the patient-reported outcome (PRO)-evaluable WT population.

## Safety objectives

The safety objectives for this study were as follows:

- To evaluate the incidence, nature, and severity of adverse events (AEs) graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v4.0
- To  evaluate  the  changes  in  vital  signs  and  clinical  laboratory  results  during  and  following atezolizumab administration
- To evaluate the incidence and titers of anti-drug antibody (ADA; also known as anti-therapeutic antibody)  response  to  atezolizumab  and  potential  correlation  with  pharmacokinetic  (PK), pharmacodynamic, safety, and efficacy parameters

## Pharmacokinetic objectives

The PK objectives for this study were as follows:

- To evaluate the maximum observed serum concentration (Cmax) of atezolizumab after infusion on Cycle 1 Day 1 (C1D1) and minimum observed serum concentration (Cmin) of atezolizumab prior to infusion at selected cycles, at treatment discontinuation, and at 120 days (±30 days) after the last dose of atezolizumab for patients randomized to Atezo-CnP
- To evaluate the plasma concentrations of carboplatin (Atezo-CnP and CnP arms)
- To evaluate the plasma concentrations of nab-paclitaxel reported as total paclitaxel (Atezo-CnP and CnP arms)

## Exploratory objectives

The exploratory objectives for this study were as follows:

- To evaluate the efficacy of atezolizumab as measured by investigator-assessed PFS, ORR, and DOR according to RECIST v1.1 and OS in the T-effector (Teff)-high population (with Teff gene signature expression in tumor tissue as determined by an RNA-based assay) and the Teff-high population excluding patients with an activating EGFR mutation or ALK translocation (Teff-high WT)
- To evaluate the PFS rates at 6 months and 1 year after randomization, as assessed by the investigator according to RECIST v1.1
- To evaluate the OS rate at 3 years after randomization
- To  determine  the  impact  of  atezolizumab  as  measured  by  the  utility  scores  of  the  EuroQol 5-Dimension 3-Level (EQ-5D-3L) questionnaire
- To  evaluate  the  impact  of  atezolizumab  on  the  change  from  baseline  and  the  number  and proportion of patients with a clinically meaningful change in PROs of health-related quality of life (HRQoL), lung cancer-related symptoms, and health status as assessed by the EORTC QLQ-C30 and EORTC QLQ-LC13.

## Outcomes/endpoints

The endpoints and analyses described in this summary are based on the IMpower130 Statistical Analysis Plan (SAP) v4, dated 4 May 2018.  The analyses described in the SAP supersede those specified in the study protocol, as applicable.

<div style=\"page-break-after: always\"></div>

Definitions of key efficacy endpoints are given below table.

The co-primary efficacy outcome measures for IMpower130 were as follows:

- Investigator-assessed PFS in the ITT-WT population
- OS in the ITT-WT population

As per the pre-specified analysis hierarchy and α -spending algorithm, PFS in the ITT-WT population was tested first and, if this test was significant, the α allocated to PFS was to be recycled for the test of OS in the ITT-WT population.

The secondary efficacy outcome measures included:

- PFS and OS in the ITT population
- PFS and OS in the PD-L1 expression and PD-L1 expression WT populations
- Objective response rate (ORR; confirmation not required)
- Duration of response (DOR; confirmation not required)
- OS rates at the 1- and 2-year landmark timepoints
- Time to deterioration (TTD) in patient-reported lung cancer symptoms per European Organisation for Research and Treatment of Cancer (EORTC) questionnaires
- Change from baseline in patient-reported lung cancer symptoms using the Symptoms in Lung Cancer (SILC) scale
- Proportion of patients improved, remained stable, worsened in patients-reported lung cancer symptoms, HRQOL and functioning

## Table 8: Key Efficacy Endpoint Definitions in IMpower130

| Endpoint   | Definition                                                                                                                                                                                                   |
|------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PFS        | Time from randomization to first documented PD, as determined by the investigator using RECIST v1.1, or death from any cause, whichever occurred first                                                       |
| OS         | Time from randomization to death from any cause                                                                                                                                                              |
| ORR        | Proportion of patients with an objective response (either CR or PR), as determined by the investigator using RECIST v1.1; confirmation not required                                                          |
| DOR        | Time from first documented objective response (CR or PR) to documented PD, as determined by the investigator using RECIST v1.1, or death from any cause, whichever occurred first; confirmation not required |

CR = complete response; DOR = duration of response; ORR = objective response rate; OS = overall survival; PD = progressive disease; PFS = progression-free survival; PR = partial response; RECIST = Response Evaluation Criteria in Solid Tumours.

Confirmation of response according to RECIST v1.1 was not required, but for exploratory purposes, ORR with confirmation may be reported. For exploratory purposes, DOR for patients with confirmed response may be reported.

Tumour assessments were conducted every 6 weeks for the first 48 weeks following Cycle 1, then every 9 weeks thereafter.

## Sample size

This study planned to randomize approximately 715 patients. Patients with an activating EGFR mutation or ALK translocation were excluded from the primary analysis population (i.e., ITT-WT). There were expected to be approximately 650 patients in the ITT-WT population given the approximate 10% prevalence of these genetic variations.

The sample size of this study was based on the number of events required to demonstrate efficacy with regard to both PFS and OS (co-primary endpoints) for the comparison of the Atezo-CnP arm versus the CnP arm. The estimate of the number of events required to demonstrate efficacy with regard to PFS in the primary comparison of the Atezo-CnP arm versus the CnP arm was based on the following assumptions:

- One-sided significance level of 0.003 in the ITT-WT population

<div style=\"page-break-after: always\"></div>

- 95% power to detect a hazard ratio (HR) of 0.65, corresponding to an improvement in median PFS from 6 months to 9.2 months in the ITT-WT population
- No interim PFS analysis
- Dropout rate of 5% per 12 months

The estimate of the number of events required to demonstrate efficacy with regard to OS in the comparison of the Atezo-CnP arm versus the CnP arm was based on the following assumptions:

- One-sided significance level of 0.022 in the ITT-WT population
- 80% power to detect an HR of 0.75, corresponding to an improvement in median OS from 12 months to 16 months in the ITT-WT population
- One interim OS analysis performed when approximately 77% of the total OS events required for the final analysis had occurred using the Lan-DeMets approximation to the O'Brien-Fleming boundary
- Dropout rate of 5% per 24 months

## Randomisation

For patients who were eligible for enrollment, the study site obtained the patient's randomization number and treatment assignment from the IxRS. The number of cycles of induction treatment (four or six) was determined by the investigator and documented prior to randomization. Randomization to one of the two treatment arms occurred in a 2:1 ratio. Permuted-block randomization was applied to ensure a balanced assignment to each treatment arm.

Randomization was stratified by the following criteria:

- Sex (male vs. female)
- Presence of liver metastases at baseline (yes vs. no)
- PD-L1 tumour expression by IHC (TC3 and any IC vs. TC0/1/2 and IC2/3 vs. TC0/1/2 and IC0/1)

Following PD, patients who were consented under v1-v4 of the protocol and randomized to the CnP arm were given the option to receive atezolizumab monotherapy, provided they continued to meet eligibility criteria to receive atezolizumab (with the exception of no prior treatment for Stage IV non-squamous NSCLC and no prior treatment with immune checkpoint blockade therapy).

## Blinding (masking)

IMpower130 is an open-label study. The Sponsor was blinded to treatment arm allocation and patient-level data on PD-L1 expression until the database had been locked for analysis.

## Statistical methods

## Analysis Population

Populations analysed are defined as follows, in alphabetical order:

- ITT: All randomized patients, regardless of receipt of the assigned treatment.
- ITT-WT :  All randomized patients regardless of assigned treatment, excluding patients with an activating EGFR mutation or ALK translocation.

<div style=\"page-break-after: always\"></div>

- PD-L1 expression population: ITT patients with PD-L1 IHC TC1/2/3 (defined as PD-L1 staining in &lt;1%, ≥1% to &lt;5%, ≥5% to &lt;50%, and ≥50% of TCs) or IC1/2/3 (defined as PD-L1-stained ICs covering &lt;1%, ≥1% to &lt;5%, ≥5% to &lt;10%, and ≥10% of the tumour area) expression in baseline tumour tissue (TC1/2/3 or IC1/2/3 subgroup); ITT patients with PD-L1 IHC TC3 or IC3 expression in baseline tumour tissue (TC3 or IC3 subgroup); and ITT patients with PD-L1 IHC TC2/3 or IC2/3 expression in baseline tumour tissue (TC2/3 or IC2/3 subgroup).
- PD-L1 expression WT population: As defined above for the PD-L1 expression population, excluding patients with an activating EGFR mutation or ALK translocation.
- Patient-reported outcome (PRO)-evaluable WT population :  Patients randomized into the ITT-WT population who completed a given PRO questionnaire at the baseline visit and at least one post-baseline visit.

## Primary analysis

The co-primary efficacy endpoints are PFS and OS in the ITT-WT population.

To control the overall Type I error rate for the one-sided test at 0.025, a one-sided alfa of 0.003 and a one-sided alfa of 0.022 were allocated to PFS and OS, respectively. The primary comparison of PFS was tested at a one-sided alfa level of 0.003 in the ITT-WT population. The primary comparison of OS was to be tested in the ITT-WT population at the allocated alpha together with the alfa recycled from the PFS analysis  if  the  PFS  comparison  was  statistically  significant.  The  PFS  and  OS  analysis  hierarchy  and alfa-allocation, including possible alfa-recycling.

Figure 7: PFS and OS analysis hierarchy, alpha allocation, and alpha recycling

<!-- image -->

OS was planned to be tested using the group sequential method at the interim and final OS analyses. Statistical significance at the interim and final OS analyses was planned to be tested.

The HRs, λA/λB, where λA, and λB represent the hazard of having a PFS event in the Atezo-CnP and CnP arms, respectively, comparing the treatment effect between the two treatment arms, were estimated using  a  stratified  Cox  regression  model  with  the  same  stratification  variables  used  for  the  stratified log-rank test, and the 95% CIs were provided. For each comparison, analyses were conducted according to an analysis hierarchy and an alfa-spending algorithm to control for the Type I error rate and to account for an interim OS analysis.

The stratification factors were, in principle, planned to be those used during randomization as recorded in the IxRS. Due to the potential risk of over-stratification (Akazawa et al. 1997), if at least one stratum had fewer than 15 events (PFS or OS events), the stratification factor that contained the level with the smallest  number  of  patients  was  to  be  removed  from  the  stratified  analyses.  The  removal  of  the stratification factor continued until there were no strata with fewer than 15 events (PFS or OS events).

<div style=\"page-break-after: always\"></div>

The final set of stratification factors used in stratified analyses following the pre-specified rule in the SAP v4  were  applied  to  all  endpoints  where  stratified  analyses  were  planned.  Results  from  unstratified analysis were also provided.

Kaplan-Meier (KM) methodology was used to estimate median PFS and OS and to construct survival curves  for each  treatment  arm  for  a  visual description  of  the  difference  among  arms.  The Brookmeyer-Crowley  methodology  was  used  to  construct  the  95%  CI  for  median  PFS  and  OS (Brookmeyer and Crowley 1982).

Follow-up for OS was summarized for all patients included in the analysis (whether the patient was alive or had died). Follow-up was summarized using the KM method with data for patients who died, censored at the date of death.

Note that the OS boundaries were updated to use the Lan-DeMets approximation to the Pocock boundaries; therefore, the overall power for the OS analysis in the ITT-WT population was reduced from 80% to 77%.

## Primary Analysis Timing for PFS

No interim analyses were planned for the co-primary endpoint of PFS in this study. The primary PFS analysis was conducted at the time of the interim OS analysis. At this timepoint, it was expected that approximately 475 PFS events would have occurred in the ITT-WT population based on the assumptions specified in the SAP v4. This number of events would allow for a minimum detectable difference in HR of approximately 0.76 in the ITT-WT population.

Table 9: Primary analysis for PFS

<!-- image -->

| Population   |   Analysis Timing, MonthsfromFPI | No.ofEvents, Event Ratio (%)   |   MDDinHazardRatio | Power   |
|--------------|----------------------------------|--------------------------------|--------------------|---------|
| ITT-WT       |                               32 | 475 (73%)                      |               0.76 | 95%     |

FPI=first patient in; ITT=intent-to-treat; MDD=minimum detectable difference; WT=wild type.

## Interim and Final Analysis Timing for Overall Survival

One interim analysis was planned for the co-primary endpoint of OS to be conducted when approximately 352 OS events had occurred in the ITT-WT population. The final OS analysis was planned to be conducted when there were approximately 457 OS events in the ITT-WT population.

The stopping boundaries for the interim and final OS analyses considering different scenarios with alfa-recycling were calculated using the Lan-DeMets approximation to the Pocock boundary, assuming the specified observed number of events (352 and 457, respectively), and are shown in Table 10. The p-value was used to claim crossing of the boundaries. For example, if approximately 352 events had occurred in the ITT-WT population at the time of the interim OS analysis, then statistical significance of the OS endpoint in ITT-WT population was declared if p≤0.0211 when PFS had claimed significance in the ITT-WT population.

Table 10: Analysis timing and stopping boundary for OS (ITT-WT population)

<!-- image -->

|                    | Stopping Boundary in HR (p-value)   | Stopping Boundary in HR (p-value)   |
|--------------------|-------------------------------------|-------------------------------------|
| Analysis           | Ifα=0.022                           | Ifα=0.025                           |
| InterimOS analysis | HR ≤0.790 (p-value ≤0.0185)         | HR ≤0.795 (p-value ≤0.0211)         |
| Final OS analysis  | HR ≤0.795 (p-value ≤0.0103)         | HR ≤0.799 (p-value ≤0.0119)         |

HR=hazard ratio; ITT=intent-to-treat; OS=overall survival; WT=wild type.

Note: α and p-value are one-sided.

<div style=\"page-break-after: always\"></div>

## Sensitivity analyses

## Impact of non-protocol-specified anti-cancer therapy

The impact of non-protocol-specified anti-cancer therapy (NPT) on PFS as determined by the investigator will be assessed, depending on the number of patients who received NPT before a PFS event. If &gt; 5% of patients received NPT before a PFS event in the control arm, a sensitivity analysis may be performed for the comparisons between two treatment arms in which data from patients who receive NPT before a PFS event will be censored at the last tumor assessment date before receipt of NPT.

The impact of subsequent NPT on OS will be assessed depending on the number of patients who received NPT. If &gt; 10% of patients received a NPT in the control arm, the following analyses may be performed to compare treatment arms:

·  The  discount  method  uses  a  'discounted'  survival  time  after  switching  for  patients  who  switch treatments based on a user-specified assumption for the effect on OS. OS may be discounted according to a range of possible effects on OS of the subsequent NPT after treatment switching occurred (e.g., 10%, 20%, 30%, etc.).

· Rank preserving structural failure time provides an estimate of the OS time for the control group had NPT not occurred (Robins and Tsiatis 1991). It estimates OS measured from the time of NPT by applying an estimate of the benefit of the NPT. The total OS time (sum of time to NPT and the estimated survival time after NPT started) may then be analyzed using the same methodology as for the primary analysis of OS.

· The inverse probability of censoring weighting method censors patients at start of NPT and uses the control arm patients to create weights that represent how NPT treated patient is like a non-NPT-treated patient (Robins and Finkelstein 2000). These time-varying weights are included into the OS analysis to correct the effect of NPT by giving increased weight to non-censored patients with similar characteristics to censored patients.

## Secondary analyses

PFS and OS in the ITT Population will be analyzed using the same methods as described for PFS and OS. If the difference in OS between Arm A and Arm B in the ITT-WT population was statistically significant, a comparison of Arm A versus Arm B was to be conducted in the ITT population. The alpha allocation will follow  the  same  alpha-spending  algorithm  and  allocation  ratio  (3:22)  described  for  analysis  of  the co-primary efficacy endpoints.

PFS and OS in the TC1/2/3 or IC1/2/3-WT, and the TC1/2/3 or IC1/2/3 populations will be analyzed using similar methods as described for OS and PFS. Analyses of PFS and OS may be conducted in other PD-L1 expression populations and PD-L1 expression WT populations (e.g., TC2/3 or TC2/3-WT, TC3 or IC3-WT, TC2/3 or IC2/3, TC3 or IC3, and the corresponding complementary groups, as well as TC0 and IC0-WT, TC0 and IC0).

ORR will be compared between treatment arms using the stratified Cochran-Mantel-Haenszel test. The 95% CI for the difference in ORRs between the two treatment arms will be computed using the normal approximation to the binomial distribution. An estimate of ORR and its 95% CI will be calculated for each treatment arm using the Clopper-Pearson method.

Because the determination of DOR is based on a non-randomized subset of patients, formal hypothesis testing was not performed. DOR was estimated using KM methodology. Comparisons between treatment arms were made using the stratified and unstratified log-rank test for descriptive purposes only.

The OS rate at the 1- and 2-year landmark time points after randomization was estimated for each treatment arm using KM methodology, along with 95% CI calculated with the standard error derived from

<div style=\"page-break-after: always\"></div>

the Greenwood formula. The 95% CI for the difference in OS rates between the two treatment arms will be  estimated  using  the  normal  approximation  method,  with  standard  errors  computed  using  the Greenwood method.

Patient-Reported  Outcomes:  Through  the  use  of  the  SILC  scale,  the  EORTC  QLQ-C30,  and  EORTC QLQ-LC13, lung cancer symptom data will be collected about symptoms commonly associated with cancer treatments, and disease and treatment impact on patients' functioning.

The EORTC QLQ-C30 and EORTC QLQ-LC13 will be scored according to the EORTC scoring manual. For multi-item subscales, if ≤ 50% of items within the multi-item subscale are missing at a given timepoint, the multi-item score will be calculated on the basis of the non-missing items. If &gt; 50% of items are missing or if a single-item measure is missing, the subscale is missing.

The SILC questionnaire will be scored at the individual symptom level, thus will have a dyspnea score, chest pain score, and cough score. Each individual symptom score will be calculated as the average of responses for the symptom items (e.g., Chest Pain Score = mean [item 1; item 2]). An increase in score is suggestive of a worsening in symptomology (i.e., frequency or severity). A score change of ≥ 0.3 points for the dyspnea and cough symptom scores is considered to be clinically significant; whereas a score change of ≥ 0.5 points for the chest pain score is considered to be clinically significant.

Time to deterioration in PRO: TTD with use of the EORTC is defined as the time from baseline to the first confirmed clinically meaningful deterioration in the EORTC symptom score. TTD will be documented for a 3-symptom composite endpoint using the following EORTC QLQ-LC13 symptom scores: cough, chest pain,  and  dyspnea  multi-item  scale.  Confirmed  clinically  meaningful  deterioration  in  lung  cancer symptoms is defined as a ≥ 10-point increase above baseline in a symptom score that must be held for at least two consecutive assessments or an initial ≥ 10-point increase above baseline followed by death within 3 weeks from the last assessment. A ≥ 10-point change in the EORTC scale score is perceived by patients as clinically significant.

Summary statistics  (mean,  SD,  median,  25th  and  75th  percentiles,  and  range)  of  the  change  from baseline per SILC scale may be provided.

<div style=\"page-break-after: always\"></div>

## Results

## Participant flow

<!-- image -->

Atezo=atezolizumab; CnP=carboplatin+nab-paclitaxel; ITT=intent-to-treat.

Figure 8: Patient disposition (ITT population)

Table 11 : Patient Disposition from Study (ITT Population)

Patient Disposition from Study

Intent-to-Treat Patients

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

Protocol: GO29537 (Data Cutoff: 15MAR2018)

| _________________________________________________________________________________________   |   CnP | (Randomized) (N=240)   |   Atezo+CnP | (Randomized) (N=483)   |
|---------------------------------------------------------------------------------------------|-------|------------------------|-------------|------------------------|
| Received Treatment                                                                          |   232 | (96.7%)                |         473 | (97.9%)                |
| Received Treatment During The Induction Phase                                               |   232 | (96.7%)                |         473 | (97.9%)                |
| Received Treatment During The Maintenance Phase                                             |    49 | (20.4%)                |         353 | (73.1%)                |
| On-study Status                                                                             |    88 | (36.7%)                |         214 | (44.3%)                |
| Alive: On Treatment                                                                         |    37 | (15.4%)                |         104 | (21.5%)                |
| Alive: In Follow-Up                                                                         |    51 | (21.3%)                |         110 | (22.8%)                |
| Discontinued Study                                                                          |   152 | (63.3%)                |         269 | (55.7%)                |
| Death                                                                                       |   136 | (56.7%)                |         240 | (49.7%)                |
| Lost To Follow-Up                                                                           |     1 | ( 0.4%)                |           0 |                        |
| Non-Compliance                                                                              |     0 |                        |           1 | ( 0.2%)                |
| Other                                                                                       |     4 | ( 1.7%)                |           8 | ( 1.7%)                |
| Physician Decision                                                                          |     0 |                        |           1 | ( 0.2%)                |
| Protocol Violation                                                                          |     1 | ( 0.4%)                |           0 |                        |
| Withdrawal By Subject                                                                       |    10 | ( 4.2%)                |          19 | ( 3.9%)                |

Atezo=Atezolizumab, CnP=Carboplatin+Nab-Paclitaxel.

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

Data Cutoff: 15MAR2018; RAVE Data Extracted: 18 May 2018.

## Recruitment

First patient randomized: 16 April 2015. Last patient randomized: 13 February 2017. Data cutoff date: 15 March 2018

131 centers in 8 countries: Belgium 21 (4), Canada 52 (5), France 45 (11), Germany 132 (25), Italy 52 (6), Israel 35 (10), Spain 71 (13), United States 315 (57).

<div style=\"page-break-after: always\"></div>

## Conduct of the study

## Protocol Amendments

The first version (v1) of the protocol was issued on 21 November 2014 and amended (v2) on 29 March 2015, prior to the first patient randomized (16 April 2015). The protocol was subsequently amended five times (v3-v7). The key changes to the protocol are summarized below.

Table 12: Comparison of key features in IMpower130 Protocol versions 1-7

|                                               | ProtocolVersions1-4 11 November 2015(v4)                                                                                                          | ProtocolVersion5 15 June 2016                                                                                         | ProtocolVersion6 1 March 2017 (global) 15 July 2017(Germany)                            | ProtocolVersion7 28February2018(VHP) 25 April 2018(Germany)   |
|-----------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------|---------------------------------------------------------------|
| Totalnumberofpatients toberandomized          | 550                                                                                                                                               | 650                                                                                                                   | 715                                                                                     | No changes                                                    |
| Primary endpoints                             | Investigator-assessedPFSin PD-L1-selected and ITTpopulation                                                                                       | Investigator-assessedPFS and OS in PD-L1-selected andITTpopulation                                                    | Investigator-assessedPFSin tGE-WT and ITT-WTpopulation and OS in ITT-WT population      | No changes                                                    |
| Secondaryefficacy endpoints                   | ORR,OS,DOR,TIR, IRF-assessedPFS,1-and 2-yearOS, TTD,patient-reported outcomes                                                                     | ORR,DOR,TTR,TIR,IRF-aSSeSSd PFS,1-and2-year OS,TTD, patient-reportedoutcomes                                          | PFS andOS insecondary populationsb,ORR,DOR, 1-and2-yearOS,TTD, patient-reportedoutcomes | No changes                                                    |
| Type Ierrorrate (α) and α allocation          | One-sided α=0.025 PFS:0.02(PD-L1-selected) and 0.005 (ITT) ORR:0.005(PD-L1-selected) and 0.001 (ITT) OS:0.02or0.015(PD-L1-selected)               | One-sidedα=0.025 PFS:0.003(PD-L1-selected) then 0.003 (ITT) OS:0.025or0.022°(PD-L1-selected) then 0.025 or0.022*(ITT) | One-sidedα=0.025 PFS:0.003(tGE-WT) then 0.003 (ITT-WT) ° OS:0.025 or0.022°(ITT-WT)d     | No changes                                                    |
| Crossovertoreceive atezolizumab monotherapy   | Allowed                                                                                                                                           | Not allowed                                                                                                           | No change                                                                               | No change                                                     |
| Biomarkersubgroup (PD-L1-selected population) | Not specified                                                                                                                                     | TC1/2/3orIC1/2/3                                                                                                      | TC2/3orIC2/3 and TC1/2/3orIC1/2/3                                                       | No changes                                                    |
| Stratificationfactorsfor randomization        | Sex(malevs.female),presenceof livermetastasesatbaseline (yesvs.no),PD-L1tumorexpression status(TC3and anyICvs.TC0/1/2 andIC2/3vs.TC0/1/2andIC0/1) | No changes                                                                                                            | No changes                                                                              | No changes                                                    |

- aORR andOSwill beformallytested ifPFSispositive.
- Secondary populations refer to tGE-WT (for OS) and TC2/3 or IC2/3-WT, TC1/2/3 or IC1/2/3-WT, tGE, and ITT populations.
- First αwasplanned tobeused if thepreceding analysisin thehierarchywasstatisticallysignificant;otherwise,thesecondαwould beused.

If OSinITT-WTispositive,formal testswillbeconductedin thetGEandITTpopulationswithsame testingstrategy andα allocation asPFSandOSin thetGE-WT andITT-WTpopulations.

## Changes to Planned Analyses

The first version (v1) of the SAP was issued on 19 May 2017 and was amended three times (v2-v4). The key changes to the SAP are summarized below.

<div style=\"page-break-after: always\"></div>

Table 13: Comparison of key features in IMpower130 statistical analysis plan versions 1-4

|                                                                        | SAP Version 1 19 May 2017                                                                                                                                                      | SAP Version 2 17 0ctober 2017          | SAP Version 3 13 March 2018                                       | SAP Version 4 4 May 2018                                                                                                                                                        |
|------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------|-------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Primary endpoints                                                      | Investigator-assessedPFSin tGE-WTandITT-WT population and OS inITT-WT population                                                                                               | No changes                             | Investigator-assessedPFSand OS in ITT-WT population               | No changes                                                                                                                                                                      |
| Type Ierror rate (α) and α allocation                                  | One-sidedα=0.025 PFS: 0.003 (tGE-WT) then 0.003 (ITT-WT)a OS:0.025 or0.022b(ITT-WT)a                                                                                           | No changes                             | One-sidedα=0.025 PFS: 0.003 (ITT-WT)c OS:0.025 or 0.022b(ITT-WT)c | No changes                                                                                                                                                                      |
| Primary analysis timing                                                | Approximately 225PFSevents in the tGE-WT,approximately 475 PFS events in the ITT-WT, andlastpatientrandomized, whicheveroccurslast                                             | Approximately352OSevents in the ITT-WT | No changes                                                        | No changes                                                                                                                                                                      |
| Method tocalculate stoppingboundariesfor interim and final OS analyses | Lan-DeMets approximation to theO'Brien-Flemingboundary                                                                                                                         | No changes                             | Lan-DeMets approximation to thePocockboundary                     | No changes                                                                                                                                                                      |
| Stratificationfactorsfor stratified analysis d                         | Sex(male vs.female), presenceof livermetastases at baseline (yes vs.no),and PD-L1 tumor expression status ([TC3 and any IC, TC0/1/2 and IC2/3 combined] vs. TC0/1/2 and IC0/1) | No changes                             | No changes                                                        | No changes tofactors;however, ifat least onestratum has<15PFSorOSevents,the factor that containsthelevel withthesmallestnumberof patientswouldberemovedfrom stratified analysis |

HR=hazard ratio;IC=tumor-infiltratingimmune cell;ITT=intent-to-treat;OR=objectiveresponse;OS=overall survival;PD-L1=programmed death-ligand 1; PFS=progression-freesurvival;SAP=StatisticalAnalysisPlan;TC=tumor cell;tGE=tumorgeneexpression;WT=wild type.

- aIf OS in ITT-WT is positive, formal tests willbe conducted in the tGE and ITT populations with same testing strategy and α allocation as PFS and OS in the tGE-WT and ITT-WT populations.
- First α was planned to be used if the preceding analysis in the hierarchy was statistically significant; otherwise, the second α would be used.
- IfOSinITT-WTispositive,formal testswill beconducted inPFSandOSintheITTpopulationwithsame testingstrategy and αallocation as in the ITT-WT population.
- dNote that thefactors usedforthestratifiedanalysis(ie.,twolevelsof PD-L1stratification)differfrom thefactors usedforrandomization(threelevels).In addition,stratificationbyPD-L1expressionisnotusedforthetGE-WTpopulation,whereapplicable.

<div style=\"page-break-after: always\"></div>

## Protocol deviations

Table 14: Summary of major protocol deviations (ITT population) - data cut-off 15 March 2018

| Protocol Deviation Category Protocol Deviation Description   | CnP (Randomized) (N=240)   | Atezo+CnP (Randomized) (N=483)   | All Patients (N=723)   |
|--------------------------------------------------------------|----------------------------|----------------------------------|------------------------|
| Iotal number of patients with at least one deviation         | 86(35.8%)                  | 179 (37.1)                       | 265 (36.78)            |
| Overall total number of deviations                           | 150                        | 346                              | 496                    |
| PROCEDURAL                                                   |                            |                                  |                        |
| Total number of patients with at least one deviation         | 67 (27.9)                  | 135 (28.0%)                      | 202 (27.98)            |
| ON STUDY ASSESSMENT NOT DONE/OUTSIDE OF WINDOW               | 36 (15.0%)                 | 68 (14.1%)                       | 104 (14.48)            |
| OMISSION OF LAB TEST REQ.BY PROTOCOL                         | 20 8.3)                    | 33 6.8%)                         | 53 7.3                 |
| ICF- OTHER (PROCEDURAL ISSUES)                               | 14 5.88)                   | 34 7.0%)                         | 48 6.68)               |
| OMISSIONOF TUMOR ASSESSMENT                                  | 7 2.9)                     | 8 1.78)                          | 15 2.1)                |
| EX.CRITERIA PROCEDURAL （E.G.OUT OF WINDOW)                   | 7 2.9%)                    | 6 1.2%)                          | 13 1.8%j               |
| FAILURE TO REPORT SAES OR PREGNANCY PER PROTOCOL             | 2 0.8%)                    | 8 1.78)                          | 10 1.4%j               |
| INC.CRITERIA PROCEDURAL E.G.OUT OF WINDOW                    | 2 0.8)                     | 7 1.4)                           | 9 1.2)                 |
| INCLUSION CRITERIA                                           |                            |                                  |                        |
| Total number of patients with at least one deviation         | 14 (5.8%)                  | 35 (7.2)                         | 49 6.88)               |
| INCLUSION-RELATED TEST NOT DONE                              | 7 2.9%)                    | 10 2.1号)                         | 17 2.48)               |
| ICF -OTHER (E.G.PROCEDURAL ISSUES)                           | 1 0.48)                    | 11 2.38)                         | 12 1.78)               |
| OTHER INCLUSION CRITERIA                                     | 2 0.8%)                    | 7 (1.4%)                         | 9 1.28)                |
| MEDICATION                                                   |                            |                                  |                        |
| Total number of patients with at least one deviation         | 16 6.7%)                   | 28 5.88)                         | 44 6.18)               |
| SIGNIFICANT DEVIATION FROM PLANNED DOSE                      | 10 4.2%)                   | 11 2.3%)                         | 21 2.98)               |
| RECEIVEDINCORRECTSTUDY TREATMENT                             | m寸 1.3)                    | 7 1.4)                           | 10 1.4)                |
| DOSE MISSED OR SIGNIFICANT OUT OF WINDOW                     | 1.7%)                      | 4 0.88)                          | 8 1.18)                |
| RECEIVED PROHIBITED CONCOMITANT THERAPY/MEDICATION           | 0                          | 6 1.2%)                          | 6 0.8%)                |
| EXCLUSION CRITERIA                                           |                            |                                  |                        |
| Total number of patients with at least one deviation         | 6 (2.5%)                   | 23( 4.8%)                        | 29 4.08)               |
| EXCLUSION RELATED TEST NOT DONE                              | 4 1.78)                    | 10 2.1)                          | 14 1.98)               |
| RECEIVED PRIOR PROHIBITED THERAPY OR MEDICATION              | 0                          | 6 1.28)                          | 0.8%)                  |

A patient was counted once if received more than one deviation of the \\_same type. Data Cutoff: 15MAR2018; RAVE Data Extracted: 18 May 2018.

Atezo=Atezolizumab, CnP=Carboplatin+Nab-Paclitaxel.

<div style=\"page-break-after: always\"></div>

## Baseline data

Table 15: Demographic and baseline disease characteristics (ITT-WT population)

Protocol: G029537 (Data Cutoff: i5MAR2018)

<!-- image -->

|                                                                                                                  | CnP (Randomized) (N=228)                       | Atezo+CnP (Randomized) (N=451)                                                            | All Patients (N=679)                                   |
|------------------------------------------------------------------------------------------------------------------|------------------------------------------------|-------------------------------------------------------------------------------------------|--------------------------------------------------------|
| Sex                                                                                                              |                                                |                                                                                           |                                                        |
| n Female Male                                                                                                    | 228 94(41.28) 134 (58.88)                      | 451 185(41.0%) 266 (59.08)                                                                | 679 279 (41.18) 400(58.98)                             |
| Liver Metastasis at Enrollment n Yes                                                                             | 228 31                                         | 451 69                                                                                    | 100 (14.78)                                            |
| No TC/IC Strat Factor from IxRS n                                                                                | (13.68) 197 (86.48)                            | (15.38) 382 (84.7%)                                                                       | 679 579 (85.38)                                        |
| TC3orIC2/3 TC0/1/2 and IC0/1                                                                                     | 61 (26.8号) 228 167 (73.28)                     | 121 (26.8号) 451 330 (73.28)                                                               | 679                                                    |
| Age (years) Mean (SD) n Median Min - Max Age Group (years) n                                                     | 228 64.5                                       | 63.9 (9.5) 451 64.0 18-86                                                                 | 679 64.0                                               |
| <65 65 to 74 75 to 84 >=85 Ethnicity n Hispanic or Latino Not Hispanic or Latino                                 | 64.2 (8.9) 38-85                               | 451 227 (50.38) 174 (38.68)                                                               | 64.0 (9.3) 18-86 228 679                               |
| Not reported Unkmown Race                                                                                        | 114 (50.0%) 84 (36.8号) 29 (12.78) 1 (0.4%) 228 | 451 22 (4.98) 397 (88.0%) 18 (4.0%) 14(3.18) 451 12 (2.78) 17 (3.88) 402 (89.18) 1 （0.2%） | 77 (11.38) 3 0.4%) 679 32 (4.78) 601 (88.58) 27 (4.0%) |
| n Asian Black or African American White                                                                          | 10 204 9                                       |                                                                                           | 19 （2.88)                                              |
| Multiple Unkmown n.                                                                                              | 228 3 ( 1.38) 8 (3.58) (92.18)                 | 19 (4.28)                                                                                 | 679 15 (2.28) 25 (3.78) 612 (90.18) 1 (0.18)           |
|                                                                                                                  | (0.48) 228                                     |                                                                                           | 341 (50.28) 258 (38.0%)                                |
|                                                                                                                  | 0.98)                                          | 2 (0.48）                                                                                  |                                                        |
|                                                                                                                  |                                                | 48 (10.68)                                                                                |                                                        |
|                                                                                                                  | 228 218 4 0 2 02                               |                                                                                           |                                                        |
|                                                                                                                  | (4.48)                                         |                                                                                           |                                                        |
|                                                                                                                  | (89.5号) (3.98)                                 |                                                                                           |                                                        |
|                                                                                                                  | （2.2%）                                         |                                                                                           |                                                        |
|                                                                                                                  | 210                                            |                                                                                           | 26 (3.8%)                                              |
| Weight (kg) at baseline                                                                                          |                                                |                                                                                           |                                                        |
| Mean (SD)                                                                                                        |                                                |                                                                                           | 678                                                    |
| Median                                                                                                           |                                                | 451                                                                                       | 72.55                                                  |
| Min - Max                                                                                                        | 227                                            | 75.32 (16.67) 72.00 42.0 - 144.0                                                          | 75.61 (17.24) 40.9 -145.2                              |
|                                                                                                                  | 74.00                                          |                                                                                           |                                                        |
| Tobacco Use History n                                                                                            | 76.18 (18.36)                                  |                                                                                           |                                                        |
|                                                                                                                  | 40.9 -145.2                                    |                                                                                           | 679                                                    |
| Never                                                                                                            |                                                | 451 48 (10.68)                                                                            | 65 (9.68) 143 (21.18) 471 (69.48)                      |
| Current                                                                                                          | 228 17 (7.58) 5i (22.48)                       | 92 (20.48) 311( (69.08)                                                                   |                                                        |
| Previous                                                                                                         | 160 (70.28)                                    |                                                                                           |                                                        |
| Pathology/Histology n. Non-Squamous -Adenocarcinoma                                                              |                                                |                                                                                           | 679                                                    |
| Non-Squamous                                                                                                     | (95.6号)                                        | 451 432 (95.8%) 4 0.98)                                                                   | 650 (95.78) 8 1.28) 4 0.6%)                            |
| Non-Scuamous Adenoscuamous Non-Souamous Bronchioloalveolar carcincma                                             | 0.4%)                                          | 4 0.98) 1 0.28) 6 1.38)                                                                   | 2 0.3号) 8 1.28) 2                                      |
| Non-Squamous Large cell Non-Squamous Sarcomatoid                                                                 | 0.9%)                                          | 2 0.48)                                                                                   | 0.38)                                                  |
| Non-Scuamous                                                                                                     |                                                | 1 0.28)                                                                                   |                                                        |
| Non-Squamous NA                                                                                                  |                                                | 1 0.28)                                                                                   | 3 0.48)                                                |
| -Unkmown                                                                                                         |                                                |                                                                                           | 0.18)                                                  |
| Non-Squamous                                                                                                     |                                                |                                                                                           |                                                        |
|                                                                                                                  |                                                |                                                                                           | 0.18)                                                  |
| n                                                                                                                |                                                |                                                                                           |                                                        |
| Positive                                                                                                         |                                                |                                                                                           |                                                        |
|                                                                                                                  |                                                | 451 56 (12.48) 73 (16.28)                                                                 | 679 79 (11.68)                                         |
|                                                                                                                  |                                                | 322 (71.48)                                                                               |                                                        |
| KRAS Mutation Status                                                                                             |                                                |                                                                                           |                                                        |
|                                                                                                                  | 23 (10.18)                                     |                                                                                           | 109 (16.18) 491 (72.38)                                |
| Negative                                                                                                         | 36 (15.88)                                     |                                                                                           |                                                        |
| Unimown                                                                                                          |                                                | 450 189 (42.0号)                                                                           |                                                        |
|                                                                                                                  |                                                | 261 (58.0号) 0                                                                             | 397 (58.6%) (0.18)                                     |
| 0 12                                                                                                             | 228 91 (39.98) 136 (59.6号)                     | 451 (50.38)                                                                               | 679                                                    |
|                                                                                                                  | 1                                              | 227 224                                                                                   | 346                                                    |
| n                                                                                                                | 228                                            |                                                                                           |                                                        |
|                                                                                                                  |                                                | (49.78)                                                                                   | 333 (49.0%)                                            |
|                                                                                                                  | 119 (52.28)                                    |                                                                                           |                                                        |
|                                                                                                                  | 109 (47.8%)                                    |                                                                                           |                                                        |
|                                                                                                                  |                                                |                                                                                           | (51.08)                                                |
| 4 Cycles                                                                                                         |                                                |                                                                                           |                                                        |
| 6 Cycles                                                                                                         |                                                |                                                                                           | 678 280 (41.38)                                        |
| Sum ofLongest Diameters (mm)at baseline n                                                                        |                                                |                                                                                           |                                                        |
| n                                                                                                                | (0.4%)                                         |                                                                                           |                                                        |
|                                                                                                                  | (74.18)                                        |                                                                                           |                                                        |
|                                                                                                                  |                                                | 449                                                                                       |                                                        |
|                                                                                                                  |                                                | 74.00                                                                                     |                                                        |
| Undifferentiated                                                                                                 |                                                |                                                                                           |                                                        |
|                                                                                                                  |                                                | 84.01 (51.46) 10.0-392.0                                                                  |                                                        |
| Baseline ECOG                                                                                                    |                                                |                                                                                           |                                                        |
| -                                                                                                                |                                                |                                                                                           |                                                        |
| EGFR mutation=                                                                                                   |                                                |                                                                                           |                                                        |
|                                                                                                                  |                                                | 677 82.29 (51.35) 71.00 10.0-392.0                                                        |                                                        |
| Data Cutoff: 15MAR2018;RAVE Data Extracted:18 May 2018.                                                          |                                                |                                                                                           |                                                        |
|                                                                                                                  | 67.00 10.0 - 287.0                             |                                                                                           |                                                        |
| Sensitizing EGER mutations include all EGFR activating mutations in exons 18-2l.ALK positive =AIK translocation. |                                                |                                                                                           |                                                        |
|                                                                                                                  | 169                                            |                                                                                           |                                                        |
| Median                                                                                                           |                                                |                                                                                           |                                                        |
| Mean (SD)                                                                                                        |                                                |                                                                                           |                                                        |
|                                                                                                                  | 228 78.90 (51.08)                              |                                                                                           |                                                        |
| Intended Cycles at Induction Tx Period                                                                           |                                                |                                                                                           |                                                        |
|                                                                                                                  |                                                | (1.8%)                                                                                    |                                                        |
| Adenocarcinoma with neuroendocrine features                                                                      |                                                |                                                                                           |                                                        |

<div style=\"page-break-after: always\"></div>

Table 16: Baseline PD-L1 expression status (ITT-WT population)

|                                           | CnP (Rendomised) (N=228)   | Ateso+CnP (Randomised) (N=451)   | All Patients (N=679)   |
|-------------------------------------------|----------------------------|----------------------------------|------------------------|
| IC3ic23 vs T0012ic0l from Initial Read    |                            |                                  |                        |
| n                                         | 228                        | 451                              | 679                    |
| TC3 or_IC2/3                              | 61 [26.81) 167             | 121 [26.81)                      | 182 (26.83)            |
| Tc0/1/2 and 1c0/1                         | (73.24)                    | 330(73.24)                       | 497 (73.24)            |
| IC31C3 vs TC012iC012 per TC31C3 Reread    |                            |                                  |                        |
|                                           | 228                        | 451                              | 679                    |
| TC3 or 1C3                                | 42(16.44)                  | 88(19.51)                        | 130 (19.1)             |
| TC0/1/2 and 1c0/1/2                       | 186 (81.64)                | 363(80.54)                       | 549(80.94)             |
| IC231C23 vs 1c011c0l per TC2IC2 Reread    |                            |                                  |                        |
| n                                         | 228                        | 451                              | 679                    |
| TC2/3 or 1C2/3                            | 81(35.54)                  | 158 (35.0)                       | 239 (35.24)            |
| Tc0/1 snd Ic0/1                           | 147(64.51)                 | 293(65.0)                        | 440 (64.8)             |
| Pe2128 101131 1ed 001001 60 8210187131    |                            |                                  |                        |
| n                                         | 228                        | 451                              | 679                    |
| TC1/2/3 or IC1/2/3                        | 107 [46.91)                | 216(47.98)                       | 323 (47.64)            |
| TcO and Ic0                               | 121 (53.14)                | 235 152.11)                      | 356 (52.48)            |
| TC/Ic 4 Ineremental Subgroups             |                            |                                  |                        |
|                                           | 228                        | 451                              | 679                    |
| TC3 or 1C3                                | 42 (18.4*)                 | 88 (19.51)                       | 130 (19.14)            |
| TC2/3 or IC2/3 exelude TC3 or IC3         | 39 (17.11)                 | 70 (15.51)                       | 109 (16.14) 90         |
| TC1/2/3 9r.IC1/2/3 emc1ude 102/3 or 1C2/3 | 27 111.031                 | 63 [14.93)                       | (13.331                |
| TCO and Ico                               | 120 (52.61)                | 230 (51.04)                      | 350 (51.5)             |

<!-- image -->

## Prior Cancer Therapy

At the time of study enrollment, 10.0% of ITT-WT patients had received at least one prior anti-cancer therapy,  with  9.0%  in  the  adjuvant/neoadjuvant  setting,  0.7%  in  other  settings,  and  0.3%  in  the metastatic setting. In the adjuvant/neoadjuvant setting, the majority of ITT-WT patients who received prior anti-cancer therapy had chemotherapy, with the most common chemotherapy treatments being cisplatin (6.3%), carboplatin (3.1%), vinorelbine (2.1%), pemetrexed disodium (1.6%), and paclitaxel (1.5%).

## Prior Surgery and Radiotherapy

Overall, 49.3% of patients in the ITT-WT population had prior surgery for cancer, with other surgeries (33.4%), lobectomy (11.5%), and fine needle aspiration (8.7%) being the most commonly reported procedures. Similar findings were observed in the ITT population.

A total of 38.3% of ITT-WT patients had received prior radiotherapy, including 29.0% of patients in the metastatic  setting,  6.2%  in  the  adjuvant/neoadjuvant  setting,  and  5.0%  in  other  settings.  Similar findings were observed in the ITT population.

## Numbers analysed

|                                                                                                                                                                                                                                                                                                                                                                                                                                                          | CnP (Randemiged) (N=240)                    | Ateso+CnP (Randemiged) (N=484)      | All Patients (N=724)                       |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------|-------------------------------------|--------------------------------------------|
| Randomined Patients Randamiwed Intent-to-TreatPatients Bafety Evalusble Patients WT in Intent-to-Treat Patients WT in Safety Evaluable Patients PRO-Evalurbie Patients for EoRrC QLQ-C30 Among the Randomised Patients PRO-Evaluable Patients for EoRrc QlQ-Cl3 Among the Randomised Patients PRO-Evalurble Patients for SliC Rmong theRandomiged Patients Measurable Disease at Baseline-INV Flag Messurable Disease at Baseline-IRF Flag ADA Evalurble | 240 240 232 228 222 184 178 133 237 227 100 | 483 473 451 386 369 253 480 467 446 | 724 723 705 679 664 570 547 386 717 69 546 |

Table 17: Overview of analysis populations

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Outcomes and estimation

## Co-primary endpoint: OS

Table 18: Time-to-event summary for OS (primary analysis - ITT-WT population)

<!-- image -->

Atezo=Atezolizumab,CnP=Carboplatin+Nab-Paclitaxel. Wild Type patients are EGFR/AiK wild type patients who did not have an activating EGFR mutation or ALK-positive disease. Censored, ^\\_Censored and event, NE = Not estimable. Summaries of Time-to-Event (median, percentiles) were Kaplan-Meier estimates. 95e CI for median was computed using\\_the method of Brookmeyer and Crowley. Hazard ratios were estimated by Cox regression. Stratification factors are: sex and PD-Ll tumor expression by IHC per IxRs.

Data Cutoff: 15MAR2018: RAVE Data Extracted: 18 May 2018.

<div style=\"page-break-after: always\"></div>

<!-- image -->

Atezo=Atezolizumab, CnP=Carboplatin+Nab-Paclitaxel.

Wild Type patients are EGFR/ALK wild type patients who did not have an activating EGFR muation or ALK-positive disease. Randomized treatments are displayed.

Stratification factors are: sex and PD-L1 tumor expression by IHC per IxRS.

Data Cutoff: 15MAR.2018; RAVE Data Extracted: 18 May 2018.

Figure 9: Kaplan-Meier plot for OS with stratified analysis (primary analysis - ITT-WT population)

## Updated OS

Table 19: Time to event summary for overall survival (cut-off: 04 September 2018)

<!-- image -->

Atezo=Atezolizumab,CnP=Carboplatin+Nab-Paclitaxel

Summaries of Time-to-Event (median, percentiles) were Kaplan-Meier estimates. 95&amp; CI for median was computed using the method of Brookmeyer and Crowley. Hazard ratios were estimated by Cox regression. Stratification factors are: sex and PD-Ll tumor expression by IHC per IxRS.

Censored, Censoredandevent，NE=Not estimable

DataCutoff:04SEP2018;RAVE DataExtracted:19 0ct 2018.

<div style=\"page-break-after: always\"></div>

Time toEventSummaryfor overallSurvival

<!-- image -->

Intent-to-Treat Patients,Wild rype

Data Cutoff:04SEP2018;RAVE Data Extracted:19 Oct 2018.

<!-- image -->

Atezo=Atezolizumab,CnP=Carboplatin+Nab-Paclitaxel.

Randomizedtreatmentsaredisplayed.

Stratificationfactorsare:sexandPD-L1tumorexpressionbyIHCperIxRS.

DataCutoff:04SEP2018;RAVEDataExtracted:19Oct2018.

Figure 10: Kaplan-Meier plot of OS with stratified analysis (ITT-WT patients)

<div style=\"page-break-after: always\"></div>

## Co-primary endpoint: PFS by INV

Table 20: Time-to-event summary for investigator-assessed PFS (primary analysis - ITT-WT population)

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

Atezo=Atezolizumab, CnP=Carboplatin+Nab-Paclitaxel.

Wild Type patients are EGFR/ALK wild type patients who did not have an activating EGFR muation or ALK-positive disease. Randomized treatments are displayed.

Stratification factors are: sex and PD-L1 tumor expression by IHC per IxRS.

Data Cutoff: 15MAR2018; RAVE Data Extracted: 18 May 2018.

Figure 11: Kaplan-meier plot for investigator-assessed PFS (primary analysis - ITT-WT population)

## Censoring

Table 21 : Reasons for Censoring from Primary PFS analysis for All Censored Patients (ITT-WT)

|                                       |                                       | CnP (N = 228)   | Atezo+CnP (N = 451)   |
|---------------------------------------|---------------------------------------|-----------------|-----------------------|
| Reason for Censoring                  | Reason for Censoring                  |                 |                       |
| Absence of events at data cutoff date | Absence of events at data cutoff date | 21 (9.2%)       | 89 (19.7%)            |
| Study discontinuation                 | Withdrawal by subject                 | 6 (2.6%)        | 10 (2.2%)             |
| Study discontinuation                 | Other                                 | 2 (0.9%)        | 4 (0.9%)              |
| Study discontinuation                 | Protocol violation                    | 1 (0.4%)        | 0                     |
| Study discontinuation                 | Non-compliance                        | 0               | 1 (0.2%)              |
| Total number of patients censored     | Total number of patients censored     | 30 (13.2%)      | 104 (23.1%)           |

PFS = Progression free survival; ITT-WT = intent to treat wild-type.

The MAH conducted a placebo multiple imputation analysis to address potential informative censoring for those 24 patients censored due to early study discontinuation.

Table 22: Placebo multiple imputation analysis in patients censored due to early study discontinuation

| PFS in ITT-WT               | HR (95% CI)          | p-value   |
|-----------------------------|----------------------|-----------|
| Primary                     | 0.643 (0.539, 0.768) | <0.0001   |
| Placebo Multiple Imputation | 0.650 (0.545, 0.776) | <0.0001*  |

<div style=\"page-break-after: always\"></div>

## Secondary endpoints

## Secondary PFS analyses

## Table 23: Time-to-event summary for investigator-assessed PFS (ITT, PD-L1 expression, and PD-L1 expression WT populations)

|                                    | CnP                   | Atezo+CnP             |
|------------------------------------|-----------------------|-----------------------|
|                                    | n=240                 | n=483                 |
| Patients with event (%)            | 209 (87.1%)           | 375 (77.6%)           |
| Median PFS (95% Cl), months        | 5.6 (4.5, 5.9)        | 7.0 (6.3, 7.3)        |
| Stratified hazard ratio (95% Cl)   | 0.65 (0.54, 0.77)     | 0.65 (0.54, 0.77)     |
| p-value (log-rank)                 | <0.0001               | <0.0001               |
| TC1/2/3 or IC1/2/3                 | n=111                 | n=230                 |
| Patients with event (%)            | 97 (87.4%)            | 168 (73.0%)           |
| Median PFS (95% CI), months        | 5.7 (4.5, 6.6)        | 7.5 (7.0, 9.1)        |
| Unstratified hazard ratio (95% Cl) | 0.55 (0.43, 0.71)     | 0.55 (0.43, 0.71)     |
| TC1/2/3 or IC1/2/3-WT              | n=107                 | n=216                 |
| Patients with event (%)            | 93 (86.9%)            | 157 (72.7%)           |
| Median PFS (95% Cl), months        | 5.9 (4.5, 6.6)        | 7.5 (7.0, 9.0)        |
| Unstratified hazard ratio (95% Cl) | 0.56 (0.43, 0.73)     | 0.56 (0.43, 0.73)     |
| Exploratory Subgroups              | Exploratory Subgroups | Exploratory Subgroups |
| TC3 or IC3-WT                      | n=42                  | n=88                  |
| Patients with event (%)            | 41 (97.6%)            | 61 (69.3%)            |
| Median PFS, months                 | 4.6                   | 6.4                   |
| Unstratified hazard ratio (95% Cl) | 0.51 (0.34, 0.77)     | 0.51 (0.34, 0.77)     |
| TC2/3 or IC2/3-WT                  | n=81                  | n=158                 |
| Patients with event (%)            | 72 (88.9%)            | 109 (69.0%)           |
| Median PFS, months                 | 5.9                   | 7.1                   |
| Unstratified hazard ratio (95% Cl) | 0.54 (0.40, 0.73)     | 0.54 (0.40, 0.73)     |
| TC1/2 or IC1/2-WT                  | n=65                  | n=128                 |
| Patients with event (%)            | 52 (80.0%)            | 96 (75.0%)            |
| Median PFS, months                 | 6.0                   | 8.3                   |
| Unstratified hazard ratio (95% Cl) | 0.61 (0.43, 0.85)     | 0.61 (0.43, 0.85)     |
| TC0/1/2 and IC0/1/2-WT             | n=186                 | n=363                 |
| Patients with event (%)            | 157 (84.4%)           | 286 (78.8%)           |
| Median PFS, months                 | 5.5                   | 7.0                   |
| Unstratified hazard ratio (95% Cl) | 0.67 (0.55, 0.82)     | 0.67 (0.55, 0.82)     |
| TCO and ICo-WT                     | n=121                 | n=235                 |
| Patients with event (%)            | 105 (86.8%)           | 190 (80.9%)           |
| Median PFS, months                 | 4.7                   | 6.2                   |
| Unstratified hazard ratio (95% Cl) | 0.72 (0.56, 0.91)     | 0.72 (0.56, 0.91)     |

<div style=\"page-break-after: always\"></div>

## Secondary OS analyses

Table 24: Time-to-event summary for OS (ITT, PD-L1 expression, and PD-L1 expression WT populations)

|                                    | CnP                   | Atezo+CnP             |
|------------------------------------|-----------------------|-----------------------|
|                                    | n=240                 | n=483                 |
| Patients with event, %             | 138 (57.5%)           | 246 (50.9%)           |
| Median OS (95% Cl). months         | 13.9(12.0, 18.2)      | 18.1 (15.3, 20.8)     |
| Stratified hazard ratio (95% Cl)   | 0.80 (0.65, 0.99)     | 0.80 (0.65, 0.99)     |
| p-value (log-rank)                 | 0.0393                | 0.0393                |
| TC1/2/3 or IC1/2/3                 | n=111                 | n=230                 |
| Patients with event, %             | 58 (52.3%)            | 104 (45.2%)           |
| Median OS (95% Cl), months         | 16.9 (12.5, 22.0)     | 21.2 (17.3, 28.2)     |
| Unstratified hazard ratio (95% Cl) | 0.75 (0.55, 1.04)     | 0.75 (0.55, 1.04)     |
| TC1/2/3 or IC1/2/3-WT              | n=107                 | n=216                 |
| Patients with event, %             | 56 (52.3%)            | 97 (44.9%)            |
| Median Os (95% Cl), months         | 16.9 (12.5, 22.0)     | 21.2 (18.1, 28.2)     |
| Unstratified hazard ratio (95% Cl) | 0.75 (0.54, 1.04)     | 0.75 (0.54, 1.04)     |
| Exploratory Subgroups              | Exploratory Subgroups | Exploratory Subgroups |
| TC3 or IC3-WT                      | n=42                  | n=88                  |
| Patients with event, %             | 23 (54.8%)            | 43 (48.9%)            |
| Median OS, months                  | 16.9                  | 17.3                  |
| Unstratified hazard ratio (95% Cl) | 0.84 (0.51, 1.39)     | 0.84 (0.51, 1.39)     |
| TC2/3 or IC2/3-WT                  | n=81                  | n=158                 |
| Patients with event, %             | 42 (51.9%)            | 75 (47.5%)            |
| Median OS, months                  | 16.9                  | 18.6                  |
| Unstratified hazard ratio (95% Cl) | 0.81 (0.55, 1.18)     | 0.81 (0.55, 1.18)     |
| TC1/2 or IC1/2-WT                  | n=65                  | n=128                 |
| Patients with event, %             | 33 (50.8%)            | 54 (42.2%)            |
| Median OS, months                  | 15.9                  | 23.7                  |
| Unstratified hazard ratio (95% Cl) | 0.70 (0.45, 1.08)     | 0.70 (0.45, 1.08)     |
| TC0/1/2 and IC0/1/2-WWT            | n=186                 | n=363                 |
| Patients with event, %             | 108 (58.1%)           | 183 (50.4%)           |
| Median OS, months                  | 13.4                  | 18.6                  |
| Unstratified hazard ratio (95% Cl) | 0.78 (0.61, 0.99)     | 0.78 (0.61, 0.99)     |
| TCO and IC0-WT                     | n=121                 | n=235                 |
| Patients with event (%)            | 75 (62.0%)            | 129 (54.9%)           |
| Median OS, months                  | 12.0                  | 15.2                  |
| Unstratified hazard ratio (95% Cl) | 0.81 (0.61, 1.08)     | 0.81 (0.61, 1.08)     |

Atezo=atezolizumab; CnP=carboplatin+nab-paclitaxel; IC=tumor-infiltrating immune cell; ITT=intent to treat; OS=overall survival; PD-L1=programmed death-ligand 1; TC=tumor cell; WT=wild type.

## Secondary endpoint: Landmark Overall Survival Rates at the 1- and 2-Year Time points

OS rates in the ITT-WT population at landmark timepoints were higher in the Atezo-CnP arm compared with the CnP arm at 1 year (63.1% vs. 55.5%) and 2 years (39.6% vs. 30.0%) after randomization. The results of this analysis were consistent with those observed in the ITT population.

<div style=\"page-break-after: always\"></div>

Secondary endpoint: Objective response rate (ORR; confirmation not required)

Table 25: Summary of unconfirmed objective response rate by investigator (ITT-WT population)

|                                                                                                             | CnP( (Randomized) (N=226)   | Atezo+CnP (Randomized) (N=447)   |
|-------------------------------------------------------------------------------------------------------------|-----------------------------|----------------------------------|
| Responders Non-Responders                                                                                   | 93 (41.23) 133 (58.8)       | 267(59.75) 180 (40.3)            |
| 95 CI for Response Rate (Clopper-Pearson) Difference in Response Rates                                      | (34.67,47.87)               | (55.02,64.31)                    |
| 95% CI for Difference in Response Rates (Wald with Continuity Correction) p-Value*(Cochran-Mantel-Haenszel) |                             |                                  |
| Odds Ratio* 95CI for Odds Ratio*                                                                            |                             |                                  |
| Complete Response (CR) 12.396                                                                               | 4(1.8%) (0.48, 4.47)        | 13(2.9) (1.56, 4.92)             |
| Partial Response (PR) 95 CI                                                                                 | 89 (39.46) (32.97,46.08)    | 254 (56.85) (52.09,61.47)        |
| Stable Disease (SD) 95CI                                                                                    | 67 (29.6) (23.77,36.06)     | 91 (20.43) (16.72,24.39)         |
| Progressive Disease (PD) 95 CI                                                                              | 40 (17.7%) (12.96, 23.31)   | 48 (10.7) (8.02, 13.98)          |
| Non-CR / Non-PD 95 CI                                                                                       | 0 (0.00, 1.62)              | 0 (0.00,0.82)                    |
| Missing or wnevaluable                                                                                      | 26 (11.5%)                  | 41 (9.23)                        |

<!-- image -->

Table 26: Summary of unconfirmed objective response rate by investigator (ITT population)

<!-- image -->

|                                                                                                              | CnP（ (Randcmized) (N=237)   |                     | Atezo+CnP (Randomized) (N=479)   |
|--------------------------------------------------------------------------------------------------------------|-----------------------------|---------------------|----------------------------------|
| Responders Non-Responders                                                                                    | 100 (42.29) 137 (57.8)      |                     | 283(59.15) 196 (40.9)            |
| 95% CI for Response Rate (Clopper-Pearson) Difference in Response Rates                                      | (35.83,48.76)               | 16.89               | (54.53,63.52)                    |
| 95g CI for Difference in Response Rates (Wald with Continuity Correction) p-Value* (Cochran-Mantel-Haenszel) |                             | (8.90,24.88) <.0001 |                                  |
| Oddls Ratio* 95CI for Odds Ratio*                                                                            |                             | 1.98 (1.44, 2.71)   |                                  |
| Ccmplete Response (CR) 95CI                                                                                  | 4 (1.7) (0.46,4.26)         |                     | 13(2.7) (1.45, 4.60)             |
| Partial Response (PR) 95CI                                                                                   | 96 (40.5) (34.20, 47.05)    |                     | 270 (56.4) (51.79,60.86)         |
| Stable Disease (SD) 95 CI                                                                                    | 69 (29.15) (23.41, 35.35)   |                     | 102 (21.3) (17.71, 25.24)        |
| Progyessive Disease (PD) 95CI                                                                                | 41_(17.3) (12.71, 22.73)    |                     | 52 (10.96) (8.21, 13.99)         |
| Non-CR / Non-PD 95CI                                                                                         | 0 (0.00, 1.54)              |                     | 0 (0.00, 0.77)                   |
| Missing or wnevaluable                                                                                       | 27 (11.4)                   |                     | 42 ( 8.8%)                       |

```
Atezo-Atezolizumab, Cnp=Carboplatin+Nab-Paclitaxel. Wald is the normal approximation. Patients were classified as missing or unevaluable when no post-baseline response assessments were available or all post-baseline responseassessments wereunevaluable. Data Cutoff:15MAR2018; RAVE Data Extracted: 18 May 2018.
```

<div style=\"page-break-after: always\"></div>

Forestplot-SubgroupAnalysisofUnconfirmedBestOverallResponseperRECiSTv1.1-Investigator MeasurableDiseaseatBL-InvestigatorinIntent-to-TreatPatients,WildType

Protocol:GO29537(DataCutoff:15MAR2018)

<!-- image -->

|                                        |                                        | CnP (Randomized) (N=226)               | CnP (Randomized) (N=226)               | CnP (Randomized) (N=226)               | Atezo+CnP (Randomized) (N=447)         | Atezo+CnP (Randomized) (N=447)         | Atezo+CnP (Randomized) (N=447)         |                                        |                                        |                                        |                               |
|----------------------------------------|----------------------------------------|----------------------------------------|----------------------------------------|----------------------------------------|----------------------------------------|----------------------------------------|----------------------------------------|----------------------------------------|----------------------------------------|----------------------------------------|-------------------------------|
| Subgroups                              | Total n                                | n                                      | n Responder                            | Response Rate (%)                      | n                                      | n Responder                            | Response Rate (%)                      | Odds Ratio                             | 95% CI                                 | CnP (Randomized) better                | Atezo+CnP (Randomized) better |
| All Patients                           | 673                                    | 226                                    | 93                                     | 41.2                                   | 447                                    | 267                                    | 59.7                                   | 2.12                                   | (1.53, 2.94)                           |                                        |                               |
| TC/IC Strat Factorfrom lxRS Group 2    | TC/IC Strat Factorfrom lxRS Group 2    | TC/IC Strat Factorfrom lxRS Group 2    | TC/IC Strat Factorfrom lxRS Group 2    | TC/IC Strat Factorfrom lxRS Group 2    | TC/IC Strat Factorfrom lxRS Group 2    | TC/IC Strat Factorfrom lxRS Group 2    | TC/IC Strat Factorfrom lxRS Group 2    | TC/IC Strat Factorfrom lxRS Group 2    | TC/IC Strat Factorfrom lxRS Group 2    | TC/IC Strat Factorfrom lxRS Group 2    |                               |
| TC3 or IC2/3                           | 182                                    | 61                                     | 27                                     | 44.3                                   | 121                                    | 81                                     | 66.9                                   | 2.55                                   | (1.36, 4.79)                           |                                        |                               |
| TC0/1/2 and ICQ/1                      | 491                                    | 165                                    | 66                                     | 40.0                                   | 326                                    | 186                                    | 57.1                                   | 1.99                                   | (1.36, 2.92)                           |                                        |                               |
| TC3IC3vs TC012IC012perTC3IC3Reread     | TC3IC3vs TC012IC012perTC3IC3Reread     | TC3IC3vs TC012IC012perTC3IC3Reread     | TC3IC3vs TC012IC012perTC3IC3Reread     | TC3IC3vs TC012IC012perTC3IC3Reread     | TC3IC3vs TC012IC012perTC3IC3Reread     | TC3IC3vs TC012IC012perTC3IC3Reread     | TC3IC3vs TC012IC012perTC3IC3Reread     | TC3IC3vs TC012IC012perTC3IC3Reread     | TC3IC3vs TC012IC012perTC3IC3Reread     | TC3IC3vs TC012IC012perTC3IC3Reread     |                               |
| TC3 or IC3                             | 130                                    | 42                                     | 19                                     | 45.2                                   | 88                                     | 59                                     | 67.0                                   | 2.46                                   | (1.16, 5.23)                           |                                        |                               |
| TC0V1/2 and IC0H1/2                    | 543                                    | 184                                    | 74                                     | 40.2                                   | 359                                    | 208                                    | 57.9                                   | 2.05                                   | (1.43, 2.94)                           |                                        |                               |
| TC23ICZ3vsTC01IC01perTC2IC2 Reread     | TC23ICZ3vsTC01IC01perTC2IC2 Reread     | TC23ICZ3vsTC01IC01perTC2IC2 Reread     | TC23ICZ3vsTC01IC01perTC2IC2 Reread     | TC23ICZ3vsTC01IC01perTC2IC2 Reread     | TC23ICZ3vsTC01IC01perTC2IC2 Reread     | TC23ICZ3vsTC01IC01perTC2IC2 Reread     | TC23ICZ3vsTC01IC01perTC2IC2 Reread     | TC23ICZ3vsTC01IC01perTC2IC2 Reread     | TC23ICZ3vsTC01IC01perTC2IC2 Reread     | TC23ICZ3vsTC01IC01perTC2IC2 Reread     |                               |
| TC2/3 orIC2/3                          |                                        | 81                                     | 34                                     | 42.0                                   | 157                                    | 108                                    | 68.8                                   | 3.05                                   | (1.75, 5.31)                           |                                        |                               |
| TC0/1 and IC0/1                        | 435                                    | 145                                    | 59                                     | 40.7                                   | 290                                    | 159                                    | 54.8                                   | 1.77                                   | (1.18, 2.65)                           |                                        |                               |
| TC123IC123 vs TC0IC0 per TC1IC1 Reread | TC123IC123 vs TC0IC0 per TC1IC1 Reread | TC123IC123 vs TC0IC0 per TC1IC1 Reread | TC123IC123 vs TC0IC0 per TC1IC1 Reread | TC123IC123 vs TC0IC0 per TC1IC1 Reread | TC123IC123 vs TC0IC0 per TC1IC1 Reread | TC123IC123 vs TC0IC0 per TC1IC1 Reread | TC123IC123 vs TC0IC0 per TC1IC1 Reread | TC123IC123 vs TC0IC0 per TC1IC1 Reread | TC123IC123 vs TC0IC0 per TC1IC1 Reread | TC123IC123 vs TC0IC0 per TC1IC1 Reread |                               |
| TC1/2/3orIC1/2/3                       | 321                                    | 106                                    | 49                                     | 46.2                                   |                                        | 141                                    | 65.6                                   | 2.22                                   | (1.38, 3.56)                           |                                        |                               |
| TC0 and IC0                            | 352                                    | 120                                    | 44                                     | 36.7                                   | 212                                    | 126                                    | 54.3                                   | 2.05                                   | (1.31, 3.23)                           |                                        |                               |

Atezo=Atezolizumab,CnP=Carboplatin+Nab-Paclitaxel.

Wild Typepatients areEGFR/ALKwild typepatientswhodid nothavean activating EGFRmuation orALK-positivedisease. NE=Not estimable.BL=Baseline.Oddsratiosrelative to CnPandWaldconfidenceinterval were estimated using unstratifiedlogisticregression.Theverticaldashedlineindicatestheoddsratioforallpatients.Thediameterof DataCutoff:15MAR2018;RAVEDataExtracted:18May2018.

Figure 12: Subgroup analysis of ORR by PD-L1 expression level (ITT-WT population)

Secondary endpoint: Duration of response (DOR; confirmation not required)

|                                                                                                                                                              | CnP( (Randomized) (N=93)                                      | Atezo+CnP (Randomized) (N=267)                                    |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------|-------------------------------------------------------------------|
| Patients with event (t) Earliest contributing event Death Disease Progression Patients without event Time to Event (Months) Median 95CI 25tand 756-ile Range | 79 (84.96) 6 73 14 (15.1) 5.4 (3.9, 5.8) 2.8,9.1 0.3 to 17.8* | 183 (68.5) 17 166 84(31.54) 6.7 (5.6, 8.0) 3.4,17.9 0.0* to 24.3* |
| Unstratified Analysis p-value (log-rank)                                                                                                                     |                                                               | 0.0002                                                            |
| Hazard Ratio 95 CI                                                                                                                                           |                                                               | 0.600 (0.458,0.785)                                               |
| Stratified Analysis p-value (log-rank)                                                                                                                       |                                                               | 0.0002                                                            |
| Hazard Ratio 95+ CI                                                                                                                                          |                                                               | 0.599 (0.457, 0.786)                                              |

Table 27: Summary of unconfirmed duration of response (ITT-WT population, patients with unconfirmed response assessed by investigator per RECIST v1.1)*

<!-- image -->

<div style=\"page-break-after: always\"></div>

*Formal  hypothesis  testing  was  not  performed.  The  p  values  and  hazard  ration  estimates  are  for  descriptive  purpose  only.

<!-- image -->

Atezo=Atezolizumab,CnP=Carboplatin+Nab-Paclitaxel.

Wild Type patients are EGFR/ALK wild type patients who did not have an activating EGFR muation or ALK-positive disease. Randomized treatments are displayed.

Data Cutoff: 15MAR2018; RAVE Data Extracted: 18 May 2018.

Figure 13: Kaplan-meier plot for unconfirmed duration of response (ITT-WT population, patients with unconfirmed response assessed by investigator per RECIST v1.1)

<div style=\"page-break-after: always\"></div>

Table 28: Summary of unconfirmed duration of response (ITT population, patients with unconfirmed response assessed by investigator per RECIST v1.1)*

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

Atezo=Atezolizumab, CnP=Carboplatin+Nab-Paclitaxel Randomized treatments are displayed.

Data Cutoff: 15MAR2018: RAVE Data Extracted: 18 May 2018.

Figure 14: Kaplan-meier plot for unconfirmed duration of response among patients with unconfirmed response assessed by investigator per RECIST v1.1 (ITT population)

Secondary endpoint: Time to deterioration (TTD) in patient-reported lung cancer symptoms per EORTC questionnaires

At baseline (i.e., randomization/C1D1), before initiating study treatment, patients in both arms in the PRO-evaluable WT population had similar mean (SD) PRO scores in lung-related symptoms of cough (Atezo-CnP 40.76 [29.54] vs. CnP 41.76 [26.91]), chest pain (20.14 [27.86] vs. 18.82 [26.37]), and dyspnoea (27.66 [24.78] vs. 29.67 [23.37]) on the EORTC QLQ-LC13, based on a 0-100 scale, with 100 being the most severe, indicating that most patients reported low symptom burden at baseline with the exception of cough.

Delayed deterioration of lung-related symptoms (cough, chest pain, or dyspnoea) was observed in the ITT-WT population favoring Atezo-CnP (median 2.2 months) over CnP (median 1.9 months; HR=0.89; range:  0.71-1.12).  A  confirmed  deterioration  in  symptoms  or  an  initial  deterioration  in  symptoms followed by death was documented in 71.6% versus 66.5% patients receiving Atezo-CnP versus CnP, respectively. The event-free rate at 6 months was higher in the Atezo-CnP arm (34.2%) versus the CnP arm (30.1%) and remained higher in the Atezo-CnP arm (26.1%) versus the CnP arm (17.6%) at 1 year.

Secondary  endpoint:  Change  from  baseline  in  patient-reported  lung  cancer  symptoms  using  the Symptoms in Lung Cancer (SILC) scale

At baseline (i.e., randomization/C1D1), before initiating study treatment, patients in both arms in the PRO-evaluable WT population had similar mean (SD) PRO scores in lung-related symptoms of chest pain (Atezo-CnP 1.05 [1.08] vs. CnP 0.93 [1.03]), cough (1.48 [1.03] vs. 1.55 [0.99]), and dyspnoea (1.24 [1.02] vs. 1.16 [0.99]) on the SILC, based on a 0-4 scale, with 4 being the most severe, confirming minimal symptom burden at baseline.

Cough, chest pain, and dyspnoea scores were less severe throughout the study for patients receiving Atezo-CnP, with larger differences seen for dyspnoea followed by chest pain and minimal differences between arms for cough. Cough and chest pain were the first symptoms to show improvement as early as Week  3  following  a  first  report  of  deterioration  after  treatment  initiation.  Dyspnoea  scores  showed clinically meaningful deterioration (mean change in score &gt;0.3) between Weeks 8 and 14 in patients receiving Atezo-CnP and between Weeks 2 and 24 in patients receiving CnP; however, patients in the Atezo-CnP  arm  reported  lower  mean  severity  scores  compared  with  patients  receiving  CnP  when dyspnoea was at its worst (1.61 [1.08] at Week 11 vs. 1.75 [1.13] at Week 13, respectively).

<div style=\"page-break-after: always\"></div>

Secondary endpoint: Proportion of patients improved, remained stable, worsened in patients-reported lung cancer symptoms, HRQOL and functioning

At baseline (i.e., randomization/C1D1), before initiating study treatment, patients in both arms in the PRO-evaluable WT population had similar mean (SD) PRO scores in HRQoL and functioning as measured by global health status (60.34 [23.92] vs. 57.43 [22.45]), physical functioning (72.81 [23.23] vs. 71.20 [22.01]), and role functioning (64.85 [32.30] vs. 62.19 [31.57]) on the EORTC QLQ-C30, based on a 0-100  scale,  with  100  being  the  best  HRQoL/functioning,  indicating  moderate-to-high  HRQoL  and functioning at baseline.

Patients in both arms reported no clinically meaningful changes (defined as a ≥10 point difference in 0-100 score) for HRQoL, physical functioning, and role functioning. Patients in both arms reported a worsening during the weeks of induction followed by a rebound towards baseline scores during the maintenance phase, following induction. The proportion of patients who improved, remained stable, or worsened on these domains were relatively similar (within approximately 10%) for patients in both arms.

At baseline (i.e., randomization/C1D1), before initiating study treatment, patients in both arms had similar mean (SD) PRO scores in lung-related symptoms as measured by fatigue (39.53 [27.77] vs. 42.03 [24.78]), diarrhoea (5.79 [14.27] vs. 7.81 [18.81]), constipation (20.07 [28.90] vs. 19.05 [27.08]), nausea/vomiting (8.82 [17.69] vs. 10.38 [20.42]), and sore mouth (3.71 [13.98] vs. 3.73 [13.78]) on the EORTC QLQ-C30 and EORTC QLQ-LC13, based on a 0-100 scale, with 100 being the most severe, indicating minimal symptom burden at baseline, with the exception of fatigue. There were no clinically meaningful changes detected from baseline in any of the common treatment-related symptoms assessed by the EORTC QLQ-C30 and EORTC QLQ-LC13 (i.e., fatigue, diarrhoea, constipation, nausea/vomiting, and  sore  mouth)  in  either  treatment  arm.  Although  patients  in  both  arms  reported  worsening  in symptoms during the induction phase, changes from baseline in symptoms were nominal in both arms during  the  maintenance  phase.  All  treatment-related  symptoms  returned  to  baseline  following  the completion of platinum-based chemotherapy.

## Exploratory endpoints: Confirmed ORR

Table 29: Confirmed Best Overall Response per RECIST v1.1 - ITT-WT

|                                                                                                              | CnP（ (Randomized) (N=226)   |                     | Atezo+CnP (Randomized) (N=447)   |
|--------------------------------------------------------------------------------------------------------------|-----------------------------|---------------------|----------------------------------|
| Responders Non-Responders                                                                                    | 72 (31.98) 154 (68.18)      |                     | 220 (49.28) 227 (50.88)          |
| 95& CI for Response Rate (Clopper-Pearson) Difference in Response Rates                                      | (25.84, 38.36)              | 17.36               | (44.49, 53.96)                   |
| 95% CI for Difference in Response Rates (Wald with Continuity Correction) p-Value* (Cochran-Mantel-Haenszel) |                             | (9.38,25.33) <.0001 |                                  |
| Odds Ratio* 95CI for Odds Ratio*                                                                             |                             | 2.07 (1.48, 2.89)   |                                  |
| Complete Response (CR) 958CI                                                                                 | 3(1.3%) (0.27,3.83)         |                     | 11 (2.58) (1.23,4.36)            |
| Partial Response (PR) 95$CI                                                                                  | 69(30.5%) (24.60, 36.98)    |                     | 209 (46.8%) (42.05, 51.50)       |
| Stable Disease (SD) 958CI                                                                                    | 86_(38.18) (31.70,44.73)    |                     | 136 (30.48) (26.19, 34.92)       |
| Progressive Disease (PD) 95%CI                                                                               | 41 (18.18) (13.34,23.80)    |                     | 49 (11.0%) (8.22,14.23)          |
| Non-CR / Non-PD 95%CI                                                                                        | 0 (0.00, 1.62)              |                     | 0 (0.00,0.82)                    |
| Missing or unevaluable                                                                                       | 27 (11.98)                  |                     | 42(9.48)                         |

Atezo=Atezolizumab, CnP=Carboplatin+Nab-Paclitaxel

Wald is the normal approximation.

Data Cutoff:15MAR2018;RAVE Data Extracted:18May 2018.

Patients were classified as missing or unevaluable when no post-baseline response assessments were available or all post-baseline response assessments were unevaluable.

## Exploratory endpoints: Confirmed DOR

<div style=\"page-break-after: always\"></div>

Table 30: Time to Event Summary for Duration of confirmed Response per RECIST v1.1 - ITT-WT*

<!-- image -->

Atezo=Atezolizumab,CnP=Carboplatin+Nab-Paclitaxel.

* Censored,^Censored and event，NE = Not estimable.

Wild Type patients are EGFR/ALK wild type patients who did not have an activating EGFR muation or AIK-positive disease.

Summaries of Time-to-Event (median, percentiles) were Kaplan-Meier estimates. 95&amp; CI for median was computed using the method of by IHC per IxRS.

Brookmeyer and Crowley.Hazard ratios were estimated by Cox regression. Stratification factors are: sex and PD-Ll tumor expression

Data Cutoff:15MAR2018;RAVE DataExtracted:18May 2018.

*Formal hypothesis testing was not performed. The p values and hazard ration estimates are for descriptive purpose only.

## Ancillary analyses

Time to event summary for patients who received pemetrexed in the CnP arm in the WT population

Overall, 49 patients (21%) in the CnP arm received at least 1 cycle of pemetrexed; in the WT population, 45 patients (20%) received at least 1 cycle of pemetrexed

Table 31: Time to Event Summary for Investigator Assessed PFS (ITT-WT Population, Assigned CnP and Pemetrexed Treated)

<!-- image -->

Wild TypepatientsareEGrR/AlKwildtype patients who did not have an activatingEGFRmutation or ALK-positive disease. Atezo=Atezolizumab,CnP=Carboplatin+Nab-Paclitaxel. Censored,^ Censored and event,NE=Not estimable. Summaries of Time-to-Event (median,percentiles) were Kaplan-Meier estimates. 95&amp; CI for median was computed using the method of Brookmeyerand Crowley.

DataCutoff:15MAR2018;RAVR Data Extracted:18 May 2018.

<div style=\"page-break-after: always\"></div>

Table 32: Time to Event Summary for Overall Survival (ITT-WT Population, Assigned CnP and Pemetrexed Treated)

<!-- image -->

|                                                                                   | CnP（Randomized) (N=45)            |
|-----------------------------------------------------------------------------------|-----------------------------------|
| Patients with event(&) Rarliest contributing event Death Patients without event() | 20（44.48) 20 25(55.68)            |
| Time to Event （Months) Median 95CI 25and 75s-ile Range                            | 19.9 (16.9,NE) 13.9,NE 5.7to27.4* |
| Time Point Analysis 1year Patients remaining at risk Event Free Rate (s) 95CI     | 36 80.00 (68.31,91.69)            |
| years Patients remaining at risk Bvent Free Rate （) 95CI                          | 5 48.09 (31.35,64.82)             |

Wild Type patients are BGrR/ALKwild type patients who did nothave an activating EGFR mutation or ALK-positive disease. Atezo=Atezolizumab,CnP=Carboplatin+Nab-Paclitaxel. *Censored, Censored and event，NE = Not estimable.

DataCutoff:15MAR2018;RAVEDataExtracted:18May2018.

Summaries of Time-to-Event (median,percentiles) were Kaplan-Meier estimates.95s CI for median was computed using the method of Brookmeyer and Crowley.

## Subgroup analysis for PFS:

<!-- image -->

|                                              |              | CnP (Randomized) (N=228)   | CnP (Randomized) (N=228)   | CnP (Randomized) (N=228)   | Atezo+CnP (Randomized) (N=451)   | Atezo+CnP (Randomized) (N=451)   | Atezo+CnP (Randomized) (N=451)   |                      |                                             |                        |                  |
|----------------------------------------------|--------------|----------------------------|----------------------------|----------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------|---------------------------------------------|------------------------|------------------|
| Subgroups                                    | Tolal n      | Median                     | Median                     | Median                     | Median                           | Median                           | Median                           | Hazard               | 95% Wald                                    | Ateze+CnP (Randomized) | CnP (Randomized) |
|                                              |              | n                          | Everts                     | (Months)                   |                                  | Events (Moetha)                  |                                  | Ratio                | CI                                          | beter                  | bifter           |
| All Patierts                                 | 679          | 228                        | 198                        | 5.5                        | 451                              | 347                              | 7.0                              | 0.54                 | (0.53, 0.76)                                |                        |                  |
| Se Femile Male                               | 279 400      | 94 134                     | 79 119                     | 4.8 5.6                    | 18.5 266                         | 138 602                          | 7.4 6.4                          | 0.59 0.67            | (0.45, 0.78) 00.54, 0.86)                   |                        |                  |
| Tobacco Use History Never Curert or Previous | 614          | 17 Z11                     | 16 182                     | 4,6                        | 48 403                           | 4                                | B1 i9                            | 0.53 0.64            | (0.35, 1.12 (0.53, 0.77                     |                        |                  |
| Age Croup (years) ≤65 65-to 74 75·to 84 2=85 | 341 258 77 3 | 114 84 29                  | 99 72 26                   | 5.5 4.8 8.5 2.7            | 227 174 48 2                     | 173 138. 34                      | 6.8 7.1 66                       | 0.64 0.65 c[L.01 850 | (0.50, 0.82) (0.49, 0.87) (0.34, 0.98) N00) |                        |                  |
| Liver Metastasis at Enrolliment. Yes No      | 100 579      | 31 197                     | 26 172                     | 4.4 5.6                    | 69 382                           | 61 286                           | 42 7.3                           | 0.93 0.59            | (0.59, 1.47 (0.49, 0.71                     |                        |                  |
| DaselneEcoG 2                                | 280 A        | 136 1                      | 78 119 1                   | 5.6 5.0 3.7                | 189 261                          | 142 205                          | 7.9 6.1                          | 0.59 0.68 NE         | 00.44, 0.78) (0.54, 0.86) (NE.NE}           |                        |                  |

Atezo=Atezolizumab, CnP=Carboplatin+Nab-Paclitaxel.

Wild Type patients are EGFR/ALK wild type patients who did not have an activating EGFR muation or ALK-positive disease.

NE = Not estimable; Median progression-free survival was estimated from Kaplan-Meier method. Unstratified hazard ratio relative to CnP and 95% Cl for the hazard ratio were estimated using Cox regression. The vertical dashed line indicates the hazard ratio for all patients, The diameter of the circle is proportional to the square root of the total number of events.

Randomized treatments are displayed.

Data Cutoff: 15MAR2018; RAVE Data Extracted: 18 May 2018.

Figure 15: Subgroup analysis of investigator-assessed PFS by selected demographics and baseline disease characteristics (ITT-WT population)

<div style=\"page-break-after: always\"></div>

<!-- image -->

|                                       |                                       | CnP(Randomized) (N=228)               | CnP(Randomized) (N=228)               | CnP(Randomized) (N=228)               | Alezo+CnP(Randomized) (N=451)         | Alezo+CnP(Randomized) (N=451)         | Alezo+CnP(Randomized) (N=451)         |                                       |                                       |                                |                         |
|---------------------------------------|---------------------------------------|---------------------------------------|---------------------------------------|---------------------------------------|---------------------------------------|---------------------------------------|---------------------------------------|---------------------------------------|---------------------------------------|--------------------------------|-------------------------|
| subgroups                             | Total n                               | n                                     | Events                                | Median (Months)                       | n                                     | Events                                | Median (Monthis)                      | Hazard Ratio                          | 95% Wald CI                           | Atezo+CnP (Randomized) better  | CnP (Randomized) better |
| All Patients                          | 679                                   | 228                                   | 198                                   | 5.5                                   | 451                                   | 347                                   | 7.0                                   | 0.64                                  | (0.53, 0.76)                          |                                |                         |
| Lymph Node Metastasis at Enrollment   | Lymph Node Metastasis at Enrollment   | Lymph Node Metastasis at Enrollment   | Lymph Node Metastasis at Enrollment   | Lymph Node Metastasis at Enrollment   | Lymph Node Metastasis at Enrollment   | Lymph Node Metastasis at Enrollment   | Lymph Node Metastasis at Enrollment   | Lymph Node Metastasis at Enrollment   | Lymph Node Metastasis at Enrollment   |                                |                         |
| Yes                                   | 463                                   | 159                                   | 140                                   | 弱                                     | 304                                   | 922                                   | 7.0                                   | 0.63                                  | (0.51,0.78)                           |                                |                         |
| No                                    | 216                                   | 69                                    | 58                                    |                                       | 147                                   | 111                                   | 6.9                                   | 0.65                                  | (0.47,0.89)                           |                                |                         |
| Adrenal GlandMetastasis at Enrollment | Adrenal GlandMetastasis at Enrollment | Adrenal GlandMetastasis at Enrollment | Adrenal GlandMetastasis at Enrollment | Adrenal GlandMetastasis at Enrollment | Adrenal GlandMetastasis at Enrollment | Adrenal GlandMetastasis at Enrollment | Adrenal GlandMetastasis at Enrollment | Adrenal GlandMetastasis at Enrollment | Adrenal GlandMetastasis at Enrollment |                                |                         |
| Yes No                                | 129 550                               | 185 43                                |                                       | 3.6                                   | 365                                   | 2号                                    | 另差                                    | 0.79 0.60                             | (0.53,1.19) (0.49,0.73)               |                                |                         |
|                                       |                                       |                                       |                                       |                                       |                                       |                                       | 7.0                                   |                                       | (0.55, 0.80) (0.24, 0.75)             |                                |                         |
| Brain Metastasis at Enrollment        | Brain Metastasis at Enrollment        | Brain Metastasis at Enrollment        | Brain Metastasis at Enrollment        | Brain Metastasis at Enrollment        | Brain Metastasis at Enrollment        | Brain Metastasis at Enrollment        | Brain Metastasis at Enrollment        | Brain Metastasis at Enrollment        | Brain Metastasis at Enrollment        | Brain Metastasis at Enrollment |                         |
| Yes                                   | 67                                    | 27                                    |                                       |                                       | 40                                    | 32                                    | 7.0                                   | 0.43                                  |                                       |                                |                         |
| No                                    | 612                                   | 201                                   |                                       |                                       | 1                                     | 315                                   |                                       | 0.66                                  |                                       |                                |                         |
| BoneMetastasisatEnrollment Yes        | 189                                   |                                       | 1.48                                  |                                       |                                       | 111                                   | 59                                    | 0.74                                  | (0.54,1.03)                           |                                |                         |
| No                                    | 490                                   |                                       |                                       |                                       |                                       | 236                                   |                                       | 0.60                                  | (0.48, 0.74)                          |                                |                         |

Atezo=Atezolizumab,CnP=Carboplatin+Nab-Paclitaxel.

WildTypepatientsareEGFR/ALKwildtypepatientswhodidnothaveanactivatingEGFRmuationorALK-positivedisease. NE = Not estimable; Median progression-free survival was estimated from Kaplan-Meier method. Unstratified hazard ratio relative to CnP and 95%Clfor the hazard ratiowere estimated using Coxregression.Thevertical dashed line indicates thehazard ratiofor all patients.The diameter of the circle is proportional to the squareroot of the total number of events. Randomizedtreatmentsaredisplayed.

DataCutoff:15MAR2018:RAVEDataExtracted:18May2018.

Figure 16 : Forest Plot - Subgroup Analysis of Investigator-Assessed PFS (ITT -WT patients )

## Subgroup analysis for OS:

<!-- image -->

|                                          |            | CrP (Randomized) (N=228)   | CrP (Randomized) (N=228)   | CrP (Randomized) (N=228)   | Abezo+CnP (Randomized) (N=品1)   | Abezo+CnP (Randomized) (N=品1)   | Abezo+CnP (Randomized) (N=品1)   |                   |                                                      |                        |                  |
|------------------------------------------|------------|----------------------------|----------------------------|----------------------------|---------------------------------|---------------------------------|---------------------------------|-------------------|------------------------------------------------------|------------------------|------------------|
|                                          | Total in   | Median                     | Median                     | Median                     |                                 |                                 | Mecian                          | Hiazard           | 95% Wald                                             | Afeza+CnP (Randomized) | CnP (Randomi2ed) |
| Subgroupa                                |            |                            | Evants (Morths)            |                            |                                 | Ewirts (Months)                 |                                 | Ratlo             |                                                      | Beber                  | bdter            |
| All Patients                             | 679        | 228                        | 131                        | 13.9                       | 451                             | 226                             | 18.6 0.79                       |                   | (60 90)                                              |                        |                  |
| Sex Female Malle                         | 279 400    | 94 134                     | 52 79                      | 12.8 14.2                  | 185 99E                         | 83 143                          | 21.4 16.0                       | 0.66 0.87         | (0.46, 0.93) (0.66, 1.15)                            |                        |                  |
| Never Cumer't or Previous                | 614        | 17 211                     | 10 f21                     | 19.5 6EI                   | 48 403                          | iZ                              | 28.2 18.1                       | 0.55 0.81         | 0.25, 1.19 0.65, 1.02                                |                        |                  |
| Tobaicco Use History                     | 55         |                            |                            |                            | 227                             | 902                             |                                 |                   |                                                      |                        |                  |
| Age Group (years) 65 651o 74 75tn 84 =85 | 341 258 77 | 114 84 29 1                | 63 50 17 1                 | 15.6 10.0 187 5.5          | 174 48                          | 108 97 19                       | 19.2 14.4 28.2 9.0              | 60 0.84 0.54 0.71 | 40.58. 1.08) 40.60.1.19) (0.27, 1.05) 00:.04, 11.79) | 中 0                    |                  |
| Livrer Metastasis at:Enirellment. Yes No | 100 579    | IE 197                     | 22 604                     | 88 15.2                    | 382                             | 52 174                          | 10.0 21.1                       | 1.04 6/'0         | 221 90 26 0°50                                       |                        |                  |
| BasHline ECOG                            | 280        | 1                          | 45 85                      | 19.7 11.9                  | 189                             | 88                              | 20.8                            | 0.85              | (0.59, 1.22) (0.58, 1.00)                            |                        |                  |
|                                          | 397        |                            |                            | 3.7                        | 261                             | 138                             |                                 |                   |                                                      |                        |                  |
| 1 2                                      |            | 136                        |                            |                            |                                 |                                 | 15.2                            | 0.77              |                                                      |                        |                  |
|                                          |            |                            |                            |                            |                                 |                                 |                                 |                   |                                                      |                        | 2                |
|                                          |            | 1                          |                            |                            |                                 |                                 |                                 |                   |                                                      |                        |                  |
|                                          |            |                            | 1                          |                            |                                 |                                 |                                 |                   | ( NE, NE]                                            |                        |                  |
|                                          |            |                            |                            |                            |                                 |                                 |                                 | NE                |                                                      |                        |                  |
|                                          | 1          |                            |                            |                            |                                 |                                 |                                 |                   |                                                      |                        |                  |
|                                          |            |                            |                            |                            |                                 |                                 |                                 |                   |                                                      | 1/2                    |                  |
|                                          |            |                            |                            |                            |                                 |                                 |                                 |                   | 1/5                                                  |                        |                  |

Atezo=Atezolizumab, CnP=Carboplatin+Nab-Paclitaxel.

Wild Type patients are EGFR/ALK wild type patients who did not have an activating EGFR muation or ALK-positive disease. NE = Not estimable; Median survival was estimated from Kaplan-Meier method. Unstratified hazard ratio relative to CnP and 95% Cl for the hazard ratio were estimated using Cox regression. The vertical dashed line indicates the hazard ratio for all patients. The diameter of the circle is proportional to the square root of the total number of events.

Randomized treatments are displayed.

Data Cutoff: 15MAR2018; RAVE Data Extracted: 18 May 2018.

Figure 17: Subgroup analysis of overall survival by selected demographics and baseline characteristics (ITT-WT population)

<div style=\"page-break-after: always\"></div>

<!-- image -->

|                                        |                                        | CnP(Randomized) (N=228)                | CnP(Randomized) (N=228)                | CnP(Randomized) (N=228)                | Atezo+CnP(Randomized) (N=451)          | Atezo+CnP(Randomized) (N=451)          | Atezo+CnP(Randomized) (N=451)          |                                        |                                        |                                        |                                        |                                        |
|----------------------------------------|----------------------------------------|----------------------------------------|----------------------------------------|----------------------------------------|----------------------------------------|----------------------------------------|----------------------------------------|----------------------------------------|----------------------------------------|----------------------------------------|----------------------------------------|----------------------------------------|
| subgroups                              | Total n                                | n                                      | Events                                 | Median (Months)                        | n                                      | Events                                 | Median (Monthis)                       | Hazard Ratio                           |                                        | 95% Wald CI                            | Atezo+CnP (Randomized) better          | CnP (Randomized) better                |
| All Patients                           | 679                                    | 228                                    | 131                                    | 13.9                                   | 451                                    | 226                                    | 18.6                                   | 0.79                                   |                                        | (0.63, 0.97)                           |                                        |                                        |
| Lymph Node Metastasis at Enrollment    | Lymph Node Metastasis at Enrollment    | Lymph Node Metastasis at Enrollment    | Lymph Node Metastasis at Enrollment    | Lymph Node Metastasis at Enrollment    | Lymph Node Metastasis at Enrollment    | Lymph Node Metastasis at Enrollment    | Lymph Node Metastasis at Enrollment    | Lymph Node Metastasis at Enrollment    | Lymph Node Metastasis at Enrollment    | Lymph Node Metastasis at Enrollment    | Lymph Node Metastasis at Enrollment    | Lymph Node Metastasis at Enrollment    |
| Yes                                    | 463                                    | 159                                    | 35                                     | 13.4                                   | 304                                    | 154                                    | 18.6                                   | 0.76                                   |                                        | (0.59,0.98)                            |                                        |                                        |
| No                                     | 216                                    | 69                                     |                                        | 15.9                                   | 147                                    | 72                                     | 18.6                                   |                                        | 0.87                                   | (0.58, 1.30)                           |                                        |                                        |
| Adrenal Gland Melastasis at Enrollment | Adrenal Gland Melastasis at Enrollment | Adrenal Gland Melastasis at Enrollment | Adrenal Gland Melastasis at Enrollment | Adrenal Gland Melastasis at Enrollment | Adrenal Gland Melastasis at Enrollment | Adrenal Gland Melastasis at Enrollment | Adrenal Gland Melastasis at Enrollment | Adrenal Gland Melastasis at Enrollment | Adrenal Gland Melastasis at Enrollment | Adrenal Gland Melastasis at Enrollment | Adrenal Gland Melastasis at Enrollment | Adrenal Gland Melastasis at Enrollment |
| Yes No                                 | 129 550                                | 43 185                                 | 164                                    | 133                                    |                                        | 粥                                      | 14.9 19.2                              |                                        | 0.93 0.75                              | (0.57,1.51) (0.59,0.96)                |                                        |                                        |
| Brain Metastasis atEnrollment          | Brain Metastasis atEnrollment          | Brain Metastasis atEnrollment          | Brain Metastasis atEnrollment          | Brain Metastasis atEnrollment          | Brain Metastasis atEnrollment          | Brain Metastasis atEnrollment          | Brain Metastasis atEnrollment          | Brain Metastasis atEnrollment          | Brain Metastasis atEnrollment          | Brain Metastasis atEnrollment          | Brain Metastasis atEnrollment          | Brain Metastasis atEnrollment          |
| Yes                                    | 67                                     | 27                                     | 15                                     | 12.1                                   | 40                                     | 18                                     | 18.7                                   |                                        | 0.72                                   | (0.36, 1.44)                           |                                        |                                        |
| No                                     | 612                                    | 201                                    | 116                                    | 14.2                                   | 411                                    | 208                                    | 18.6                                   |                                        | 0.79                                   | (0.63, 1.00)                           |                                        |                                        |
| Bone Metastasis atEnrollment Yes       | 189                                    |                                        |                                        |                                        |                                        | 81                                     | 12.5                                   |                                        | 0.79                                   | (0.55,1.14)                            |                                        |                                        |
| No                                     | 490                                    |                                        | 45                                     | 183                                    | 125                                    |                                        |                                        |                                        | 0.77                                   | (0.59, 1.01)                           |                                        |                                        |

Atezo=Atezolizumab,CnP=Carboplatin+Nab-Paclitaxel.

Wild Type patients are EGFR/ALK wild type patients who did nothave an activating EGFR muation or ALK-positive disease. NE=Notestimable;MediansurvivalwasestimatedfromKaplan-Meiermethod.UnstratifiedhazardratiorelativetoCnP and 95%Clfor the hazard ratio were estimated using Cox regression. The vertical dashed line indicates the hazard ratiofor allpatients.The diameterof thecircleisproportional tothesquarerootof thetotal numberofevents.

Randomizedtreatmentsaredisplayed.

DataCutoff.15MAR2018:RAVEDataExtracted:18May2018.

Figure 18 : Forest Plot - Subgroup Analysis of Overall Survival (ITT -WT patients )

<!-- image -->

|                                   |                                   | CnP(Randomized) (N=31)            | CnP(Randomized) (N=31)            | Atezo+CnP(Randomized) (N=69)      | Atezo+CnP(Randomized) (N=69)      | Atezo+CnP(Randomized) (N=69)      |                                   |                                   |                                   |                                   |                                   |
|-----------------------------------|-----------------------------------|-----------------------------------|-----------------------------------|-----------------------------------|-----------------------------------|-----------------------------------|-----------------------------------|-----------------------------------|-----------------------------------|-----------------------------------|-----------------------------------|
|                                   | Total n                           | Median                            | Median                            |                                   |                                   | Median                            | Median                            | Hazard                            | PIPM %S6                          | Atezo+CnP (Randomized)            | CnP (Randomized)                  |
| Subgroups                         |                                   | n                                 | Events                            | (Months)                          | n                                 | Events                            | (Months)                          | Ratio                             | CI                                | better                            | better                            |
| AllPatients                       | 100                               | 31                                | 22                                | 8.8                               | 69                                | 52                                | 10.0                              | 1.04                              | (0.63, 1.72)                      |                                   |                                   |
| TC/ICStratFactorfromIxRSGroup2    | TC/ICStratFactorfromIxRSGroup2    | TC/ICStratFactorfromIxRSGroup2    | TC/ICStratFactorfromIxRSGroup2    | TC/ICStratFactorfromIxRSGroup2    | TC/ICStratFactorfromIxRSGroup2    | TC/ICStratFactorfromIxRSGroup2    | TC/ICStratFactorfromIxRSGroup2    | TC/ICStratFactorfromIxRSGroup2    | TC/ICStratFactorfromIxRSGroup2    |                                   |                                   |
| TC3orIC2/3 TC0/1/2andIC0/1        |                                   | 6 22                              | .6 16                             | 8.9                               | 29                                | 13                                | 10.9 9.6                          | 0.84 1.16                         | (0.31.2.24) (0.65.2.08)           |                                   |                                   |
| TC3IC3vsTC012IC012perTC3IC3Reread | TC3IC3vsTC012IC012perTC3IC3Reread | TC3IC3vsTC012IC012perTC3IC3Reread | TC3IC3vsTC012IC012perTC3IC3Reread | TC3IC3vsTC012IC012perTC3IC3Reread | TC3IC3vsTC012IC012perTC3IC3Reread | TC3IC3vsTC012IC012perTC3IC3Reread | TC3IC3vsTC012IC012perTC3IC3Reread | TC3IC3vsTC012IC012perTC3IC3Reread | TC3IC3vsTC012IC012perTC3IC3Reread |                                   |                                   |
| TC3orIC3 TC0/1/2 and IC0/1/2      | 23                                | 7 24                              | 5 17                              | 14.4 8.5                          | 16 53                             | 10 42                             | 13.1 8.7                          | 0.89 1.11                         | (0.30.2.64) (0.63. 1.96)          |                                   |                                   |
| TC23IC23vsTC01IC01perTC2IC2Reread | TC23IC23vsTC01IC01perTC2IC2Reread | TC23IC23vsTC01IC01perTC2IC2Reread | TC23IC23vsTC01IC01perTC2IC2Reread | TC23IC23vsTC01IC01perTC2IC2Reread | TC23IC23vsTC01IC01perTC2IC2Reread | TC23IC23vsTC01IC01perTC2IC2Reread | TC23IC23vsTC01IC01perTC2IC2Reread | TC23IC23vsTC01IC01perTC2IC2Reread | TC23IC23vsTC01IC01perTC2IC2Reread |                                   |                                   |
| TC2/3orIC2/3 TCO/1 and IC0/1      | 34 66                             | 9                                 | .6 16                             | 8.8 8.7                           | 25                                | 18 34                             | 9.6 10.0                          | 0.96 1.07                         | (0.37.2.47) (0.59.1.94)           |                                   |                                   |
| TC1/2/3or IC1/2/3                 |                                   | 22                                |                                   | 15.9                              | 28                                | 21                                | 10.3                              | 1.11                              |                                   |                                   |                                   |
| TC123IC123vsTC0IC0perTC1IC1Reread | TC123IC123vsTC0IC0perTC1IC1Reread | TC123IC123vsTC0IC0perTC1IC1Reread | TC123IC123vsTC0IC0perTC1IC1Reread | TC123IC123vsTC0IC0perTC1IC1Reread | TC123IC123vsTC0IC0perTC1IC1Reread | TC123IC123vsTC0IC0perTC1IC1Reread | TC123IC123vsTC0IC0perTC1IC1Reread | TC123IC123vsTC0IC0perTC1IC1Reread | TC123IC123vsTC0IC0perTC1IC1Reread | TC123IC123vsTC0IC0perTC1IC1Reread | TC123IC123vsTC0IC0perTC1IC1Reread |
|                                   | 40                                | 12                                | 8                                 |                                   |                                   | 31                                |                                   |                                   | (0.49.2.53)                       |                                   |                                   |
|                                   | 60                                | 19                                | 14                                | 7.4                               |                                   |                                   | 8.7                               | 1.05                              | (0.56. 1.98)                      |                                   |                                   |
| TC12IC12Patients (0.39,5.37)      | TC12IC12Patients (0.39,5.37)      | TC12IC12Patients (0.39,5.37)      | TC12IC12Patients (0.39,5.37)      | TC12IC12Patients (0.39,5.37)      | TC12IC12Patients (0.39,5.37)      | TC12IC12Patients (0.39,5.37)      | TC12IC12Patients (0.39,5.37)      | TC12IC12Patients (0.39,5.37)      | TC12IC12Patients (0.39,5.37)      | TC12IC12Patients (0.39,5.37)      | TC12IC12Patients (0.39,5.37)      |
| TCO and ICO                       |                                   |                                   |                                   |                                   |                                   | 11                                | 8.7                               | 1.45                              |                                   |                                   |                                   |
| TC1/2orIC1/2                      | 17                                | 5                                 | 3                                 | 15.9                              | 12                                |                                   |                                   |                                   |                                   |                                   |                                   |

Wild Type patients are EGFR/ALK wild type patients who did not have an activating EGFR mutation or ALK-positive disease. Atezo=Atezolizumab,CnP=Carboplatin+Nab-Paclitaxel.

NE =Notestimable; Median survival wasestimated fromKaplan-Meier method.Unstratified hazard ratiorelative to CnP

Randomizedtreatmentsaredisplayed.

DataCutoff:15MAR2018;RAVEDataExtracted:18May2018.

Figure 19: Forest plot - subgroup analysis of OS (ITT-WT population) liver metastasis at baseline

## Sensitivity Analysis for PFS

## Missing Tumour Assessment

At the time of clinical cutoff date (CCOD), 6 patients in Atezo+CnP arm and 3 patients in CnP arm missed two or more tumor assessments prior to the date of disease progression or death in ITT-WT population. The potential impact of missing tumor assessment on PFS was assessed by the following sensitivity analyses:

Patients who missed two or more scheduled assessments immediately prior to the date of disease progression per RECIST v1.1 or death were censored at the last tumor assessment prior to the missed visits.

<div style=\"page-break-after: always\"></div>

Patients who missed two or more scheduled assessments immediately prior to the date of disease progression per RECIST v1.1 or death were counted as having progressed on the date of the first of these missing assessments.

| PFS in ITT-WT           | HR (95% CI)          | p-value   |
|-------------------------|----------------------|-----------|
| Primary Analysis        | 0.643 (0.539, 0.768) | <0.0001   |
| Sensitivity Analysis a) | 0.641 (0.536, 0.766) | <0.0001*  |
| Sensitivity Analysis b) | 0.643 (0.539, 0.768) | <0.0001*  |

HR = hazard ratio; ITT-WT = intent to treat- wild type; PFS = progression-free survival.

*p-value of sensitivity analysis is for descriptive purpose only.

Potential Impact of Non-Protocol-Specified Anti-Cancer Therapy (NPT)

At the time of CCOD, 9 patients in Atezo+CnP arm and 8 patients in CnP arm received NPT before a PFS event.  The potential impact of NPT on PFS was assessed using a sensitivity analysis by which patients who received NPT before a PFS event were censored at the last tumor assessment date before receipt of NPT.

| PFS in ITT-WT        | HR (95% CI)          | p-value   |
|----------------------|----------------------|-----------|
| Primary Analysis     | 0.643 (0.539, 0.768) | <0.0001   |
| Sensitivity Analysis | 0.626 (0.522, 0.750) | <0.0001*  |

HR = hazard ratio; ITT-WT = intent to treat- wild type; PFS = progression-free survival. *p-value of sensitivity analysis is for descriptive purpose only.

PFS by Independent Review Facility (IRF)

PFS as assessed by the IRF was defined as the time from randomization to the first documented PD, as determined by the IRF using RECIST v1.1, or death from any cause, whichever occurred first.

At the time of the CCOD, 506 deaths or PD events had occurred among patients in the ITT-WT population for the Atezo-CnP and CnP arms combined; the event/patient ratio was 72.9% in the Atezo-CnP arm, 77.6% in the CnP arm, and 74.5% overall.

The stratified HR was 0.75 (95% CI: 0.63, 0.91) in the ITT-WT population. PFS as assessed by the IRF in the ITT-WT population was consistent with the primary analysis of investigator-assessed PFS.

<div style=\"page-break-after: always\"></div>

Table 33: Time-to-event summary for IRF-assessed PFS (sensitivity analysis - ITT-WT population)

<!-- image -->

|                                                                                                          | CnP (Randomized) (N=228)           | Atezo+CnP (Randomized) (N=451)   |
|----------------------------------------------------------------------------------------------------------|------------------------------------|----------------------------------|
| Patients with event （&) Earliest contributing event Death Disease Progression Patients without event (8) | 177 (77.68) 71 106 51 (22.48)      | 329 (72.98) 91 238 122 (27.18)   |
| Time to Event (Months) Median 958CI 25g and 75s-ile Range                                                | 6.4 (5.6,7.4) 3.0,11.2 0.0^to 25.6 | (6.7,8.3) 4.0,15.7 0.0*to 29.8   |
| Unstratified Analysis p-value (log-rank)                                                                 |                                    | 0.0017                           |
| Hazard Ratio 958CI                                                                                       |                                    | 0.746 (0.621, 0.897)             |
| Stratified Analysis p-value (log-rank)                                                                   |                                    | 0.0026                           |
| Hazard Ratio 958 CI                                                                                      |                                    | 0.754 (0.627,0.907)              |
| Time Point Analysis 6 Months                                                                             |                                    |                                  |
| Patients remaining at risk Event Free Rate（ (8) 958 CI                                                   | 102 51.82 (45.03, 58.60)           | 249 57.97 (53.34,62.60)          |
| Difference in Event Free Rate 958CI p-value (Z-test) year Patients remainingat risk                      |                                    | 6.15 (-2.06,14.37) 0.1421 128    |
| Event Free Rate (名) 1096                                                                                 | 36 23.16 (17.07, 29.25)            | 32.32 (27.85,36.79)              |
| Difference in Event Free Rate 958CI p-value (Z-test)                                                     |                                    | 9.16 (1.61,16.71) 0.0174         |

Atezo=Atezolizumab,CnP=Carboplatin+Nab-Paclitaxel, ALK-positive disease. Censored, ^ Censored and event, NE = Not estimable. Summaries of Time-to-Event (median, percentiles) were Kaplan-Meier estimates. 95s CI for median was computed using the method of Brookmeyer and Crowley.Hazard ratios were estimated by Cox Data Cutoff:15MAR2018;RAVE Data Extracted:18 May 2018.

<!-- image -->

Atezo=Atezolizumab, CnP=Carboplatin+Nab-Paclitaxel.

Wild Type patients are EGFR/ALK wild type patients who did not have an activating EGFR muation or ALK-positive disease. Randomized treatments are displayed.

Stratification factors are: Sex and PD-L1 tumor expression by IHC per IxRS.

Data Cutoff: 15MAR2018; RAVE Data Extracted: 18 May 2018.

Figure 20: Kaplan-Meier plot for IRF-assessed PFS with stratified analysis (sensitivity analysis - ITT-WT population)

## Patients eligible for maintenance therapy

<div style=\"page-break-after: always\"></div>

Table 34: Subgroup Analyses of PFS for Patients Eligible for Maintenance Therapy According to Maintenance Received (ITT-WT)

|                           | CnP Pem+ (N=40)   | CnP Pem - (N=67)   | Atezo+CnP Atezo main. (N=274)   |
|---------------------------|-------------------|--------------------|---------------------------------|
| Progression-Free Survival |                   |                    |                                 |
| Event                     | 33 (83%)          | 59 (88%)           | 190 (69%)                       |
| Median (mon, 95%CI)       | 8.6 (8.1, 12.6)   | 7.4 (6.5, 9.0)     | 10.0 (8.6, 11.4)                |
| Unstratified HR (95%CI)*  |                   | 1.43 (0.93 ,2.20)  | 0.78 (0.53, 1.13)               |

*Reference group: CnP maintenance eligible, received pemetrexed maintenance

CnP = carboplatin+Nab-Paclitaxel; CI = confidence interval; HR = hazard ratio; mon = months; NE = not evaluable; OS = overall survival; PFS = progression free survival; ITT = intent-to-treat; WT = wild type.

## Sensitivity Analysis for OS

## Potential Impact of NPT

At the time of CCOD, the proportion of patients who received at least one NPT was similar between the two treatment arms in the ITT-WT population (Atezo + CnP 39.0% vs. CnP 39.5%)

Table 35: Non-Protocol Follow-up Cancer Therapy Regimens (ITT-WT)

|                          | CnP (All Randomized) (n = 228)   | CnP (Randomized And Received Pem Maintenance) (n = 45)   | Atezo+CnP (All Randomized) (n = 451)   |
|--------------------------|----------------------------------|----------------------------------------------------------|----------------------------------------|
| Patient with >=1 regimen | 90 (39.5%)                       | 15 (33.3%)                                               | 176 (39.0%)                            |
| Patient with >=2 regimen | 20 (8.8%)                        | 1 (2.2%)                                                 | 55 (12.2%)                             |
| Patient with >=3 regimen | 4 (1.8%)                         | 0                                                        | 16 (3.5%)                              |

ITT-WT = Intent-to-treat, Wild Type. Data cut-off: 15 March 2018

In the Atezo + CnP arm, the most common treatments received were chemotherapy (34.1%) and targeted therapy (11.1%).  In the CnP arm, the most common treatments received were chemotherapy (23.2%) and immunotherapies (19.3%).  Among immunotherapies, anti -PD-1 or anti-PD-L1 agents were the most common.

The potential impact of NPT on OS was assessed by a discount method in the ITT-WT population.  Survival time after patients received NPT was discounted at 30% for both treatment arms.

The results of this analysis are presented in the table below.

<div style=\"page-break-after: always\"></div>

Table 36: Time-to-event summary for OS discounting for non-protocol-specified anti-cancer therapy (sensitivity analysis - ITT-WT population)

<!-- image -->

| OS in ITT-WT         | HR (95% CI)          | p-value   |
|----------------------|----------------------|-----------|
| Primary Analysis     | 0.791 (0.637, 0.982) | 0.0331    |
| Sensitivity Analysis | 0.790 (0.637, 0.981) | 0.0322*   |

HR = hazard ratio; ITT-WT = intent to treat- wild type; OS = overall survival. *p-value of sensitivity analysis is for descriptive purpose only.

Source: Primary CSR Section 5.2.3.1.

The potential impact of NPT on OS was also assessed by a rank preserving structural failure time method which provides an estimate of the OS time for the control group had NPT not occurred (Robins and Tsiatis 1991).  The HR was estimated to be 0.778.

## Delayed Clinical Effect

The OS K -M curves started to separate at approximately 2 months (minimal delay).  The potential impact of delayed clinical effect on OS was assessed by a weighted log-rank analysis in the ITT-WT population, whereby a piecewise linear weight function was specified (Lin and Leon 2017) assuming no treatment effect during the first month or the first two months, respectively, and then a full treatment effect afterwards.  The corresponding unstratified weighted log-rank test p-values of Atezo+CnP compared with CnP were 0.0197 and 0.0328, respectively.

## Loss to Follow-up

<div style=\"page-break-after: always\"></div>

At the time of CCOD, one patient (CnP arm) was lost to follow-up.  The potential impact of loss to follow-up on OS was assessed using a sensitivity analysis by which the two treatment arms are compared for any patients lost to follow-up and considered as having died at the last date they were known to be alive.

| OS in ITT-WT         | HR (95% CI)          | p-value   |
|----------------------|----------------------|-----------|
| Primary Analysis     | 0.791 (0.637, 0.982) | 0.0331    |
| Sensitivity Analysis | 0.785 (0.633, 0.974) | 0.0276*   |

Source: t\\_ef\\_lm\\_IT\\_WT\\_os\\_15Mar2018\\_29537; t\\_ef\\_lm\\_IT\\_WT\\_osltfu\\_15Mar2018\\_29537.

## Patients eligible for maintenance therapy

Table 37: Subgroup Analyses of OS for Patients Eligible for Maintenance Therapy According to Maintenance Received (ITT-WT) (Cut-off 4. September 2018)

|                          | CnP Pem + (N = 40)   | CnP Pem - (N = 68)   | Atezo + CnP Atezo main. (N = 279)   |
|--------------------------|----------------------|----------------------|-------------------------------------|
| Overall Survival         |                      |                      |                                     |
| Event                    | 19 (48%)             | 32 (47%)             | 124 (44%)                           |
| Median (mon, 95%CI)      | 24.4 (17.0, NE)      | 24.5 (20.6, NE)      | 28.2 (25.0, NE)                     |
| Unstratified HR (95%CI)* |                      | 1.05 (0.59, 1.86)    | 0.91 (0.56, 1.47)                   |

CnP = carboplatin+Nab-Paclitaxel; CI = confidence interval; HR = hazard ratio; mon = months; NE = not evaluable; OS = overall survival; ITT = intent-to-treat; WT = wild type.

Figure 21: Kaplan-Meier plot of OS by assigned arm and by maintenance treatment received (ITT-WT)

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

Atezo=Atezolizumab.CnP=Carboplatin+Nab-Paclitaxel.

WildTypepatientsareEGFR/ALKwildtypepatientswhodidnothaveanactivatingEGFRmutationorALK-positivedisease.

The5patientseligibleforAtezolizumabmaintenancetherapyanddidnotreceiveitarenotdisplayed.

Arm A:Atezo+=Assigned Atezo+CnPand Received Atezo in Maintenance:Arm B:PEM+=Assigned CnPand Received Pemetrexed in Maintenance:Arm B:PEM-=Assigned CnPand Did Not Receive PemetrexedinMaintenance.

DataCutoff04SEP2018:RAVE Data Extracted:19 Oct 2018.

Figure 22: Kaplan-Meier plot of overall survival in patients received maintenance treatment (ITT-WT) (Cut-off 4. September 2018)

Table 38: Additional Sensitivity Analysis of updated OS (ITT-WT) (Cut-off 4 September 2018)

|                             | HR (95% CI)          |
|-----------------------------|----------------------|
| Supplemental Results Report | 0.824 (0.675, 1.006) |
| Multiple Imputation         | 0.840 (0.677, 1.043) |

HR = hazard ratio; OS = Overall Survival; ITT = Intent -to -Treat; Wild Type.

Sensitivity analyses to evaluate the impact of crossover on OS:

The MAH conducted the following sensitivity analyses to evaluate the impact of crossover on OS:

## 1. Discount Methods

Survival time after patients crossed over was discounted at 10%, 20%, and 30%, as follows:

- 10% discount: The stratified HR was 0.77 (95% CI: 0.62, 0.95), and the median OS discounting for crossover with benefit reduction of 10% was 13.5 months for the CnP arm in the ITT-WT population
- 20% discount: The stratified HR was 0.74 (95% CI: 0.60, 0.92), and the median OS discounting for crossover with benefit reduction of 20% was 13.5 months for the CnP arm in the ITT-WT population
- 30% discount: The stratified HR was 0.72 (95% CI: 0.58,0.89), and the median OS discounting for crossover with benefit reduction of 30% was 12.8 months for the CnP arm in the ITT-WT population
2. Rank Preserving Structural Failure Time (RPSFT): The stratified HR was 0.71, and the median OS was estimated to be 12.9 months in the CnP arm in the ITT-WT population.

## Immunogenicity

<div style=\"page-break-after: always\"></div>

Table 39: Baseline prevalence and post-baseline incidence of ADA to atezolizumab among atezolizumab-treated patients (ADA-evaluable population)

| Baseline ADA-evaluable patients                 | Atezo+CnP n=451   | CnP (Crossover Patients) n=84   |
|-------------------------------------------------|-------------------|---------------------------------|
| No. of patients positive for ADA (%)            | 14 (3.1%)         | 4 (4.8%)                        |
| No. of patients negative for ADA                | 437               | 80                              |
| Post-baseline ADA-evaluable patients            | n=446             | n=85                            |
| No. of patients positive for ADA (%)            | 100 (22.4%)       | 20 (23.5%)                      |
| No. of patients with treatment-induced ADA·     | 98                | 20                              |
| No. of patients with treatment-enhanced ADA b   | 2                 | 0                               |
| No. of patients negative for ADA                | 346               | 65                              |
| No. of patients with treatment-unaffected ADA c | 12                | 4                               |

ADA=anti-drug antibody (also known as anti-therapeutic antibody): Atezo=atezolizumab; CnP=carboplatin+nab-paclitaxel.

- Treatment-induced ADA refers to patients who had a baseline negative ADA result who developed ADA at any time after initial drug administration.
- Treatment-enhanced ADA refers to patients who had a baseline positive ADA result in any time after initial drug administration.
- Treatment-unaffected ADA refers topatients who had a baseline positive ADA result in whom the assay signal was not enhanced (not greater than baseline titer by 20.60 titer units) at any time after initial drug administration. These patients are considered post-baseline negative for ADA.

Note: See Shankar et al. (2014) for further details on the definition of treatment-induced. treatment-enhanced, transient, and persistent ADA.

<div style=\"page-break-after: always\"></div>

Table 40: PFS by investigator and OS by atezolizumab ADA status (ADA-evaluable WT population)

|                                                                           | Atezo + CnP                                     |                                 |
|---------------------------------------------------------------------------|-------------------------------------------------|---------------------------------|
| Parameter                                                                 | Atezo ADA-Negative                              | Atezo ADA-Positive              |
| Investigator-Assessed Progression-Free Survival                           | Investigator-Assessed Progression-Free Survival |                                 |
| N No. of patients with event (%) Median time to event, months 95% CI      | 320 242 (75.6%) 7.3 (6.9, 8.3)                  | 95 75 (78.9%) 7.2 (6.1, 8.3)    |
| 6 months                                                                  | 186                                             | 54                              |
| 1 year No. of patients remaining at risk Event-free rate,% 95% CI         | 96 32.52 (27.30, 37.74)                         | 23 26.78 (17.55, 36.01)         |
| Overall Survival                                                          |                                                 |                                 |
| N No. of patients with event (%) Median time to event, months 95% CI      | 320 150 (46.9%) 20.8 (18.2, 29.8)               | 95 46 (48.4%) 19.2 (15.7, 25.1) |
| 1 year No. of patients remaining at risk Event-free rate,% 95% CI 2 years | 205 66.84 (61.62, 72.06)                        | 62 69.59 (60.18, 79.00)         |

ADA = anti-drug antibody; Atezo = atezolizumab; CnP = carboplatin + nab-paclitaxel; WT = wild type.

## Treatment beyond progression

A  total  of  308  patients  randomized  to  the  Atezo+CnP  arm  from  the  safety-evaluable  population experienced PD and were included in these analyses. Of these 308 patients:

- 253 patients received anti-cancer therapy beyond the first PD.
- o 151 patients were treated on or after first PD with atezolizumab (group 1).
- o 102 patients received other NPT (Group 2).
- 55 patients did not receive any anti-cancer treatment after the first PD (Group 3).

<div style=\"page-break-after: always\"></div>

<!-- image -->

AletomAleeolirumab CnP=Carbepiatin+Nab-Pacltacel DataCutoff: 15MAR2018:RAvE Data Exdracted:1&amp; May 2018

Figure 23: Kaplan-meier plot for post-progression OS in patients treated with atezolizumab beyond PD in the atezo+CnP arm (safety-evaluable population)

Table 41: Time-to-event summary for post-progression OS in patients treated with atezolizumab beyond PD in the atezo+CnP arm (safety-evaluable population)

Time to Event Summary for Overall Survival on or after First PD Safety-Evaluable\\_Patients, Reported Disease Progression, Atezo+CnP (Arm A) Protocol:G029537 (Data Cutoff:15MAR2018)

<!-- image -->

| Overall Survival from First PD                                                       | Atezo Treated On or After First PD (N=151)   | Other Anti-cancer Therapy On or After First PD (N=102)   | No Atezo or NPT Treatment On or After First PD (N=55)   | Atezo Treated Patients Reported Disease Progression (N=308)   |
|--------------------------------------------------------------------------------------|----------------------------------------------|----------------------------------------------------------|---------------------------------------------------------|---------------------------------------------------------------|
| Patients with event （8) Earliest contributing event Death Patients without event (8) | 69 (45.7%) 69 82 (54.38)                     | 65 (63.7%) 65 37 (36.3%)                                 | 45 (81.88) 45 10 (18.2%)                                | 179 (58.18) 179 129 (41.9%)                                   |
| Time Since First PD to Event (Months) Median 958 CI 258and 758-ile Range             | 12.3 (10.2, 14.4) 6.0, 18.0 0.1* to 24.8*    | 7.0 (6.0, 8.8) 4.1, 18.9 0.4* to 18.9                    | 0.0* to 19.8                                            | 8.3 (6.7, 9.8) 3.8, 15.6 0.0* to 24.8*                        |
| Time Point Analysis 6 Months                                                         |                                              |                                                          |                                                         |                                                               |
| Patients remaining at risk Event Free Rate (&) 958CI                                 | 88 75.57 (68.27, 82.87)                      | 54 58.03 (48.21, 67.85)                                  | 19.16 (7.31, 31.01)                                     | 149 86'65 (54.21, 65.75)                                      |
| year Patients remaining at risk Event Free Rate (&) 958 CI                           | 33 51.54 (41.64, 61.44)                      | 18 36.26 (26.33, 46.18)                                  | 2 (0.00, 16.04)                                         | 53 38.79 (32.44,45.14) 14                                     |
| 1/2years Patients remaining at risk Event Free Rate (%) 1056                         | 11 27.57 (16.05, 39.09)                      | 2 25.38 (14.03,36.73)                                    | 1 3.65 (0.00,10.33)                                     | 22.50 (15.38, 29.62)                                          |

Results from the OS analysis on or after first PD in the CnP arm for each of the three groups, i.e., patients who received immunotherapy, patients who received other anti-cancer therapies, and patients who didn't receive any further treatment after documented PD, are shown in the figure below.

<div style=\"page-break-after: always\"></div>

Figure 24: Kaplan-Meier Plot of Overall Survival on or after First PD in CnP arm (safety-evaluable patients)

<!-- image -->

Overall survival on or after the first instance of progressive disease (PD) in the atezo+CnP arm and pemetrexed-treated CnP arm was examined for each of the three groups, i.e., patients who received subsequent immunotherapy (including crossover to atezo, treatment beyond progression with atezo, and non-protocol therapies), patients who received other anti-cancer therapies, and patients who did not receive any further treatment after documented PD.

In the atezo+CnP arm (numbers updated for the ITT-WT population), 283 atezo treated patients who reported PD were included into this analysis. Out of the 283 patients, 162 had died (57.2%).

In the CnP arm, among the 45 pemetrexed-treated ITT-WT patients, 36 patients had PD and were included in this analysis (the other 9 patients had no PD as of the clinical cut-off date [CCOD]). Out of the 36 patients, 18 (50%) patients had died.

Distribution of the patients between three groups in both the arms (atezo+CnP and CnP arm) is provided in the table below.

Table 42: Number of patients who received subsequent therapies on or after first progressive diseaseITT -WT population

| Subsequent Therapies Received                                                                         | Atezo+CnP n= 283   | CnP+ pemetrexed-treated n=36   |
|-------------------------------------------------------------------------------------------------------|--------------------|--------------------------------|
| Any immunotherapy as anti-cancer treatment in second line (2L) and subsequent lines of therapy (2L+)* | 139 (49%)          | 29 (80%)                       |
| Other anti-cancer therapy                                                                             | 96 (34%)           | 1 (3%)                         |
| No treatment                                                                                          | 48 (17%)           | 6 (17%)                        |

<div style=\"page-break-after: always\"></div>

<!-- image -->

Atezo=Atezolizumab,CnP=Carboplatin+Nab-Paclitaxel. Wild Type patients are EGFR/ALK wild type patients who did not have an activating EGFR mutation or ALK-positive disease. Group 1:AtezoTreated On orAfter First PD, Group 2:Other Anti-cancer Therapy On or After First PD. Group 3: No Atezo or Other Anti-Cancer Treatment On or After First PD.

Data Cutoff: 15MAR2018;RAVE Data Extracted:18 May 2018.

PD = Progressive disease.

Figure 25: Kaplan-Meier Plot of Overall Survival on or after First PD in atezo+CnP arm (safety-evaluable patients, wild type)

<!-- image -->

Atezo=Atezolizumab.CnP=Carboplatin+Nab-Paclitaxel.

WildTypepatients areEGFR/ALKwild typepatientswho did not havean activatingEGFRmutationorALK-positivedisease. Group 1:Immunotherapy (including Crossover and NPT)Treated On or After First PD,Group 2:OtherAnti-cancer Therapy On orAfter First PD,Group 3:NoTreatment On or After First PD DataCutoff:15MAR2018:RAVEDataExtracted:18May2018.

PD = Progressive Disease; NE = Not evaluable.

Figure 26: Kaplan-Meier Plot of Overall Survival on or after First PD in CnP arm pemetrexed-treated (safety evaluable patients, WT)

Table 43: Number of patients in CnP arm who received subsequent therapies on or after first progressive disease - ITT -WT population

|                         | Immunotherapy (including Crossover and NPT) Treated On or After First PD (n=29)   |   Other Anti-cancer On or After First PD (n=1) | No Treatment On or After First PD (n=6)   | CnP Treated Patients Reported Disease Progression (n=36)   |
|-------------------------|-----------------------------------------------------------------------------------|------------------------------------------------|-------------------------------------------|------------------------------------------------------------|
| Patients with event (%) | 13 (44.8%)                                                                        |                                              0 | 5 (83.3%)                                 | 18 (50.0%)                                                 |

Patients without event (%)

16 (55.2%)

1 (100%) NE

1 (16.7%)

18 (50.0%) 11.9 (6.1, NE)

Time Since First PD to Event 15.3 (7.3, NE)

(Months, median 95% CI)

1.3 (0.1, 10.2)

<div style=\"page-break-after: always\"></div>

NE = not evaluable; NPT = non protocol therapy; PD = progressive disease; ITT-WT = Intent-to-Treat, Wild Type.

## Summary of main study

The following table summarises the efficacy results from the main study supporting the present application. This summary should be read in conjunction with the discussion on clinical efficacy as well as the benefit risk assessment (see later sections).

## Summary of efficacy for trial GO29537

Title: Phase III, Multicenter, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Atezolizumab (MPDL3280A, Anti-PD-L1 Antibody) in Combination with Carboplatin+Nab-Paclitaxel for Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer.

Study identifier

Design

Hypothesis

Treatments groups

Endpoints and definitions

Database lock

## Results and Analysis

| Analysis description                                         | Primary Analysis                                                                                                                                                                               | Primary Analysis                                                                                                                                                                               | Primary Analysis                                                                                                                                                                               |
|--------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Analysis population and time point description               | ITT-WT population (subset of ITT excluding patients with activating EGFR mutation or ALK translocation) time point: Primary analysis PFS, OS (CCOD 15 March 2018) Updated OS (CCOD 4-Sep 2018) | ITT-WT population (subset of ITT excluding patients with activating EGFR mutation or ALK translocation) time point: Primary analysis PFS, OS (CCOD 15 March 2018) Updated OS (CCOD 4-Sep 2018) | ITT-WT population (subset of ITT excluding patients with activating EGFR mutation or ALK translocation) time point: Primary analysis PFS, OS (CCOD 15 March 2018) Updated OS (CCOD 4-Sep 2018) |
| Descriptive statistics and estimate variability (stratified) | Treatment group                                                                                                                                                                                | Atezo+CnP                                                                                                                                                                                      | CnP                                                                                                                                                                                            |
| Descriptive statistics and estimate variability (stratified) | ITT-WT - Number of subject                                                                                                                                                                     | 451 456                                                                                                                                                                                        | 228 229                                                                                                                                                                                        |
| Descriptive statistics and estimate variability (stratified) | OS (Median (months))                                                                                                                                                                           | 18.6 18.1                                                                                                                                                                                      | 13.9 13.5                                                                                                                                                                                      |
| Descriptive statistics and estimate variability (stratified) | 95%-CI                                                                                                                                                                                         | (16.0, 21.2) (15.1, 20.8)                                                                                                                                                                      | (12.0, 18.7) (11.9, 17.7)                                                                                                                                                                      |
| Descriptive statistics and estimate variability (stratified) | PFS (Median (months))                                                                                                                                                                          | 7.0                                                                                                                                                                                            | 5.5                                                                                                                                                                                            |
| Descriptive statistics and estimate variability (stratified) | 95%-CI                                                                                                                                                                                         | (6.2, 7.3)                                                                                                                                                                                     | (4.4, 5.9)                                                                                                                                                                                     |
| Effect estimate per comparison                               | OS                                                                                                                                                                                             | Comparison groups                                                                                                                                                                              | Atezo+CnP vs. CnP                                                                                                                                                                              |
| Effect estimate per comparison                               | OS                                                                                                                                                                                             | HR                                                                                                                                                                                             | 0.791 0.824                                                                                                                                                                                    |
| Effect estimate per comparison                               | OS                                                                                                                                                                                             | 95%-CI                                                                                                                                                                                         | (0.637-0.982) (0.675-1.006)                                                                                                                                                                    |
| Effect estimate per comparison                               | OS                                                                                                                                                                                             | P-value                                                                                                                                                                                        | 0.0331 0.0568                                                                                                                                                                                  |

GO29537 (IMpower130)

A multicenter, randomized, open-label, controlled trial

Duration of main phase:

Duration of Run-in phase:

Duration of Extension phase:

Superiority

Atezo+CnP

CnP

Primary

(ITT-WT)

Secondary

(ITT)

18 May 2018

16-April-2015 to 04-Sep 2018 (data cutoff)

not applicable not applicable

Atezolizumab+carboplatin+nab-paclitacel,  n =

483

carboplatin+nab-paclitacel, n = 240

Death due to any cause

Progression free survival by RECIST 1.1 according investigator

Death due to any cause

Progression free survival by RECIST 1.1 according investigator

OS

PFS

OS

PFS

<div style=\"page-break-after: always\"></div>

|                                                 | PFS                                                                                                                                                                                           | HR                                                                                                                                                                                            | 0.643                                                                                                                                                                                         |
|-------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                 |                                                                                                                                                                                               | 95%-CI                                                                                                                                                                                        | (0.539 - 0.768)                                                                                                                                                                               |
|                                                 |                                                                                                                                                                                               | P-value                                                                                                                                                                                       | < 0.0001                                                                                                                                                                                      |
| Notes                                           | The analysis indicates a statistical significant superiority with regard to PFS, but not in terms of OS of Atezo+CnP vs. CnP alone in the ITT-WT population                                   | The analysis indicates a statistical significant superiority with regard to PFS, but not in terms of OS of Atezo+CnP vs. CnP alone in the ITT-WT population                                   | The analysis indicates a statistical significant superiority with regard to PFS, but not in terms of OS of Atezo+CnP vs. CnP alone in the ITT-WT population                                   |
| Analysis description                            | Secondary Analyses                                                                                                                                                                            | Secondary Analyses                                                                                                                                                                            | Secondary Analyses                                                                                                                                                                            |
| Analysis population and time point description  | Intent to treat time point: final analysis PFS, 1 st interim analysis OS                                                                                                                      | Intent to treat time point: final analysis PFS, 1 st interim analysis OS                                                                                                                      | Intent to treat time point: final analysis PFS, 1 st interim analysis OS                                                                                                                      |
| Descriptive statistics and estimate variability | Treatment group                                                                                                                                                                               | Atezo+CnP                                                                                                                                                                                     | CnP                                                                                                                                                                                           |
| Descriptive statistics and estimate variability | ITT- - Number of subject                                                                                                                                                                      | 483                                                                                                                                                                                           | 240                                                                                                                                                                                           |
| Descriptive statistics and estimate variability | OS (Median (months))                                                                                                                                                                          | 18.1                                                                                                                                                                                          | 13.9                                                                                                                                                                                          |
| Descriptive statistics and estimate variability | 95%-CI                                                                                                                                                                                        | (15.2, 20.8)                                                                                                                                                                                  | (12.0, 18.2)                                                                                                                                                                                  |
| Descriptive statistics and estimate variability | PFS (Median (months))                                                                                                                                                                         | 7.0                                                                                                                                                                                           | 5.6                                                                                                                                                                                           |
| Descriptive statistics and estimate variability | 95%-CI                                                                                                                                                                                        | (6.3, 7.3)                                                                                                                                                                                    | (4.5, 5.9)                                                                                                                                                                                    |
| Effect estimate per comparison                  | OS                                                                                                                                                                                            | Comparison groups                                                                                                                                                                             | Atezo+CnP vs. CnP                                                                                                                                                                             |
| Effect estimate per comparison                  |                                                                                                                                                                                               | HR                                                                                                                                                                                            | 0.80                                                                                                                                                                                          |
| Effect estimate per comparison                  |                                                                                                                                                                                               | 95%-CI                                                                                                                                                                                        | (0.65 - 0.99)                                                                                                                                                                                 |
| Effect estimate per comparison                  |                                                                                                                                                                                               | P-value                                                                                                                                                                                       | 0.0393                                                                                                                                                                                        |
| Effect estimate per comparison                  | PFS                                                                                                                                                                                           | HR                                                                                                                                                                                            | 0.65                                                                                                                                                                                          |
| Effect estimate per comparison                  |                                                                                                                                                                                               | 95%-CI                                                                                                                                                                                        | (0.54 - 0.77)                                                                                                                                                                                 |
| Effect estimate per comparison                  |                                                                                                                                                                                               | P-value                                                                                                                                                                                       | < 0.0001                                                                                                                                                                                      |
| Notes                                           | The secondary analysis confirms the result of the primary analysis. The primary analysis results are also supported by pre-specified subgroup analyses on the PD-L1 WT population and further | The secondary analysis confirms the result of the primary analysis. The primary analysis results are also supported by pre-specified subgroup analyses on the PD-L1 WT population and further | The secondary analysis confirms the result of the primary analysis. The primary analysis results are also supported by pre-specified subgroup analyses on the PD-L1 WT population and further |

## Clinical studies in special populations

Table 44: Elderly patients in study IMpower130

|                   | Age 65-74 (Older subjects number /total number)   | Age 75-84 (Older subjects number /total number)   | Age 85+ (Older subjects number /total number)   |
|-------------------|---------------------------------------------------|---------------------------------------------------|-------------------------------------------------|
| Controlled Trials | 276/723                                           | 82/723                                            | 3/723                                           |

## 2.4.3. Discussion on clinical efficacy

The purpose of this application is to extend the indication for atezolizumab to the use in combination with nab-paclitaxel  and  carboplatin  for  the  first-line  (1L)  treatment  of  adult  patients  with  metastatic, non-squamous NSCLC who do not have EGFR -mutant or ALK -positive NSCLC.

## Design and conduct of clinical studies

The MAH provided data from the primary analysis of IMpower130 (Study GO29537; n = 723), a Phase III trial designed to evaluate the safety and efficacy of atezolizumab-carboplatin-nab-paclitaxel (Atezo-CnP) versus treatment with carboplatin-nab-paclitaxel (CnP) in chemotherapy-naïve patients with Stage IV non-squamous NSCLC. Atezo is added to CnP in an open-label fashion. It is not clear, why a blinded design was not preferred, thus, PFS and QoL data should be interpreted with caution.

This study had two co-primary endpoints OS and PFS. The overall type I error was 5 %. The 1-sided alpha was distributed among PFS (0.003) and OS (0.022). The study was to be considered positive if at least one of the co-primary endpoints was statistically significant. The alpha allocated to the PFS was to be recycled  for  OS,  if  statistical  significance  was  demonstrated  for  PFS.  This  is  acceptable.  An  interim analysis of OS was pre-planned and appropriate stopping rules for OS were defined.  Both OS and PFS

<div style=\"page-break-after: always\"></div>

were  tested  in  two  different  populations:  ITT-WT  (all  randomized  patients  without  activating  EGFR mutation or ALK translocation) and ITT (all randomized patients). The MAH has appropriately adjusted for multiplicity caused by testing in two different populations by a hierarchical testing method.

The  MAH  amended  the  protocol  seven  times.  The  majority  of  the  protocol  amendments  are  not controversial, however with protocol amendment 4 (version 5) the co-primary endpoint OS was added. This was, according to the MAH, motivated by the fact that emerging and accumulating knowledge about immune checkpoint inhibitors showed that PFS may not be as sensitive endpoint as OS. Patients were allowed to cross over after the addition of OS as co-primary endpoint. Analyses showed that those patients that crossed over prior to the amendment had little effect on the final results.

As a consequence of the addition of OS as co-primary endpoint the SAP was accordingly amended. Also, the testing of PFS in ITT-WT Teff-high was removed from the primary testing and listed as an exploratory analysis. The  final set of stratification factors  were  amended  'due  to  the  potential risk of over-stratification'.  According to the guideline on adjustment for baseline covariates in clinical trials (EMA/CHMP/295050/2013)', the factors that are the basis of stratification should normally be included as covariates or stratification variables in the primary outcome model, except where stratification was done purely for an administrative reason.

Overall, no major concerns have been identified with regards to design and conduct of the study.

## Efficacy data and additional analyses

The demographics and baseline disease characteristics of the study population (n=723) were well balanced between the treatment arms. The median age was 64 years (range 18 to 86 years). The majority of the patients were male (57%) and white (90%). Fourteen point eight percent (14.8%) of patients had liver metastases at baseline, and most patients were current or previous smokers (88%). The majority of patients had a baseline ECOG performance status of 1 (58.7%) and PD-L1 expression &lt;1% (approximately 53%). Among 107 Arm B patients who had a response status of stable disease, partial response, or complete response after induction therapy, 40 received pemetrexed switch maintenance therapy. Prior cancer therapies at baseline were similarly reported in the ITT population and in general were well balanced between treatment arms.

The study met both its co-primary endpoints at the data cut-off 15 March 2018. With regards to OS in ITT-WT, the HR was 0.79 (95%CI; 0.64, 0.98), p = 0.033. Median OS was 18.6 months vs 13.9 months in the atezo+CnP and CnP arms respectively, an improvement of median OS by 4.7 months, which is clinically encouraging in this patient population with a dismal prognosis. However, the p-value shows that the results are not highly statistically significant and barely mature since only approximately half of the population has died. Updated OS data in the ITT-WT population are in line with the primary analysis, the HR is now 0.82 (95% CI: 0.67, 1.01) and the p-value = 0.057. As OS data has matured, the difference between the two treatment arms is no longer statistically significant, but as discussed above the study will be considered positive if at least one of the co-primary endpoints is statistically significant. The updated results are also reflected in section 5.1 of the SmPC.

PFS data at the primary analysis are considered mature. PFS results in the ITT-WT patients showed a HR of 0.64 (95%CI: 0.54, 0.77; p&lt;0.0001). The median duration of PFS was 7.0 months in the atezo+CnP arm. The landmark analyses of PFS rates at 6 and 12 months are in line with the primary endpoint, however,  these  analyses  were  exploratory,  not  adjusted  for  multiplicity,  and  should  therefore  be interpreted with caution.

<div style=\"page-break-after: always\"></div>

During the procedure, the MAH was requested to provide efficacy outcomes for those patients in the CnP arm, who received maintenance treatment with pemetrexed. The OS and PFS results are comparable to the atezolizumab arm and better than the ITT population in the CnP arm. The subgroup analyses of OS are immature (event rates are between 34% and 43%). Patients in the CnP arm eligible for maintenance pemetrexed and who received switch maintenance with pemetrexed had a better outcome compared to patients, who were eligible for maintenance, but did not receive switch maintenance with pemetrexed.

In order to support the claim of efficacy, the whole trial population was re-analysed assuming that all patients eligible for maintenance therapy received it. It is understood that in this analysis, all patients were included and only patients in the CnP arm who would have been eligible for maintenance but did not receive it were imputed by replacing their actual survival time with a randomly drawn time from the CnP patients who received maintenance. This does not take advantage of any baseline covariate information and might have led to even lower survival times than actually observed. No marked differences to the primary analyses were observed for PFS and OS.

However, the results presented need to be interpreted with caution as they rely on a post-randomization criterion, the eligibility for maintenance therapy, and thus do not compare randomized patients anymore. Furthermore, they compare patients who were eligible to maintenance under CnP with patients who were eligible to maintenance under Atezo. This might further bias the results, which can also be seen in the markedly lower number of patients under CnP who were eligible for maintenance.

Usage of pemetrexed maintenance in the CnP arm was consistent with clinical practice and the prevalence of its use did not appear to impact the outcomes of the CnP arm. Since most patients were adequately treated, the overall treatment comparison based on all patients in the ITT-WT population is the most relevant comparison.

The subgroup analysis showed consistent results in line with the primary endpoint. However, some of the subgroups were small and the CIs were wide. Most interestingly is the estimate in the subgroup of patients with liver metastasis at baseline.  The hazard ratios for PFS and OS in the subgroup of patients with liver metastases at baseline, regardless of PD-L1 status, were 0.93 (0.59 1.43) and 1.04 (0.63,1.72) respectively. These patients do not seem to derive benefit by adding atezolizumab. Although it is difficult to draw conclusions from small subgroup and post-hoc analyses, this information is relevant for individual treatment decisions and is reflected in section 5.1 of the SmPC.

Results  of  other  secondary  endpoints  were  overall  in  line  with  the  primary  analyses  in  the  ITT-WT population. A similar treatment effect is observed across all the different PD-L1 subgroups. These results are in line with the primary estimate. Secondary endpoints were not adjusted for multiplicity.

## 2.4.4. Conclusions on the clinical efficacy

Study IMpower 130 shows statistically significant and clinically relevant results in the proposed patient population across different PD-L1 subgroups in terms of PFS. Updated OS is no longer statistically significant.  Patients in the CnP arm could according to the protocol at the discretion of the investigator continue with pemetrexed maintenance treatment if they were in CR,PR or SD. Data seem to suggest no relevant difference between Atezo+CnP + atezo maintenance and patients that received CnP + pemetrexed maintenance. However, one should be careful with such conclusions due to several limiting factors.

<div style=\"page-break-after: always\"></div>

## 2.5. Clinical safety

## Introduction

The evidence for safety is based on data from the primary analysis of IMpower130 (Study GO29537).  In addition, pooled safety data from five atezolizumab combination studies in 1L lung cancer (IMpower130, IMpower131, IMpower132, IMpower133, and IMpower150) as well as eight atezolizumab monotherapy studies regardless of tumour type (OAK, POPLAR, BIRCH, FIR, IMvigor211, IMvigor210, IMmotion150, and PCD4989g) were provided for reference.

The Atezo-Chemo Combo population safety analyses are based on safety data from a total of 2421 atezolizumab-treated, safety-evaluable patients from IMpower130 (n = 473 with NSCLC), IMpower131 (n = 666 with NSCLC), IMpower132 (n = 291 with NSCLC), IMpower133 (n = 198 with small cell lung cancer [SCLC]), and IMpower150 (n = 793 with NSCLC) in the following arms:

- IMpower130 Arm A (Atezo-CnP)
- IMpower131 Arm A (Atezo-CP) and Arm B (Atezo-CnP)
- IMpower132 Arm A (atezolizumab-cisplatin or carboplatin-pemetrexed)
- IMpower133 Arm A (atezolizumab-carboplatin-etoposide)
- IMpower150 Arm A (Atezo-CP) and Arm B (Atezo-CP-bevacizumab)

Safety data from this pooled population provide the largest dataset to evaluate the clinical safety of atezolizumab in combination with platinum-based chemotherapy in patients with NSCLC (n = 2223) and SCLC (n = 198).

Note:  Some listings for the Atezo-Chemo Combo population may display GO30081 (IMpower133) as the protocol number at the header of the output.  Nonetheless, these listings reflect the same studies included in all other Atezo-Chemo Combo pooled data presentations throughout this SCS, as can be identified from the footer of each output.

<div style=\"page-break-after: always\"></div>

## Patient exposure

Table 45: Exposure to atezolizumab (safety-evaluable population) - Study IMpower130

<!-- image -->

<div style=\"page-break-after: always\"></div>

Table 46: Exposure to carboplatin (safety-evaluable population) - Study IMpower130

<!-- image -->

<div style=\"page-break-after: always\"></div>

Table 47: Exposure to Nab-paclitaxel (safety-evaluable population) - Study IMpower130

<!-- image -->

Atezc

M=Months.Treatment duration is the date of thelast dose of study medication minus the date of the first dose plus one day. Dose intensity is\\_thenumber of dosesactuallyreceiveddivided bythe expected number of doses.

Data Cutoff: i5MAR2018; RAVE Data Extracted: i8 May 2018.

## Adverse events

## Overview of adverse events

## Table 48: Safety Summary Comparing IMpower130 and IMpower150

| Parameter                                        | IMpower 130 Atezo+CnP (n = 473)             | IMpower 150 Atezo+CP (n = 400)              |
|--------------------------------------------------|---------------------------------------------|---------------------------------------------|
| Total number of adverse events                   | 8766                                        | 4851                                        |
| Total number of patients with at least one:      | Total number of patients with at least one: | Total number of patients with at least one: |
| Adverse event                                    | 471 (99.6%)                                 | 391 (97.8%)                                 |
| Treatment-related AE                             | 455 (96.2%)                                 | 377 (94.3%)                                 |
| Grade 3 - 4 AE                                   | 381 (80.5%)                                 | 230 (57.5%)                                 |
| Treatment-related Grade 3 - 4 AE                 | 346 (73.2%)                                 | 172 (43.0%)                                 |
| Grade 5 AE                                       | 25 ( 5.3%)                                  | 10 ( 2.5%)                                  |
| Treatment-related Grade 5 AE                     | 8 ( 1.7%)                                   | 4 ( 1.0%)                                   |
| Serious AE                                       | 240 (50.7%)                                 | 157 (39.3%)                                 |
| Treatment-related serious AE                     | 112 (23.7%)                                 | 78 (19.5%)                                  |
| AE leading to withdrawal from any treatment      | 125 (26.4%)                                 | 53 (13.3%)                                  |
| AE leading to any dose modification/interruption | 402 (85.0%)                                 | 207 (51.8%)                                 |
| Total number of patients with at least one AESI  | 213 (45.0%)                                 | 192 (48.0%)                                 |

Only events reported in the Adverse Events Form are included. Investigator text for AEs encoded using MedDRA v20.1. Percentages are based on N in the column headings.  Multiple occurrences of the same AE in one individual are counted only once except for \"Total number of events\" row in which multiple occurrences of the same AE are counted separately.  AEs collected after first treatment dose are included.

<div style=\"page-break-after: always\"></div>

Table 49: Overview of Adverse Events (Safety-Evaluable Population), Safety Summary Profile, Adverse Event with Onset Date before Cross Over - Study IMpower130

|                                                                                 | CnP (Actual) (N=232)   | CnP (Actual) (N=232)   | Atezo+CnP (Actual) (N=473)   | Atezo+CnP (Actual) (N=473)   |
|---------------------------------------------------------------------------------|------------------------|------------------------|------------------------------|------------------------------|
| Total number of patients with at least one adverse event Total number of events | 230                    | (99.18) 2990           | 471                          | (99.68) 8766                 |
| Total number of patients with at least one                                      |                        |                        |                              |                              |
| Treatment-related AE                                                            | 215                    | (92.78)                | 455                          | (96.28)                      |
| Grade3-4 AE                                                                     | 164                    | (70.7%)                | 381                          | (80.58)                      |
| Treatment-related Grade 3-4 AE                                                  | 140                    | (60.3%)                | 346                          | (73.28)                      |
| Grade 5 AE                                                                      | 13                     | 5.6%)                  | 25                           | (5.3%)                       |
| Treatment-related Grade 5 AE                                                    | 1                      | 0.4%)                  | 8                            | (1.7%)                       |
| Serious Adverse Event                                                           | 88                     | (37.98)                | 240                          | (50.78)                      |
| Treatment-Related Serious Adverse Event                                         | 30                     | (12.9)                 | 112                          | (23.78)                      |
| AE leading to withdrawal from any treatment                                     | 51                     | (22.0)                 | 125                          | (26.48)                      |
| -MPDL3280A                                                                      | 0                      |                        | 59                           | (12.58)                      |
| -Nab-Paclitaxel                                                                 | 44                     | (19.0)                 | 97                           | (20.55)                      |
| -Carboplatin                                                                    | 36                     | (15.58)                | 85                           | (18.0号)                      |
| -Pemetrexed                                                                     | 6                      | (2.6)                  | 1                            | (0.2)                        |
| AE leading to any dose modification/interruption                                | 186                    | (80.2)                 | 402                          | (85.0号)                      |
| -MPDL3280A                                                                      | 6                      | (2.6)                  | 297                          | (62.88)                      |
| -Nab-Paclitaxel                                                                 | 181                    | [78.0号)                | 377                          | (79.7号)                      |
| -Carboplatin                                                                    | 158                    | (68.1号)                | 328                          | (69.3号)                      |
| -Pemetrexed                                                                     | 23                     | 9.98)                  | 8                            | (1.78)                       |

Atezo=Atezolizumab, CnP=Carboplatin+Nab-Paclitaxel. Only events reported in\\_the Adverse Events Form are included. Investigator text for AEs encoded using MedDRA v2l.0. Percentages are based on N in the column headings. Multiple occurrences of the same AE in one individual are counted only once except for \"Total number of events\" row in which multiple occurrences of the same AE are counted separately. Counts in \"Grade 3-4 AE\" are number of patients whose highest grades of AE are 3 or 4. Data Cutoff: 15MAR2018; RAVE Data Extracted: 18 May 2018.

<div style=\"page-break-after: always\"></div>

## Most common adverse events

Table 50: Adverse events with an incidence of at least 10% in any treatment arm by system organ class and preferred term (safety evaluable population) - Study IMpower130

| MedDRA System Organ Class MedDRA Preferred Tem                                                           | CnP (Actual) (N=232)   | Ateso+CnP (Actual) (N=473)   |
|----------------------------------------------------------------------------------------------------------|------------------------|------------------------------|
| Total mumber of patients with at least one adverse event                                                 | 230(99.1#)             | 471 (99.6)                   |
| GASTROINTESTINALDISORDERS                                                                                |                        |                              |
| Total number of patients with at least one adverse event                                                 | 173 (74.6)             | 381 (80.54)                  |
| NAUSPA                                                                                                   | 107 (46.13)            | 234 (49.53)                  |
| DIARRHOEA                                                                                                | 73 (31.5+)             | 201 (42.54)                  |
| CONSTIPATION                                                                                             | 72 (31.0)              | 171 (36.23) 128 (27.1)       |
| VOMITING ABDOMINAL PAIN                                                                                  | 45 (19.4$) 18 (7.8)    | 53 (11.2#)                   |
| BLOOD AND LYMPHATIC SYSTEM DISORDERS                                                                     |                        |                              |
| Total number of patients with at least one adverse event                                                 | 181 (78.0#)            | 370 (78.2)                   |
| ANAEHTA                                                                                                  | 124 (53.4)             | 265 (56.0) 220               |
| NEUTROPENIA THROHBOCYTOFENIA                                                                             | 105 (45.34) 60 (25.9)  | (46.54) 133 (28.1)           |
| LEUKOPENIA                                                                                               | 18 (7.8)               | 51 (10.8)                    |
| GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS                                                     |                        |                              |
| Total nimber of patients with at lesst one adverse event                                                 | 161 (69.48)            | 372 (78.6)                   |
| FATIGUE                                                                                                  | 109 (47.0)             | 223 (47.1)                   |
| ASTHENIA                                                                                                 | 88 (16.4#)             | 87 (18.4*)                   |
| PYREXIA                                                                                                  | 23 (46*6]              | 82 (17.33)                   |
| OEDEHAFERIPHERAL                                                                                         | 26 (11.24)             | 64 (13.5)                    |
| RESPIRATORY,THORACICAND VEDIASTINALDISORDERS                                                             |                        |                              |
|                                                                                                          | 123 (53.0#)            | 304 (64.3)                   |
| DYSPNOEA                                                                                                 | 47 (20.33)             | 133 (28.13)                  |
| COUGH                                                                                                    | (16.6+)                | 126 (26.6*)                  |
| EPISTAXIS                                                                                                | 39 28 (12.1#)          | 89 (14.4)                    |
| NERVOUS SYSTEM DISORDERS                                                                                 |                        |                              |
| Total number of patients with at least one adverse event                                                 | 106 (45.7)             | 279 (59.04)                  |
| HEADACHE                                                                                                 | 23 (46*6]              | 77 (16.38)                   |
| DIZZINESS                                                                                                | 25 (10.8)              | 76 (16.1)                    |
| FERIPHERALSENSORY NEUROPATHY                                                                             | 23 (46*6)              | 60 (12.74)                   |
| DYSGEUSTA NEUROPATHY PERIPHERAL                                                                          | 14 6.0) 21 9.1#)       | 57 (12.1) 53 (11.2)          |
| METABOLTSMANDNUTRTTIONDISORIERS                                                                          |                        |                              |
| Totel.nuber.of.patients with at least one adverse event                                                  | 114 (49.13)            | 260 (55.03)                  |
| DECRPASED APPETITE                                                                                       | 60 (25.94)             | 142 (30.04)                  |
| HYPOMAGNESAEMTA                                                                                          | 39 (16.8#)             | 96 (20.18)                   |
| HYPORALAEMTA                                                                                             | 26 (11.23)             | 74 (15.63)                   |
| DEHYDRATION                                                                                              | 25 (10.64)             | 6 (10.4)                     |
| INEECTIONS AND INFESTATIONS                                                                              |                        |                              |
| Totel nuber_of patients with at least one adverse event URINARYTRACTINEECTION                            | 99 (42.7)              | 252 (53.3)                   |
| ENEUNONIA                                                                                                | 20 (6.64) 19 (6.2#)    | 62 (13.1#) 54 (11.4#)        |
| SKIN AND SUBCUTANEOUS TISSUE DISORDERS Total number of patients with at least one adverse event ALOPECIA | 86 (40.1#) 63 (27.2#)  | 247 (52.24) 151 (31.9)       |
| RASH                                                                                                     | 16 6.9)                | 66 (14.03)                   |
| FRURITUS                                                                                                 | 12 5.2)                | 53 (11.2)                    |
| INVESTIGATIONS                                                                                           |                        |                              |
| Totel number of patients with at lesst one adverse event                                                 | 101 (43.5)             | 227 (48.03)                  |
| PLATELETCOUNTDECREASED                                                                                   | 39 (16.6)              | 108 (22.8*)                  |
| NEUTROPHTLCOUNTDECREASED                                                                                 | 35 (15.1)              | 95 (20.13)                   |
| WEIGHT DECREASED WHITE BIOOD CELLCOUNT DECREASED                                                         | 28 (12.1$) 18 (7.8)    | 53 (11.28) 52 (11.08)        |
| MUSCULOSKELETALAND CONNECTIVE TISSUEDISORDERS                                                            |                        |                              |
| Totalnumberofpatientswith atleast oneadverse event                                                       | 85 (36.6)              | 239 (50.5)                   |
| BACK PATN                                                                                                | 16 (.6.91) 24 (10.3+)  | 82 (17.3#) 72                |
| ARTHRALGIA                                                                                               | 14 ( 6.04)             | (15.2) 52 (11.04)            |
| PSYCHTATRICDISORDERS                                                                                     |                        |                              |
| Total number of patients with at least one adverse event INSOMNIA                                        | 45 (19.4) 31 (13.4*)   | 129 (27.3) 68 (14.4)         |
| ENDOCRINE DISORIERS                                                                                      |                        |                              |
| Totalmwmber of patients with at least one adverse event HYPOTHYROIDISM                                   | 0.94) 0.44)            | 74 (15.6) 53 (11.2)          |

Ateso=Atesoliewmsb,CnP=Carboplatin+Neb-Paclitawel.

Investigator text for AEs encoded using MadDRA v2l.0. Fercentages are based on N in the coluum headings. For frequency counts by preferred tem, multiple occirrences of the same AE in an individusl are counted only once. For frequency counts of \"Total mumber of events\" row5, the myltiple oeewrrenees of the grne Ae in an individual are counted separately. AEs colleeted aftar first treatment dose are ineluded. Data Cutoff: 15MAR2018: RAVE Data Entracted: 18 May 2018.

<div style=\"page-break-after: always\"></div>

Table 51: Summary of adverse events with at least 5% difference between treatment arms by system organ class and preferred term (safety evaluable population) - Study IMpower130

| MedDRA System Organ Cla99 MedDRA Preferred Tem                       | CnP (Actual) (N=232)   | Ateso+CnP (Aetual) (N=473)   |
|----------------------------------------------------------------------|------------------------|------------------------------|
| Total nlnher of patients with at lesst one edverse event             | 230(99.1)              | 471(99.61)                   |
| Overall total number of events                                       | 2990                   | 8766                         |
| ENDOCRINE DISORIERS                                                  |                        |                              |
| Total mumber of patients with at lesgt one aduerse event             | 2 (0.98)               | 74 (15.61)                   |
| Totsl mmber of euents                                                | 2                      | 95                           |
| HYEOTHYROIDISM                                                       | (0.48)                 | 53(11.24)                    |
| GASTROTNTESTINAL.DISORDERS                                           |                        |                              |
| Total number of patients with at least one adverse event             | 173 (74.68)            | 381(80.51)                   |
| Total nmber of t events                                              | 544                    | 1460                         |
| DIARRHOEA                                                            | 73 (31.51)             | 201 (42.58]                  |
| CONSTIPATION                                                         | 72 (31.08)             | 171 (36.21)                  |
| SNTLINON                                                             | 45 (19.48)             | 128 (27.18)                  |
| GENERALDISORDERS AND AOMINISTRATIONSTTECONDITIONS                    |                        |                              |
| Total nmber of patients with at least one aduerse event  16l (69.48) |                        | 372 149'8L)                  |
| Total nmber of aventg                                                | 231                    | 870                          |
| PYREKTA                                                              | 23( 9.94)              | 82(17.38)                    |
| TNVESTIGATTONS                                                       |                        |                              |
| Total mumber of patients with at least one aduerse event             | 101 (43.58]            | 227 (80'81]                  |
| Total mmber of events                                                | 276                    | 778                          |
| PLATELETCOUNT DECREASED                                              | 39 (16.81)             | 108 (22.8)                   |
| MUBCULOSIELETAL ANDCONNECTIVE TISSUE DISORDERS                       |                        |                              |
| Total nmber of patients with at least one adverse event              | 85(36.61)              | 239(50.51)                   |
| Total mumber of events                                               | 133                    | 541                          |
|                                                                      | 16 (6.98]              | 82 (17.38)                   |
| MUSCULOSRELETAL PATN                                                 | 10 (4.31)              | 45(9.51)                     |
| NERUOUS SYSTEM DISORDERS                                             |                        |                              |
| Total mumber of patients with at least one aduerse event             | 106 (45.78)            | 279 159.04]                  |
| Total mmber of events                                                | 194                    | 591                          |
| DI2Z1NES8                                                            | 25 (10.84)             | 76 (16.18)                   |
| HEADACHE                                                             | 23 186.6.              | 77 (16.31)                   |
| DYSGEUSTA                                                            | 14 (6.01)              | 57 (12.18)                   |
| RESPIRATORY,THORACIC AND MEDIASTINAL DISORDERS                       |                        |                              |
| Total nmber of patients with at least one aduerse event              | 123 (53.01)            | 204(64.38)                   |
| Total nimber of avents                                               | 231                    | 775                          |
| DISPNOEA. COUGH                                                      | 47 (20.31) 39 (16.81)  | 133 (28.18) 126 (26.68)      |
| SKINANDSUBCUTANEOUSTISSUEDISORDERS                                   |                        |                              |
| Total nimber of patients with at lesst one aduerse event             | 93 (40.18)             | 247 (52.21)                  |
| Total nmber of events                                                | 146                    | 483                          |
| H618                                                                 | 16 6.911               | 66 (14.04)                   |
| ERURITUS                                                             | 12 5.281               | 53 (11.24)                   |

## Ateso-Atesolisumeb,Cnp-tarboplatin+Neb-Pacllitawel

Data Cutoff: 15MAR2018: RAVE Data Extractad: 18 May 2018.

Investigator tent for AEs encoded using MedDRA v2l.0. Fercentages are based on N in the columm headings. For frequency counts by preferred tem, multiple oeeirrenees of the sene AE in an rpws. the multiple occurrenees of the sane AE in an individual are counted separately. AEs colleeted after first treatment dose are ineluded.

<div style=\"page-break-after: always\"></div>

| MedDRA Sygtem Orgen_Class KadDRA Preferred Tem           | CnP (Actual) (N=232)   | Ateso+CnP (Actual) (N=473)   |
|----------------------------------------------------------|------------------------|------------------------------|
| Total number of patients with at least one adverse event | 215 (92.78)            | 455(96.28)                   |
| Overall total number of events                           | 1720                   | 4665                         |
| BLOODANDLYMPHATICSYSTEMDISORDERS                         |                        |                              |
| Totel number of patients with at least one aduerse event | 169 (72.84)            | 354 (74.88)                  |
| ANAEHTA                                                  | 109 (47.08]            | 248 (52.48)                  |
| NEUTROPENIA                                              | 104 (48'16)            | 218 (46.18)                  |
| THROMBOCYTOPENIA                                         | 58 (25.04)             | 127 (26.88)                  |
| LEUNOPENIA                                               | 17 ( 7.38)             | 48 (10.18)                   |
| GASTROINTESTINALDISORDERS                                |                        |                              |
| Total number of patients with at least one adverse event | 137 (59.18)            | 325 (68.74)                  |
| NAUSEA                                                   | 96 (Hb'TH)             | 207 [43.84)                  |
| DIARRHOEA                                                | 55 (23.74)             | 150 (31.78)                  |
| WOMITING                                                 | 33 (14.24)             | 66 (20.94)                   |
| CONSTTPATION                                             | 33 (14.24)             | 73 (15.48)                   |
| GENERALDISORDERS AND AIMINISTRATION SITECONDITIONS       |                        |                              |
| Total number of patients with at least one adverse event | 123 (53.04)            | 277 (58.61)                  |
| FATIGUE                                                  | 91. (39.21)            | 185 139.10)                  |
| ASTHENIA                                                 | 31 (13.48)             | 61 (12.98)                   |
| SKINANDSUECUTANEOUSTISSUEDISORDERS                       |                        |                              |
| Total mumber of patients with at lerst one adverse event | 79 (34.18)             | 207 (43.81)                  |
| ALOPECIA                                                 | 61 (26.34)             | 145 (30.74)                  |
| INVESTIGATIONS                                           |                        |                              |
| Total mumber of patients with at lerst one adverse event | 73 (31.51)             | 196 (41.48)                  |
| PLATELET COUNT DECREASED                                 | 38 (16.18)             | 105 132.301                  |
| NEUTROPHIL COUNT DECREASED                               | 33 (14.28)             | 93 (19.78)                   |
| MHITE BLOOD CELLCOUNT DECREASED                          | 17 [7.38]              | 51 (10.88)                   |
| NERIOUS SYSTEM DISORDERS                                 |                        |                              |
| Total number of patients with at least one adverse event | (30.61)                | 196 (41.48)                  |
| DYSGEUSTA                                                | 11 (4.74]              | 51 (10.64)                   |
| PERIPHERAL SENSORY NEUROPATHY                            | 33 9.511               | 50 110.61)                   |
| NEUROPATHY FERIPHERAL                                    | 7.311                  | 49 (10.48)                   |
| METABOLISMAND NUTRITIONDISORDERS                         |                        |                              |
| Total number of patients with at leagt one adverse event | 77 (33.24)             | 177 (37.48)                  |
| DECREASED APPETTTE                                       | 46 (19.88)             | 107 (22.64)                  |
| HYEOMAGNESAEHTA                                          | 24 (10.31)             | 62 (13.18)                   |
| ENOOCRINEDISORIERS                                       |                        |                              |
| Total mumber of patients with at lesst one sduerse event | (Hb'0 )                | 61 (12.98)                   |
|                                                          |                        | (10.48)                      |
| HYEOTHYROIDISM                                           |                        | 49                           |

Table 52: Adverse events related to study treatment with an incidence of at least 10% in any treatment arm by system organ class and preferred term (safety evaluable population) - Study IMpower130

<!-- image -->

## Grade 3/4 AEs

Table 53: Adverse Events with Onset Date before Cross Over by System Organ Class, Preferred Term and Highest NCI CTCAE Grade - Study IMpower130

| MedDRA System Organ_Class MedDRA Preferred Term   | Grade     | CnP (Actual) (N=232)                                            | Atezo+CnP (Actual) (N=473)                                   |
|---------------------------------------------------|-----------|-----------------------------------------------------------------|--------------------------------------------------------------|
| Any adverse events                                | Any Grade | 230 (99.18) 5 (2.28) 48 (20.7%) 127(54.7%) 37 (15.9%) 13 (5.68) | 471 (99.68) 9 (1.98) 56(11.8%) 250(52.9%) 131 277%) 25 5.38) |

<div style=\"page-break-after: always\"></div>

Table 54: Grade ≥3 adverse events with at least 2% difference between treatment arms by preferred term (safety evaluable population) - Study IMpower130

| MedDRA Preferred Tem                                                            | CnP(Aetual) (N=232)   |            | Ateno+CnP_(Actual) (N=473)   |
|---------------------------------------------------------------------------------|-----------------------|------------|------------------------------|
| Total mumber of patients with at least one adverse event Total nunber of events | 173                   | (74.6) 398 | 400 (84.6) 1176              |
| NEUTROPENIA                                                                     | 66                    | (28.4*)    | 153 (32.3#)                  |
| ANREMTA                                                                         | 56                    | (24.13)    | 151 (31.9*)                  |
| NEUTROPHIL COUNT DECREASED                                                      | 20                    | 8.64)      | 59 (12.54)                   |
| THROMEOCYTOPENIA                                                                | 16                    | 6.9)       | 47 9.9*1                     |
| WHITE BIOOD CELL COUNT DECREASED                                                | 7                     | 3.081      | 32 6.881                     |
| HYPONATAPMIA                                                                    | 6                     | 2.64)      | 22 (4.7)                     |
| DYSPNOEA                                                                        | 2                     | 136.9      | 14.731                       |
| LUNG INFECTION                                                                  | 1 0.4#)               | 22 12 13   | (2.5*)                       |
| SYNCOFE                                                                         | 0                     |            | 2.7)                         |

AtesoAtesolfeumsb,Cn:-larboplatin+Neb-Paclftamel Investigator text for AEs encoded using MadDRA v2l.0. Fercentages are basad on N in the coluun headinge. For frequengy sounts by pseferred tem, multiple.geeurrences of the srme Ar in 2n multiple occurrences of the same AE in an individual are counted separately. AEs collected after first treatment dose are ineluded.

Data Cutoff: 15MAR2016: RAVE Data Extracted: 18 May 2018.

Table 55: Grade 3-4 adverse events with incidence of at least 2% in either arm/population (safety evaluable population) - Study IMpower130 and pooled safety datasets

|                                                                              | IHpower130       | IHpower130         |                            |                           |                     |
|------------------------------------------------------------------------------|------------------|--------------------|----------------------------|---------------------------|---------------------|
| MedDRA System Organ Class MedDRA Preferred Term                              | CnP (N=232)      | Ateno+CnP (N=473)  | Ateso+Chemo Cembo (N=2421) | Ateno Mono NSCIC (N=1636) | Ateso Hono (N=3176) |
| Total number of patients with at least one adverse event                     | 173(74.6)        | 402 (85.0)         | 1702 (70.3#)               | 708(43.3)                 | 1564(49.2)          |
| Ouerall total number of events                                               | 472              | 1415               | 5073                       | 1402                      | 3366                |
| BIOOD AND LYMPHATIC SYSTEM DISORDERS                                         |                  |                    |                            |                           |                     |
| Total mmber of patients with at least one adverse event                      | 112 (48.3)       | 270 (57.1#)        | 880(36.3)                  | 65 (4.0)                  | 218(6.9)            |
| Total number of events                                                       |                  |                    |                            | 63                        | 257                 |
| NEUIROFENIA                                                                  | 204              | 526 732.31)        | 1573 414 (17.1#)           | 5 0.34)                   | 11 0.31             |
|                                                                              | 66 (26. 4)       | 153                |                            |                           |                     |
| ANAEMIA                                                                      | 56 (24.13)       | 151 (31.9)         | 415 (17.1)                 | 40 2.43)                  | 160 5.01            |
| THROMEOCYTOFENIA                                                             | 16 6.9)          | 47 (6'6            | 162 (6.7#)                 | (0.45)                    | 21 (0.76)           |
| LEUKOPENIA                                                                   | 3.03)            | 22 4.73)           | 70 2.93)                   |                           | 0                   |
| FEBRTLENEUTROPENTA                                                           | 6 2.6)           | 12 2.5)            | 137 5.74)                  | (<0.14)                   | (0.3)               |
| INVESTIGATIONS                                                               |                  |                    |                            |                           |                     |
| Total mmber of patients with at least one adverse                            | 37(15.9)         | 107(22.6)          | 445 (18.4#)                | 59 (3.6)                  | 189 (5.9)           |
| event Total mumber of events                                                 | 72               | 224                | 891                        | 62                        | 274                 |
| NEUTROFHILCOUNTDECREASED                                                     | 20 8.6)          | 59 (12.51)         | 229 (9.53)                 | 1 (<0.1)                  | 2 (<0.13)           |
| PLATELET COUNT DECREASED                                                     | 14 6.04)         | 37 (7.84)          | 110 (4.54)                 | 1 (<0.14)                 | 677.23              |
| WHITE BLOOD CELLCOUNT DECREASED                                              | (3.0#)           | 32 (6.8)           | 90 (3.7#)                  | 2( 0.14)                  | 5(0.2#)             |
| INPECTIONS AND INEESTATIONS                                                  |                  |                    |                            |                           |                     |
| Total mmber of patients with at least one adverse                            | 22(9.5)          | 83(17.5)           | 355 (14.7)                 | 154 ( 9.4#)               | 347(10.9)           |
| event Totalnumber of events                                                  | 27               | 104                | 437                        | 160                       | 419                 |
| FNEUMONIA                                                                    | 10 (4.3)         | 31 6.6)            | 132 (5.5]                  | 67 ( 4.1)                 | 69(2.6)             |
| LUNG INEECTION                                                               | 0.43)            | 12 2.5)            | 27 1.1#)                   | 8 (0.53)                  | 13 (0.43)           |
| URINARY TRACT INFECTION                                                      | (0.43)           | 6 1.3+)            | 24 1.0)                    | 5 (0.3)                   | 72 (2.3)            |
| GENERALDISORDERSANDADMINISTRATION SITECONDITIONS                             |                  |                    |                            |                           |                     |
| Total mumber of patients with at least one adverse                           | 24 (10.3)        | 78 (16.5)          | 272 (11.2#)                | 118 ( 7.2#)               | 265 (8.3)           |
| event                                                                        |                  |                    |                            |                           |                     |
| Total mumber of events                                                       | 27               | 88                 | 308                        | 133                       | 315                 |
| FATIGUE ASTHENIA                                                             | 14 6.03) 5 2.24) | 36 (7.68) 16 (3.4) | 105 [4.33] 78 [3.24]       | L (2.93) 22 (1.3)         | 109(3.4) 63(2.0)    |
| METAEOLISM AND NUTRITION DISORDERS                                           |                  |                    |                            |                           |                     |
| Total mumber of patients with at least one adverse                           | 24(10.3)         | 70 (14.8)          | 273 (11.3)                 | 118 ( 7.2)                | 308 (9.7)           |
| event Total mumber of events                                                 | 32               | 97                 | 367                        | 150                       | 387                 |
| HYPORALAEMTA                                                                 | 6 2.6)           | 22 4.7)            | 51 2.1#)                   | 17 [1.93)                 | 32 [1.03)           |
| HYPONATRAEHIA                                                                | 3 1.34)          | 11 2.3)            | 99 2.331                   | 42 7 2.64)                | 86 ( 3.16)          |
| DECREASED APPETITE                                                           | 2.2              | 10 (2.13)          | 49 (2.03)                  | 12 [0.73]                 | 35(1.1)             |
| HYEOMAGNESAEMIA                                                              | 4 (1.74)         | 10 (2.14)          | 26 (0.85)                  | 1 (<0.1)                  | 2(<0.1)             |
| RESPIRATORY,THORACIC AND MEDIASTINAL DISORIERS                               |                  |                    |                            |                           |                     |
| Total mumber of patients with at least one adverse event                     | 22(9.5#)         | 65(13.7)           | 242 (10.0#)                | 195 (11.9#)               | 323(10.2)           |
|                                                                              | 23               | 90                 | 303                        | 256                       | 415                 |
| Total nunber of events DYSENOEA                                              | 2 (0.9#)         | 22 4.7#)           | 59 [2.4#)                  | 68 (4.2#)                 | 117 (3.7)           |
| PULMONARY EMEOLISM                                                           | 7 3.0+)          | 16 [ 3.4)          | 50 2.1)                    | 32 （ 2.0±)                | 59(1.93)            |
| CHRONIC OBSTRUCTIVE FULMONGRY DISEASE                                        | 2 (0.9)          | 11 (2.3)           | 29 (1.2#)                  | (0.4#)                    | 9(0.3)              |
| GASTROINTESTINALDISORIERS Total mumber of patients with at least one adverse | 29 (12.5)        | 63 (13.3)          | 257 (10.6)                 | 91( 5.6)                  | 242(7.6)            |
| event Total nuumber of events                                                | 40               | 93                 | 342                        | 113                       | 319                 |
| DIARRHOEA                                                                    | 5 2.24)          | 25 5.3)            | 85 (3.5)                   | 17 1.05)                  | 35 1.1)             |
| NAUSEA                                                                       | 14 6.03)         | 16                 | 53 2.2#)                   | 14 (0.93)                 | 36(1.1)             |
| VOMITING                                                                     | 5 (2.24)         | 13 (2.7#)          | 43 (1.8)                   | 14 ( 0.9)                 | 26(0.6)             |

<div style=\"page-break-after: always\"></div>

<!-- image -->

Table 56: Grade 4 AEs by SOC - Study IMpower130

| Grade 4 Adverse Events (by System Organ Class)                      | CnP (n = 232)   | Atezo+CnP (n = 473)   |
|---------------------------------------------------------------------|-----------------|-----------------------|
| Total Number of Grade 4 AEs                                         | 37 (15.9%)      | 131 (27.7%)           |
| Blood and lymphatic system disorders                                | 24 (10.3%)      | 75 (15.9%)            |
| Cardiac disorders                                                   | 0               | 7 (1.5%)              |
| Congenital, familial and genetic disorders                          | 0               | 0                     |
| Ear and labyrinth disorders                                         | 0               | 0                     |
| Endocrine disorders                                                 | 0               | 0                     |
| Eye disorders                                                       | 0               | 0                     |
| Gastrointestinal disorders                                          | 0               | 3 (0.6%)              |
| General disorders and administration site conditions                | 0               | 2 (0.4%)              |
| Hepatobiliary disorders                                             | 0               | 1 (0.2%)              |
| Immune system disorders                                             | 0               | 0                     |
| Infections and infestations                                         | 1 (0.4%)        | 16 (3.4%)             |
| Injury, poisoning and procedural complications                      | 0               | 1 (0.2%)              |
| Investigations                                                      | 10 (4.3%)       | 33 (7.0%)             |
| Metabolism and nutrition disorders                                  | 4 (1.7%)        | 11 (2.3%)             |
| Musculoskeletal and connective tissue disorders                     | 1 (0.4%)        | 1 (0.2%)              |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | 0               | 0                     |
| Nervous system disorders                                            | 1 (0.4%)        | 3 (0.6%)              |
| Pregnancy, puerperium and perinatal conditions                      | 0               | 0                     |
| Product Issues                                                      | 0               | 0                     |
| Psychiatric disorders                                               | 0               | 3 (0.6%)              |
| Renal and urinary disorders                                         | 0               | 3 (0.6%)              |
| Reproductive system and breast disorders                            | 0               | 0                     |
| Respiratory, thoracic and mediastinal disorders                     | 4 (1.7%)        | 14 (3.0%)             |
| Skin and subcutaneous tissue disorders                              | 0               | 0                     |
| Social circumstances                                                | 0               | 0                     |
| Surgical and medical procedures                                     | 0               | 0                     |
| Vascular disorders                                                  | 0               | 0                     |

Atezo = atezolizumab; CnP = carboplatin+nab-paclitaxel. Investigator text for AEs encoded using MedDRA v21.0. Multiple occurrences of the same AE in one individual are counted once at the highest grade for this patient. To the SOC (System Organ Class) Overall row counts, a patient contributes only with the AE occurring with the highest grade within the SOC. Percentages are based on N in the column headings. AEs collected after first treatment dose are included. Data Cutoff: 15MAR2018; RAVE Data.

Table 57: Time to Onset for First Grade 4 Event of Neutropenia and Thrombocytopenia

| Parameter                                                           | CnP (N = 232)                                                       | Atezo+CnP (N = 473)                                                 | All patients (N = 705)                                              |
|---------------------------------------------------------------------|---------------------------------------------------------------------|---------------------------------------------------------------------|---------------------------------------------------------------------|
| Time to onset for first Grade 4 event of neutropenia (months):      | Time to onset for first Grade 4 event of neutropenia (months):      | Time to onset for first Grade 4 event of neutropenia (months):      | Time to onset for first Grade 4 event of neutropenia (months):      |
| n                                                                   | 19 (8.2%)                                                           | 60 (12.7%)                                                          | 79 (11.2%)                                                          |
| Mean (SD)                                                           | 1.77 (2.71)                                                         | 1.29 (0.83)                                                         | 1.40 (1.50)                                                         |
| Median                                                              | 1.08                                                                | 1.18                                                                | 1.15                                                                |
| Min-Max                                                             | 0.4-12.5                                                            | 0.2-3.6                                                             | 0.2-12.5                                                            |
| Time to onset for first Grade 4 event of thrombocytopenia (months): | Time to onset for first Grade 4 event of thrombocytopenia (months): | Time to onset for first Grade 4 event of thrombocytopenia (months): | Time to onset for first Grade 4 event of thrombocytopenia (months): |
| n                                                                   | 3 (1.3%)                                                            | 16 (3.4%)                                                           | 19 (2.7%)                                                           |
| Mean (SD)                                                           | 1.76 (1.09)                                                         | 0.85 (0.59)                                                         | 1.00 (0.73)                                                         |
| Median                                                              | 1.87                                                                | 0.64                                                                | 0.69                                                                |
| Min-Max                                                             | 0.6-2.8                                                             | 0.0-2.3                                                             | 0.0-2.8                                                             |

<div style=\"page-break-after: always\"></div>

Atezo=Atezolizumab, CnP=Carboplatin+Nab-Paclitaxel. Investigator text for AEs encoded using MedDRA v21.0. Data Cutoff: 15MAR2018; RAVE Data Extracted: 18 May 2018.

Table 58: Duration of Event for First Grade 4 Event of Neutropenia and Thrombocytopenia

| Parameter                                                                                  | CnP (N = 232)                                                                              | Atezo+CnP (N = 473)                                                                        | All Patients (N = 705)                                                                     |
|--------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------|
| Time from onset to time of resolution for first Grade 4 event of neutropenia (months):     | Time from onset to time of resolution for first Grade 4 event of neutropenia (months):     | Time from onset to time of resolution for first Grade 4 event of neutropenia (months):     | Time from onset to time of resolution for first Grade 4 event of neutropenia (months):     |
| n                                                                                          | 19 (8.2%)                                                                                  | 60 (12.7%)                                                                                 | 79 (11.2%)                                                                                 |
| Median                                                                                     | 0.26                                                                                       | 0.44                                                                                       | 0.33                                                                                       |
| 95% CI                                                                                     | (0.23, 0.36)                                                                               | (0.26, 0.49)                                                                               | (0.26, 0.49)                                                                               |
| 25% and 75% percentile                                                                     | 0.23, 0.49                                                                                 | 0.26, 0.95                                                                                 | 0.23, 0.72                                                                                 |
| Range                                                                                      | 0.2 to 1.9                                                                                 | 0.1 to 16.8*                                                                               | 0.1 to 16.8*                                                                               |
| Time from onset to time of resolution for first Grade 4 event of thrombocytopenia (months) | Time from onset to time of resolution for first Grade 4 event of thrombocytopenia (months) | Time from onset to time of resolution for first Grade 4 event of thrombocytopenia (months) | Time from onset to time of resolution for first Grade 4 event of thrombocytopenia (months) |
| n                                                                                          | 3 (1.3%)                                                                                   | 16 (3.4%)                                                                                  | 19 (2.7%)                                                                                  |
| Median                                                                                     | 0.49                                                                                       | 0.57                                                                                       | 0.56                                                                                       |
| 95% CI                                                                                     | (0.13, 3.06)                                                                               | (0.49, 1.41)                                                                               | (0.49, 1.41)                                                                               |
| 25% and 75% percentile                                                                     | 0.13, 3.06                                                                                 | 0.46, 2.22                                                                                 | 0.43, 3.02                                                                                 |
| Range                                                                                      | 0.1 to 3.1                                                                                 | 0.2 to 20.1*                                                                               | 0.1 to 20.1*                                                                               |

Atezo = atezolizumab; CnP = carboplatin+nab-paclitaxel. * Censored, ^ Censored and event, NE = Not estimable. Summaries of duration of adverse events (median, percentiles) are Kaplan-Meier estimates. 95% CI for median was computed using the method of Brookmeyer and Crowley. Investigator text for AEs encoded using MedDRA v21.0. Data Cutoff: 15MAR2018; RAVE Data Extracted: 18 May 2018.

## Adverse events by relationship/Treatment-related AEs

The most common treatment-related AEs with an incidence of ≥10% in any arm are presented in the table below AEs considered by the investigator as related to any study treatment

<div style=\"page-break-after: always\"></div>

Table 59: Most common treatment-related AEs with an incidence of &gt;10% in any arm with Onset Date before Cross Over - Study IMpower130

| MedDRA System Organ Class MedDRA Preferred Tenm           | CnP (Actual) (N=232)   | Atezo+CnP (Actual) (N=473)   |
|-----------------------------------------------------------|------------------------|------------------------------|
| Total number of patients with at least one adverse event  | 215 (92.7%)            | 455 (96.28)                  |
| Overall total number of events                            | 1720                   | 4665                         |
| BLOOD AND LYMPHATIC SYSTEMDISORDERS                       |                        |                              |
| Total nimber of patients with at least one adverse event  | 169 (72.8%)            | 354(74.88)                   |
| ANAEMIA                                                   | 109 (47.0%)            | 248 (52.4%)                  |
| NEUTROPENIA                                               | 104 (44.8%)            | 218 (46.1%)                  |
| THROMBOCYTOPENIA                                          | 58 (25.0%)             | 127 (26.88)                  |
| LEUKOPENIA                                                | 17 (7.38)              | 48 (10.18)                   |
| GASTROINTESTINALDISORDERS                                 |                        |                              |
| Total number of patients with at least one adverse event  | 137 (59.18)            | 325 (68.78)                  |
| NAUSEA                                                    | 96 (41.4%)             | 207 (43.8%)                  |
| DIARRHOEA                                                 | 55 (23.7%)             | 150 (31.7%)                  |
| VOMITING                                                  | 33 (14.28)             | 66 (20.9%)                   |
| CONSTIPATION                                              | 33 (14.28)             | 73 (15.48)                   |
| GENERAL DISORIERS AND AIMINISTRATION SITE CONDITIONS      |                        |                              |
| Total number of patients with at least one adverse event  | 123 (53.08)            | 277 (58.68)                  |
| FATIGUE                                                   | 91 (39.28)             | 185 (39.18)                  |
| ASTHENIA                                                  | 31(13.48)              | 61 (12.98)                   |
| SKIN AND SUBCUTANEOUS TISSUE DISORDERS                    |                        |                              |
| Total number of patients with at least one adverse event  | 79 (34.18)             | 207 (43.8%)                  |
| ALOPECIA                                                  | 61(26.38)              | 145 (30.78)                  |
| INVESTIGATIONS                                            |                        |                              |
| Total mimber of patients with at least one adiverse event | 73 (31.5%)             | 196 (41.4%) 105              |
| PLATELET COUNT TECREASED                                  | 38 (16.4%)             | (22.28)                      |
| NEUTROPHIL COUNT DECREASED                                | 33 (14.28)             | 93 (19.78)                   |
| WHITE BLOOD CELL COUNT DECREASED                          | 17 (7.3%)              | 51 (10.8%)                   |
| Total number of patients with at least one adverse event  | 7127 (30.6%)           | 196 (41.4%)                  |
| DYSGEUSIA                                                 | 4.7%)                  | 51 (10.8%)                   |
| PERIPHERALSENSORYNEUROPATHY                               | 9.58)                  | 50 (10.6%)                   |
| NEUROPATHY PERIPHERAL                                     | 7.38)                  | 49 (10.4%)                   |
| METABOLISM AND NUTRITION DISORIERS                        |                        |                              |
| Total nimber of patients with at least one adverse event  | 77 (33.28)             | 177 (37.4%)                  |
| DECREASED APPETITE                                        | 46 (19.8%)             | 107 (22.6%)                  |
| HYPOMAGNESAEMIA                                           | 24 (10.3%)             | 62 (13.18)                   |
| ENDOCRINE DISORDERS                                       |                        |                              |
| Total number of patients with at least one adverse event  | (0.48)                 | 19 (12.98)                   |
|                                                           |                        | (10.4%)                      |
| HYPOTHYROIDISM                                            |                        | 49                           |

Atezo=Atezolizumab, CnP=Carboplatin+Nab-Paclitaxel. Investigator text for AEs encoded using MedDRA v2l.0. Percentages are based on N in the columm headings. For frequency counts by preferred tenm, multiple occurrences of the same AE in an individual are counted only once. For frequency counts of \"Total number of events\" rows, the multiple occurrences of the same AE in an individual are coumted separately. AEs collected after first treatment dose are\\_ included.

Data Cutoff: 15MAR2018; RAVE Data Extracted: 18 May 2018.

Table 60: Summary of All Study Treatment-Related AEs and Atezolizumab Related AEs in Study IMpower130

| Summary of AEs by System Organ Class                 | All Study Treatment Related IMpower 130 Atezo+CnP (n = 473)   | Atezolizumab Only Related IMpower 130 Atezo+CnP (n = 473)   |
|------------------------------------------------------|---------------------------------------------------------------|-------------------------------------------------------------|
| No. Patients with any AE                             | 471 (99.6%)                                                   | 471 (99.6%)                                                 |
| No. Patients with treatment-related AE               | 455 (96.2%)                                                   | 354 (74.8%)                                                 |
| Blood and lymphatic system disorders                 | 354 (74.8%)                                                   | 100 (21.1%)                                                 |
| Cardiac disorders                                    | 17 (3.6%)                                                     | 14 (3.0%)                                                   |
| Congenital, familial and genetic disorders           | 0                                                             | 0                                                           |
| Ear and labyrinth disorders                          | 12 (2.5%)                                                     | 5 (1.1%)                                                    |
| Endocrine disorders                                  | 61 (12.9%)                                                    | 60 (12.7%)                                                  |
| Eye disorders                                        | 19 (4.0%)                                                     | 12 (2.5%)                                                   |
| Gastrointestinal disorders                           | 325 (68.7%)                                                   | 191 (40.4%)                                                 |
| General disorders and administration site conditions | 277 (58.6%)                                                   | 191 (40.4%)                                                 |

<div style=\"page-break-after: always\"></div>

| Summary of AEs by System Organ Class                                | All Study Treatment Related IMpower 130 Atezo+CnP (n = 473)   | Atezolizumab Only Related IMpower 130 Atezo+CnP (n = 473)   |
|---------------------------------------------------------------------|---------------------------------------------------------------|-------------------------------------------------------------|
| Hepatobiliary disorders                                             | 7 (1.5%)                                                      | 5 (1.1%)                                                    |
| Immune system disorders                                             | 1 (0.2%)                                                      | 1 (0.2%)                                                    |
| Infections and infestations                                         | 64 (13.5%)                                                    | 35 (7.4%)                                                   |
| Injury, poisoning and procedural complications                      | 13 (2.7%)                                                     | 11 (2.3%)                                                   |
| Investigations                                                      | 196 (41.4%)                                                   | 100 (21.1%)                                                 |
| Metabolism and nutrition disorders                                  | 177 (37.4%)                                                   | 93 (19.7%)                                                  |
| Musculoskeletal and connective tissue disorders                     | 88 (18.6%)                                                    | 75 (15.9%)                                                  |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | 0                                                             | 0                                                           |
| Nervous system disorders                                            | 196 (41.4%)                                                   | 77 (16.3%)                                                  |
| Pregnancy, puerperium and perinatal conditions                      | 0                                                             | 0                                                           |
| Psychiatric disorders                                               | 15 (3.2%)                                                     | 9 (1.9%)                                                    |
| Renal and urinary disorders                                         | 39 (8.2%)                                                     | 29 (6.1%)                                                   |
| Reproductive system and breast disorders                            | 4 ( 0.8%)                                                     | 4 (0.8%)                                                    |
| Respiratory, thoracic and mediastinal disorders                     | 104 (22.0%)                                                   | 68 (14.4%)                                                  |
| Skin and subcutaneous tissue disorders                              | 207 (43.8%)                                                   | 123 (26.0%)                                                 |
| Social circumstances                                                | 0                                                             | 0                                                           |
| Surgical and medical procedures                                     | 0                                                             | 0                                                           |
| Vascular disorders                                                  | 25 (5.3%)                                                     | 13 (2.7%)                                                   |

AE = adverse event; Atezo = Atezolizumab; CCOD = clinical cutoff date; CP = Carboplatin + Paclitaxel.

Only events reported in the Adverse Events Form are included. Investigator text for AEs encoded using MedDRA v21.0. Percentages are based on N in the column headings.  Multiple occurrences of the same AE in one individual are counted only once except for \"Total number of events\" row in which multiple occurrences of the same AE are counted separately.  AEs collected after first treatment dose are included

## Adverse drug reactions

The table below reflects the ADRs from the pooled safety data for atezolizumab including study IMpower133.

| Atezolizumab monotherapy (n=3178)    | Atezolizumab monotherapy (n=3178)    | System Organ Class ADR               | Atezolizumab in combination therapy* (n=2759)   | Atezolizumab in combination therapy* (n=2759)   |
|--------------------------------------|--------------------------------------|--------------------------------------|-------------------------------------------------|-------------------------------------------------|
| Frequency (All Grades)               | Incidence% (All Grades)              | System Organ Class ADR               | Frequency (All Grades)                          | Incidence% (All Grades)                         |
| Infections and infestations          | Infections and infestations          | Infections and infestations          | Infections and infestations                     | Infections and infestations                     |
| very common                          | 368 (11.6%)                          | Urinary tract infection a            | -                                               | -                                               |
| -                                    | -                                    | Lung infection b                     | very common                                     | 377 (13.7%)                                     |
| Blood and Lymphatic System Disorders | Blood and Lymphatic System Disorders | Blood and Lymphatic System Disorders | Blood and Lymphatic System Disorders            | Blood and Lymphatic System Disorders            |
| -                                    | -                                    | Anaemia                              | very common                                     | 916 (33.2%)                                     |
| -                                    | -                                    | Neutropenia d                        | very common                                     | 930 (33.7%)                                     |
| common                               | 116 (3.7%)                           | Thrombocytopenia c                   | very common                                     | 586 (21.2%)                                     |
| -                                    | -                                    | Leukopenia e                         | very common                                     | 322 (11.7%)                                     |
| -                                    | -                                    | Lymphocyte count decreased           | common                                          | 55 (2.0%)                                       |
| Immune System Disorders              | Immune System Disorders              | Immune System Disorders              | Immune System Disorders                         | Immune System Disorders                         |
| common                               | 51 (1.6%)                            | Infusion related reaction f          | -                                               | -                                               |
| Endocrine Disorders                  | Endocrine Disorders                  | Endocrine Disorders                  | Endocrine Disorders                             | Endocrine Disorders                             |
| uncommon                             | 11 (0.3%)                            | Adrenal insufficiency j              | -                                               | -                                               |
| uncommon                             | 10 (0.3%)                            | Diabetes mellitus i                  | -                                               | -                                               |
| uncommon                             | 30 (0.9%)                            | Hyperthyroidism h                    | -                                               | -                                               |
| rare                                 | 2 (<0.1%)                            | Hypophysitis k                       | -                                               | -                                               |
| common                               | 164 (5.2%)                           | Hypothyroidism g                     | very common                                     | 420 (15.2%)                                     |
| Metabolism and nutrition disorders   | Metabolism and nutrition disorders   | Metabolism and nutrition disorders   | Metabolism and nutrition disorders              | Metabolism and nutrition disorders              |
| very common                          | 810 (25.5%)                          | Decreased appetite                   | very common                                     | 678 (24.6%)                                     |
| common                               | 138 (4.3%)                           | Hypokalemia                          | common                                          | 202 (7.3%)                                      |
| -                                    | -                                    | Hypomagnesaemia                      | common                                          | 259 (9.4%)                                      |
| common                               | 169 (5.3%)                           | Hyponatremia                         | common                                          | 145 (5.3%)                                      |
| common                               | 103 (3.2%)                           | Hyperglycaemia                       | -                                               | -                                               |

<div style=\"page-break-after: always\"></div>

| Nervous System Disorders                         | Nervous System Disorders                         | Nervous System Disorders                         | Nervous System Disorders                         | Nervous System Disorders                         |
|--------------------------------------------------|--------------------------------------------------|--------------------------------------------------|--------------------------------------------------|--------------------------------------------------|
| -                                                | -                                                | Dizziness                                        | very common                                      | 292 (10.6%)                                      |
| -                                                | -                                                | Syncope                                          | common                                           | 46 (1.7%)                                        |
| uncommon                                         | 5 (0.2%)                                         | Guillain-Barré syndrome m                        | -                                                | -                                                |
| uncommon                                         | 14 (0.4%)                                        | Meningoencephalitis n                            | -                                                | -                                                |
| rare                                             | 1 (<0.1%)                                        | Myasthenic syndrome o                            | -                                                | -                                                |
| -                                                | -                                                | Peripheral neuropathyl                           | very common                                      | 740 (26.8%)                                      |
| -                                                | -                                                | Headache                                         | very common                                      | 469 (17.0%)                                      |
| Cardiac Disorders                                | Cardiac Disorders                                | Cardiac Disorders                                | Cardiac Disorders                                | Cardiac Disorders                                |
| rare                                             | 2 (<0.1%)                                        | Myocarditis p                                    | -                                                | -                                                |
| Vascular Disorders                               | Vascular Disorders                               | Vascular Disorders                               | Vascular Disorders                               |                                                  |
| common                                           | 102 (3.2%)                                       | Hypotension                                      | -                                                | -                                                |
| Respiratory, Thoracic, and Mediastinal Disorders | Respiratory, Thoracic, and Mediastinal Disorders | Respiratory, Thoracic, and Mediastinal Disorders | Respiratory, Thoracic, and Mediastinal Disorders | Respiratory, Thoracic, and Mediastinal Disorders |
| very common                                      | 660 (20.8%)                                      | Cough                                            | very common                                      | 554 (20.1%)                                      |
| very common                                      | 651 (20.5%)                                      | Dyspnoea                                         | very common                                      | 481 (17.4%)                                      |
| common                                           | 73 (2.3%)                                        | Hypoxia                                          | -                                                | -                                                |
| common                                           | 101 (3.2%)                                       | Nasal congestion                                 | -                                                | -                                                |
| common                                           | 87 (2.7%)                                        | Pneumonitis q                                    | -                                                | -                                                |
| common                                           | 141 (4.4%)                                       | Nasopharyngitis                                  | -                                                | -                                                |
| -                                                | -                                                | Dysphonia                                        | common                                           | 155 (5.6%)                                       |
| Gastrointestinal Disorders                       | Gastrointestinal Disorders                       | Gastrointestinal Disorders                       | Gastrointestinal Disorders                       | Gastrointestinal Disorders                       |
| common                                           | 268 (8.4%)                                       | Abdominal pain                                   | -                                                | -                                                |
| common                                           | 34 (1.1%)                                        | Colitis s                                        | -                                                | -                                                |
| -                                                | -                                                | Constipation                                     | very common                                      | 745 (27.0%)                                      |
| very common                                      | 626 (19.7%)                                      | Diarrhoea r                                      | very common                                      | 814 (29.5%)                                      |
| common                                           | 82 (2.6%)                                        | Dysphagia                                        | -                                                | -                                                |
| very common                                      | 747 (23.5%)                                      | Nausea                                           | very common                                      | 1031 (37.4%)                                     |
| uncommon                                         | 18 (0.6%)                                        | Pancreatitis u                                   | -                                                | -                                                |
|                                                  | -                                                | Stomatitis                                       | common                                           | 259 (9.4%)                                       |
| - very common                                    | 477 (15.0%)                                      | Vomiting                                         | very common                                      | 527 (19.1%)                                      |
| common                                           | 131 (4.1%)                                       | Oropharyngeal pain t                             | -                                                | -                                                |
| -                                                | -                                                | Dysgeusia                                        | common                                           | 199 (7.2%)                                       |
| Hepatobiliary Disorders                          | Hepatobiliary Disorders                          | Hepatobiliary Disorders                          | Hepatobiliary Disorders                          | Hepatobiliary Disorders                          |
| common                                           | 167 (5.3%)                                       | ALT increased                                    | common                                           | 219 (7.9%)                                       |
| common                                           | 180 (5.7%)                                       | AST increased                                    | common                                           | 203 (7.4%)                                       |
| common                                           | 62 (2.0%)                                        | Hepatitis v                                      | -                                                | -                                                |
| Skin and Subcutaneous Tissue Disorders           | Skin and Subcutaneous Tissue Disorders           | Skin and Subcutaneous Tissue Disorders           | Skin and Subcutaneous Tissue Disorders           | Skin and Subcutaneous Tissue Disorders           |
| very common                                      | 400 (12.6%)                                      | Pruritus                                         | very common                                      | 363 (13.2%)                                      |
| very common                                      | 619 (19.5%)                                      | Rash w                                           | very common                                      | 785 (28.5%)                                      |
| Musculoskeletal and Connective Tissue Disorders  | Musculoskeletal and Connective Tissue Disorders  | Musculoskeletal and Connective Tissue Disorders  | Musculoskeletal and Connective Tissue Disorders  | Musculoskeletal and Connective Tissue Disorders  |
| very common                                      | 441 (13.9%)                                      | Arthralgia                                       | very common                                      | 535 (19.4%)                                      |
| very common                                      | 487 (15.3%)                                      | Back pain                                        | very common                                      | 373 (13.5%)                                      |
| very common                                      | 414 (13.0%)                                      | Musculoskeletal pain x                           | very common                                      | 510 (18.5%)                                      |
| Uncommon                                         | 13 (0.4%)                                        | Myositis y                                       | -                                                | -                                                |
| Renal Disorders                                  | Renal Disorders                                  | Renal Disorders                                  | Renal Disorders                                  | Renal Disorders                                  |
| -                                                | -                                                | Proteinuria z                                    | common                                           | 215 (7.8%)                                       |
| rare                                             | 3 (<0.1%)                                        | Nephritis aa                                     | -                                                | -                                                |
| General Disorders and Administration             | General Disorders and Administration             | General Disorders and Administration             | General Disorders and Administration             | General Disorders and Administration             |
| very common                                      | 461 (14.5%)                                      | Asthenia                                         | very common                                      | 487 (17.7%)                                      |
| common                                           | 207 (6.5%)                                       | Chills                                           | -                                                | -                                                |
| very common                                      | 1142 (35.9%)                                     | Fatigue                                          | very common                                      | 1003 (36.4%)                                     |
| common                                           | 186 (5.9%)                                       | Influenza like illness                           | -                                                | -                                                |
| very common                                      | 638 (20.1%)                                      | Pyrexia                                          | very common                                      | 473 (17.1%)                                      |

a Includes reports of urinary tract infection, cystitis, pyelonephritis, escherichia urinary tract infection, urinary tract infection bacterial, kidney infection, pyelonephritis acute, urinary tract infection fungal, urinary tract infection pseudomonal.

b Includes reports of pneumonia, bronchitis, lung infection, lower respiratory tract infection, infective exacerbation of COPD, infectious pleural effusion, tracheobronchitis, atypical pneumonia, lung abscess, pyopneumothorax.

c  Includes reports of thrombocytopenia and platelet count decreased.

d  Includes reports of neutropenia, neutrophil count decreased, febrile neutropenia, neutropenic sepsis, granulocytopenia.

e  Includes reports of white blood cell count decreased and leukopenia.

f  Includes reports of cytokine release syndrome, hypersensitivity, anaphylaxis.

g  Includes reports of autoimmune hypothyroidism, autoimmune thyroiditis, blood thyroid stimulating hormone abnormal, blood thyroid stimulating hormone decreased, blood thyroid stimulating hormone increased, euthyroid sick syndrome, goitre, hypothyroidism, myxoedema, thyroid disorder, thyroid function test abnormal, thyroiditis, thyroiditis acute, thyroxine decreased, thyroxine free decreased, thyroxine free increased, thyroxine increased, tri-iodothyronine decreased, tri-iodothyronine free abnormal, tri-iodothyronine free decreased, tri-iodothyronine free increased.

h  Includes reports of hyperthyroidism, Basedow's disease, endocrine ophthalmopathy, exophthalmos.

i Includes reports of diabetes mellitus, type 1 diabetes mellitus, diabetic ketoacidosis, ketoacidosis.

j Includes reports of adrenal insufficiency and primary adrenal insufficiency.

ak  Incudes reports of hypophysitis and temperature regulation disorder.

<div style=\"page-break-after: always\"></div>

- l  Includes reports of neuropathy peripheral, autoimmune neuropathy, peripheral sensory neuropathy, polyneuropathy, herpes zoster, peripheral motor neuropathy, neuralgic amyotrophy, peripheral sensorimotor neuropathy, toxic neuropathy, axonal neuropathy, lumbosacral plexopathy, neuropathic arthropathy, peripheral nerve infection.
- m  Includes reports of Guillain-Barré syndrome and demyelinating polyneuropathy.
- n Includes reports of encephalitis, meningitis, photophobia.
- ao  Incudes reports of myasthenia gravis.
- p  Reported in studies outside the pooled dataset. The frequency is based on the program wide exposure.
- q Includes reports of pneumonitis, lung infiltration, bronchiolitis, interstitial lung disease, radiation pneumonitis.
- r  Includes reports of diarrhoea, defaecation urgency, frequent bowel movements, and gastrointestinal hypermotility.
- s Includes reports of colitis, autoimmune colitis, colitis ischaemic, colitis microscopic, colitis ulcerative.
- t  Includes reports of oropharyngeal pain, oropharyngeal discomfort and throat irritation.
- u Includes reports of autoimmune pancreatitis, pancreatitis, pancreatitis acute, lipase increased, amylase increased.
- v Includes reports of ascites, autoimmune hepatitis, hepatocellular injury, hepatitis, hepatitis acute, hepatotoxicity, liver disorder, drug-induced liver injury, hepatic failure, hepatic steatosis, hepatic lesion, oesophageal varices haemorrhage, varices oesophageal.
- w  Includes reports of acne, acne pustular, dermatitis, dermatitis acneiform, dermatitis allergic, dermatitis bullous, dermatitis exfoliative generalised, drug eruption, eczema, eczema infected, erythema, erythema multiforme, erythema of eyelid, exfoliative rash, eyelid rash, fixed eruption, folliculitis, furuncle, generalised erythema, palmar-plantar erythrodysaesthesia syndrome, rash , rash erythematous, rash generalised, rash macular, rash maculo-papular, rash papular, rash papulosquamous, rash pruritic, rash pustular, rash vesicular, seborrhoeic dermatitis, skin exfoliation, skin toxicity, skin ulcer, toxic epidermal necrolysis, toxic skin eruption.
- x Includes reports of musculoskeletal pain and myalgia.
- y  Includes reports of myositis, rhabdomyolysis, polymyalgia rheumatica, dermatomyositis, muscle abscess, myoglobin urine present.
- z  Includes reports of proteinuria, protein urine present, haemoglobinurea, nephrotic syndrome.
- aa Includes report of nephritis, Henoch-Schonlein Purpura nephritis.
- -*includes studies GO29436, GO29438, GO29537, GO30081, WO29074, WO29637, WO29522.

## Serious adverse event/deaths/other significant events

## SAE

Table 61: Serious Adverse Events, with Onset Date Before Cross Over by Medical Concept, Preferred Term and Highest NCI CTCAE Grade - Study IMpower130

Serious Adverse Events, with Onset Date Before Cross Over by Medical Concept, Preferred Term and Highest NCI CTCAE Grade Safety-EvaluablePatients Protocol:G029537 (DataCutoff:15MAR2018)

<!-- image -->

Atezo=Atezolizumab,CnP=Carboplatin+Nab-Paclitaxel Investigator text for AEs encodedusingMedDRA v2l.0.Multiple occurrences of the same AE in one individual are counted once at the with the highest grade within the SoC.Percentages are based on N in the column headings.AEs collected after first treatment dose are included.

<div style=\"page-break-after: always\"></div>

Table 62: Serious adverse events with an incidence of at least 1% in either arm/population (safety evaluable population) - Study IMpower130 and pooled safety datasets

|                                                                                 | IHpower130    | IHpower130        |                                             |                  |                     |
|---------------------------------------------------------------------------------|---------------|-------------------|---------------------------------------------|------------------|---------------------|
| MadDRA Preferred Tem                                                            | CnP (N=232)   | Ateno+CnP (N=473) | Ateno+Chemo Combo Atero Hono NsCIC (N=2421) | (N=1636)         | Ateso Hono (N=3178) |
| Total number of patients with at least one adverse event Total number of events | 88 (37.9) 138 | 240 (80.74)       | 1073(44.3) 2023                             | 627 (38.38) 1043 | 1309 (41.2) 2267    |
| PNEUMONIA                                                                       | 14 6.031      | 28 5.91)          | 144 5.911                                   | 75 (4.6)         | 98 3.1#)            |
| DTARRHOEA                                                                       | 2 0.941       | 14 80.3           | 52 2.14)                                    | 10 10.631        | 21 0.741            |
| LUNG INFECTION                                                                  | 1 0.4)        | 14 3.0±)          | 28. 1.2+)                                   | 6 (0.6)          | 15 (0.5)            |
| NEUTROPENIA                                                                     | 2 0.94)       | 14 3.041          | 34 1.4+)                                    | 0                | 0                   |
| PULMONARY EMEOLISM                                                              | 5 2.241       | 14 3.081          | 40 1.741                                    | 20 ( 1.24)       | 42 (1.31)           |
| ANAEMIA                                                                         | 8 3.111       | 13 2.711          | 49 2.011                                    | 10 0.631         | 29 9.931            |
| CHRONIC CBSTRUCTIVE PULMONARY DISEASE                                           | 3 1.3+)       | 12 2.54)          | 35 1.4*)                                    | 9 0.64)          | 10 0.3+)            |
| DYSPNOEA                                                                        | 0.4#)         | 11 2.31)          | 32 1.311                                    | 51 [ 3.13)       | 89 2.831            |
| FEBRILE NEUTROPENIA                                                             | 2.241         | 9 1.94)           | 86 3.811                                    | 1 (<0.1+)        | 7 0.24)             |
| PLEURAL EFFUSION                                                                |               | 1.21              | 16 0.741                                    | 26 (1.6]         | 40 1.311            |
| PIREMIA                                                                         | (0.94)        | 8 1.74)           | 45 1.941                                    | 32 2.041         | 79 (2.53)           |
| PNEUMONITIS                                                                     | 3 (1.3)       | 7 1.511           | 51 2.111                                    | 24 (1.5)         | 35 (1.11)           |
| NEUTROFHIL COUNT DECREASED                                                      |               | 6 1.341           | 10 0.4*)                                    | 0                | 1 [<0.1+)           |
| PERICARDIAL EEFUSION                                                            |               | 6 1.311           | 12 9.511                                    | 10 9.631         | 14 0.4)             |
| BEPSIS                                                                          | oon (0.94)    | 6 1.34)           | 27 1.1#)                                    | 11 0.781         | 41 1.311            |
| THROMEOCYTOPENIA                                                                | 口             | 6 1.34)           | 31 1.3)                                     | 2 0.18)          | 6 0.2)              |
| TOMITING                                                                        | 中 1.7)        | 6 1.3)            | 27 1.11                                     | 11 0.73)         | 19 0.631            |
| BRONCHITIS                                                                      | Hom 0.481     | 5 1.14)           | 19 0.81)                                    | 5 0.34)          | 7 0.24)             |
| CHEST PATN                                                                      |               | 5 1.14)           | 11 0.511                                    | 10 0.68)         | 13 0.4)             |
| HAEMOPTYSIS                                                                     | 1.3)          | 1.18)             | 28 1.241                                    | 18 1.14)         | 20 0.681            |
| INELUENZA                                                                       | 1             | 5 1.1)            | 11 0.54)                                    | 3 0.23)          | 5 0.21              |
| NAUSEA                                                                          | 中 1.7+)       | 5 1.14)           | 17 0.7+1                                    | 12 0.74)         | 19 0.6*)            |
| RENAL FAILURE                                                                   | 9.931         | 5 1.1)            | 8 19.311                                    | 2 0.131          | 18 0.631            |
| SEPTIC SHOCK                                                                    |               | 1.14)             | 13                                          |                  | [0.3]               |
|                                                                                 | 0.941         | 5                 | 10.51)                                      | 5 0.3)           | 11                  |
| ACUTE KIINEY INJURY URINARY TRACT INEECTION                                     | 0 1 (0.4#)    | 4 (0.8) 4 (0.8±)  | 20 (0.6) 20 ( 0.81)                         | 6 4 ( 0.2)       | 37 (1.24) 61 (1.9#) |
| BACK PAIN                                                                       |               |                   | 0.5                                         |                  |                     |
| DEATH                                                                           | (1.7)         | 3 0.24) 0.61      | 0.61                                        | 14 (46*01 0.64)  | 98 11.13 0.6)       |

Investigator tent for AEs encoded using MedDRA v2l.0. Percentages are based on N in the column headings. For frequency counts by \"Total number of events' rows, the mltiple occurrenoes of the seme AE in an individual are counted separately. All treatment emergent AEs are included. Sort order\\_ig by decreasing frequency in Ateso+CnP treataent am. Ateso-Atesolisumeb, CnP=Carboplatin+Neb-Paelitamel. Ateso+Chemo Conbo: G029537 (IMF0WER130) Am A + G029437 (IMe0WERl31) Am A+B + (BOPLAR) + G028754 (BIRCH) +G028625 (FIR) + G027631 (BCD4969g - NSCLC Cohort).AteBo Hono: G028915 (0AK) + G028753(B0PLAR) + (IMM0T10NL50 Arm B). C1inica1 cut-off dates: G027831:31MAR2016, G028625:070AN2015, G028753:01DBC2015, G028754:01DEC2015, G030081:24APR2018,W029074:170CT2016.

## Death

Table 63: Cases of deaths (safety evaluable population) - Study IMpower130 and pooled safety datasets

|                                               | IMpower130   | IMpower130   | IMpower130        | IMpower130   |                                            |                     |             |
|-----------------------------------------------|--------------|--------------|-------------------|--------------|--------------------------------------------|---------------------|-------------|
|                                               | CnP (N=232)  |              | Atezo+CnP (N=473) | (N=2421)     | Atezo+Chemo ComboAtezo Mono NSCLC (N=1636) | Atezo Mono (N=3178) |             |
| All death                                     | (57.8%)      |              |                   |              |                                            |                     |             |
| n                                             | 134          | 240          | (50.7%)           | 1277         | (52.78) 907 (55.48)                        |                     | 1884(59.38) |
| <=30 days from laststucdy crug acministration | 24 (10.3%)   | 41           | (8.7%)            | 235          | (9.7%) 167 (10.28)                         | 352                 | (11.18)     |
| >30 days from last stuciy crug acministration | 110 (47.4%)  | 199          | (42.18)           | 1042         | (43.0%) 740 (45.28)                        | 1532                | (48.28)     |
| Primary cause of death                        |              |              |                   |              |                                            |                     |             |
| n                                             | 134 (57.8%)  | 240          | (50.7%)           | 1277         | (52.78) 907 (55.48)                        | 1884                | (59.3号)     |
| ADVERSEEVENT                                  | 15 (6.5%)    | 25           | ( 5.3号)           | 143          | (5.9%) 68 (4.2号) 774                       | 120                 | (3.8%)      |
| PROGRESSIVE DISEASE                           | 114 (49.18)  | 200          | (42.38)           | 1062         | (43.98) (47.38) 65                         | 1463                | (46.0%)     |
| OTHER                                         | 5 (2.28)     | 15           | (3.2%)            | 72           | (3.0%) (4.0%)                              | 301                 | (9.58)      |

<!-- image -->

<div style=\"page-break-after: always\"></div>

Table 64: Adverse events leading to death by system organ class and preferred term (safety evaluable population) - Study IMpower130

| MedDRA System Oegen Cless MedlRA Preferred Tem           | CnP (Actual) (N=232)   | Ateso+CnP (Actual) (N=473)   |
|----------------------------------------------------------|------------------------|------------------------------|
| Total nuber of patients with at least one adverse event  | 13 (5.6)               | 25(5.3)                      |
| Overall total number of events                           | 13                     | 25                           |
| INEECTIONS AND INFESTATIONS                              |                        |                              |
| Total number of patients with at leest one adverse event | 5 [2.23)               | 8 (1.74)                     |
| FNEUMONIA                                                | (0.93)                 | 5 [1.13)                     |
| SEPSIS                                                   | NN 70.991              | 1 16.231                     |
| SEPTIC SHOCK                                             | (0.4#)                 | 1 (0.23)                     |
| STAFHYLOCOCCALSEPSIS                                     |                        | 1 (0.24)                     |
| RESPIRATORY,THORACICAND MEDIASTINALDISORDERS             |                        |                              |
| Total number_of patients with at least one adverse event | 3 (1.3#)               | 8 [1.73)                     |
| FULMONARYEMEOLTSH                                        | 1 70.43)               | (0.84)                       |
| FNEUMONITIS                                              | 1 (0.4#)               | (0.4*)                       |
| ASPIRATION                                               | 0                      | 1 10.231                     |
| RESPIRATORYDISTRESS                                      | 0                      | 1 10.24)                     |
| CHRONICOBSTRUCTIIEPUIMONARY DISEASE                      | (0.44)                 | 0                            |
| CARDIACDISORDERS                                         |                        |                              |
| Total number of patients with at lerst one adverse event | 0                      | 7 (1.5#)                     |
| MYOCARDIALINFARCTION                                     | 0                      | 3 (0.6)                      |
| CARDTACARREST                                            | 9                      | 2 19.431                     |
| CARDIO-RESPIRATORY ARREST                                | 0                      | 1 (0.23)                     |
| VENTRICULARTACHYCARDIA                                   | 0                      | 1 (0.24)                     |
| GENERALDISORDERS AND ADMINISTRATION SITECONDITIONS       |                        |                              |
| Total mumber of patients with at lesst one adverse event | 5 (2.2#)               | 1 (0.2)                      |
| DEATH                                                    | 4 11.731               | 1 10.241                     |
| SUDDENDEATH                                              | 1 (0.45)               | 0                            |
| HEPATOBTLIARY DISORDERS                                  |                        |                              |
| Total nimber of patients with at lesst one adverse event | 0                      | 1 (0.24)                     |
| HEPATICCIRRHOSTS                                         | 0                      | 1 (0.24)                     |

AtenoAtesolisumrb,CnFtarboplatin+Neb-Paclitawel

Inwestigator text for AEs encodad using MadDRA v2l.0. Percentages are based on N in\\_the column headings. For frequency counts by preferred teim, multiple occirrences of the ssme AE in an individual are countsdonly onee. For frecyeney.sounts of \"Total mumber of events\"rowsr the first treatment dose are ineludad. Data Cutoff: 15MAR2016: RAVE Data Entracted: 18 May 2016.

## AESI for atezolizumab

Table 65: Summary of adverse events of special interest for atezolizumab (safety evaluable population) Study IMpower130 and pooled safety datasets

|                                                                             | IMpowerl30                                                        | IMpowerl30        |                            |                           |                     |
|-----------------------------------------------------------------------------|-------------------------------------------------------------------|-------------------|----------------------------|---------------------------|---------------------|
|                                                                             | CnP (N=232)                                                       | Atezo+CnP (N=473) | Atezo+Chemo Combo (N=2421) | Atezo Mono NSCLC (N=1636) | Atezo Mono (N=3178) |
| Total number of patients with at least one AESI Total number of AESI events | 58 (25.0%) 91                                                     | 213 (45.08) 436   | 1164 (48.18) 2395          | 532 (32.58) 1016          | 1098 (34.6%) 2186   |
| Totalnumber ofpatientswithatleast one                                       |                                                                   |                   |                            |                           |                     |
| Treatment-related AESI                                                      | 34 (14.78)                                                        | 168 (35.58)       | 975 (40.38)                | 382 (23.38)               | 794 (25.08)         |
| Atezo-related AESI                                                          | 2 0.98)                                                           | 156 (33.08)       | 880 (36.38)                | 382 (23.38)               | 794 (25.0名)         |
| Grade 3-4 AESI                                                              | 11 4.7%)                                                          | 33 7.08)          | 250 (10.3%)                | 105 6.48)                 | 248 7.8%)           |
| Treatment-related Grade 3-4 AESI                                            | 6 2.68)                                                           | 24 5.18)          | 213 8.88)                  | 78 4.8%)                  | 173 5.48)           |
| Atezo-related Grade 3-4AESI                                                 | 1 0.4%)                                                           | 22 4.78)          | 194 8.08)                  | 78 4.88)                  | 173 5.4%)           |
| Grade 5 AESI                                                                | 1 0.48)                                                           | 3 0.68)           | 11 0.58)                   | 2 0.18)                   | 4 0.18) 2           |
| Treatment-related Grade_5AESI                                               |                                                                   | 3 0.68)           | 11 0.58)                   |                           | (<0.18)             |
| Atezo-related Grade5AESI                                                    | 0                                                                 | 2 0.48)           | 10 0.4%)                   | 0                         | 2 (<0.1%)           |
| Serious AESI                                                                | 5 2号                                                              | 30 6.38)          | 173 7.18)                  | 77 4.78)                  | 151 4.8%)           |
| Treatment-related serious AESI                                              | 2 0.98)                                                           | 26 5.58)          | 155 6.48)                  | 64 3.9%)                  | 127 4.0%)           |
| Atezo-related serious AESI                                                  | 0                                                                 | 25 5.38)          | 149 6.28)                  | 64 3.98)                  | 127 4.0%)           |
| AESI leading to any Treatment withdrawal                                    | 5 2.28)                                                           | 13 2.78)          | 134 5.58)                  | 35 2.18)                  | 58 1.8%)            |
| AESI leading to Atezo withdrawal                                            | 0                                                                 | 12 2.58)          | 122 5.0%)                  | 35 2.18)                  | 58 1.8%)            |
| AESI leading to Treatment modification/interruption                         | 6 2.68)                                                           | 52 (11.0%)        | 299 (12.48)                | 108 6.68)                 | 210 6.6%)           |
| AESI Treated with Systemic Corticosteroids                                  | 13 5.68)                                                          | 70 (14.88)        | 373 (15.4%)                | 115 7.0%)                 | 247 7.8%)           |
| AE of SpecialInterest Medical Concepts:patients with at least one           | AE of SpecialInterest Medical Concepts:patients with at least one |                   |                            |                           |                     |
| Immune-Related Rash                                                         | 35 (15.18)                                                        | 114 (24.18)       | 616 (25.48)                | 303 (18.58)               | 620 (19.58)         |
| Immune-Related Hypothyroidism                                               | 1 0.48)                                                           | 70 (14.88)        | 277 (11.48)                | 76 4.68)                  | 164 (5.28)          |
| Immune-Related Hepatitis (Diagmosis and Lab Abnormalities)                  | 19 8.28)                                                          | 46 (9.78)         | 345（ (14.38)               | 152 (9.38)                | 343 (10.8%)         |
| Immune-Related Hepatitis (Lab Abnormalities)                                | 19 8.28)                                                          | 39 8.28)          | 315 (13.08)                | 137 8.48)                 | 315 9.98)           |
| Immune-Related Pneumonitis                                                  | 3 1.38)                                                           | 31 6.68)          | 134 5.58)                  | 56 3.48)                  | 87 2.78)            |
| Immune-Related Hyperthyroidism                                              | 1 0.48)                                                           | 23 4.98)          | 91 3.8%)                   | 15 0.98)                  | 30 0.98)            |
| Infusion-Related Reactions                                                  | 3 1.38)                                                           | 10 2.18)          | 70 2.9%)                   | 19 1.28)                  | 34 1.18)            |
| Immune-Related Hepatitis (Diagnosis)                                        | 3 1.38)                                                           | 8 1.7%)           | 44 1.8%)                   | 27 1.7%)                  | 62 2.0%)            |
| Immune-Related Adrenal Insufficiency                                        |                                                                   | 7 1.58)           | 18 0.7%)                   | 6 0.4%)                   | 12 0.4%)            |
| Immune-Related Colitis                                                      | 1 0.48)                                                           | 5 1.18)           | 38 1.68)                   | 15 0.98)                  | 34 1.18)            |
| AutoimmuneHemolyticAnemia                                                   | 0                                                                 | 4 (88'0           | 6 0.28)                    | 3 0.28)                   | 4 0.18)             |
| Immune-Related Diabetes Mellitus                                            | 2 0.98)                                                           | 4 0.88)           | 16 0.7%)                   | 5 0.38)                   | 11 0.38)            |
| Immune-Related Nephritis                                                    |                                                                   | 4 0.88)           | 12 0.58)                   | (<0.18)                   | 3 (<0.18)           |
| Immune-Related Meningoencephalitis                                          | 0                                                                 | 3 0.68)           | 10 0.48)                   | 9 0.68)                   | 13 0.48)            |
| Immune-Related Severe Cutaneous Reactions                                   | 0                                                                 | 3 0.68)           | 19 0.8%)                   | 12 (0.78)                 | 22 (0.78)           |

<div style=\"page-break-after: always\"></div>

<!-- image -->

Important AESI for Atezolizumab (IMpower130 Atezo+CnP)

AESIs for atezolizumab by medical concepts grouped under important AESIs correspond to important identified risks.

Table 66: Summary of safety information for important adverse events of special interest for atezolizumab (IMpower130 Atezo+CnP, safety-evaluable population) - Study IMpower130

<!-- image -->

|                                                  | No. of Patients (%)   | No. of Patients (%)   | No. of Patients (%)   | No. of Patients (%)   | Months (Range)        | Months (Range)              | No. of Patients (%)                                   | No. of Patients (%)                                 |
|--------------------------------------------------|-----------------------|-----------------------|-----------------------|-----------------------|-----------------------|-----------------------------|-------------------------------------------------------|-----------------------------------------------------|
|                                                  | Severity              | Severity              | Severity              | Resolved              | Median Time           | Median Duration (AllGrades) | AESIs Leading to Atezolizumab Withdrawal (All Grades) | AESIs Requiring Corticosteroids (imAEs, All Grades) |
| Important AESI                                   | AllGrades             | Grade 3-4             | Grade 5               | (All Grades) a        | to Onset (All Grades) |                             |                                                       |                                                     |
| N=213 (45.0%)                                    | Atezo+CnP             | Atezo+CnP             | Atezo+CnP             | Atezo+CnP             | Atezo+CnP             | Atezo+CnP                   | Atezo+CnP                                             | Atezo+CnP                                           |
| Immune-related:                                  |                       |                       |                       |                       |                       |                             |                                                       |                                                     |
| Hypothyroidism                                   | 70 (14.8)             | 3 (0.6%)              | 0                     | 33 (47.1%)            | 5.29 (0.1-21.5)       | 12.4 (0*-24*)               | 0                                                     | 8 (1.7%)                                            |
| Hepatitis (diagnosis and laboratory abnormality) | 46 (9.7%)             | 14 (3.0%)             | 1 (0.2%)              | 32 (69.6%)            | 1.38 (0.0-17.9)       | 1.3 (0-20*)                 | 4 (0.8%)                                              | 18 (3.8%)                                           |
| Hepatitis (diagnosis)                            | 8 (1.7%)              | 2 (0.4%)              | 1 (0.2%)              | 5 (62.5%)             | 1.38 (0.3-6.4)        | 1.5 (0*-20*)                | 4 (0.8%)                                              | 7 (1.5%)                                            |
| Hepatiis (laboratory abnormality)                | 39 (8.2%)             | 12 (2.5%)             | 0                     | 27 (69.2%)            | 1.38 (0.0-17.9)       | 1.2 (0-20*)                 | 0                                                     | 11 (2.3%)                                           |
| Hyperthyroidism                                  | 23 (4.9%)             | 1 (0.2%)              | 0                     | 15 (65.2%)            | 4.57 (0.3-22.8)       | 3.1 (1-12*)                 | 1 (0.2%)                                              | 1 (0.2%)                                            |
| Infusion-relatedreactions                        | 10 (2.1%)             | 1 (0.2%)              | 0                     | 10 (100%)             | 1.08 (0.0-14.9)       | 0.0 (0-0)                   | 0                                                     | 1 (0.2%)                                            |
| Pneumonitis                                      | 31 (6.6%)             | 0                     | 2 (0.4%)              | 22 (71.0%)            | 3.52 (0.3-24.3)       | 2.1 (0-22*)                 | 3 (0.6%)                                              | 21 (4.4%)                                           |
| Colitis                                          | 5 (1.1%)              | 5 (1.1%)              | 0                     | 4 (80.0%)             | 1.84 (0.4-17.6)       | 0.5 (0-1*)                  | 2 (0.4%)                                              | 5 (1.1%)                                            |
| Guillain-Barre syndrome                          | 0                     | 0                     | 0                     | 0                     | NE                    | NE                          | 0                                                     | 0                                                   |
| Pancreatitis                                     | 2 (0.4%)              | 0                     | 0                     | 1 (50.0%)             | 5.90 (0.5-11.3)       | NE (0-6*)                   | 0                                                     | 0                                                   |
| Diabetes mellitus                                | 4 (0.8%)              | 2 (0.4%)              | 0                     | 1 (25.0%)             | 7.80 (1.4-17.9)       | NE (0*-12*)                 | 0                                                     | 2 (0.4%)                                            |
| Hypophysitis                                     | 2 (0.4%)              | 0                     | 0                     | 0                     | 5.19 (5.1-5.3)        | NE (13*-18*)                | 1 (0.2%)                                              | 2 (0.4%)                                            |
| Nephritis                                        | 4 (0.8%)              | 3 (0.6%)              | 0                     | 3 (75.0%)             | 3.37 (2.3-4.2)        | 0.9 (0-23*)                 | 1 (0.2%)                                              | 4 (0.8%)                                            |
| Adrenal insufficiency                            | 7 (1.5%)              | 0                     | 0                     | 2 (28.6%)             | 7.13 (4.7-19.6)       | NE (1-14*)                  | 0                                                     | 4 (0.8%)                                            |
| Meningoencephalitis                              | 3 (0.6%)              | 1 (0.2%)              | 0                     | 2 (66.7%)             | 4.76 (1.7-6.2)        | 2.9 (1-3)                   | 0                                                     | 1 (0.2%)                                            |
| Myocarditis                                      | 0                     | 0                     | 0                     | 0                     | NE                    | NE                          | 0                                                     | 0                                                   |
| Myasthenia gravis                                | 0                     | 0                     | 0                     | 0                     | NE                    | NE                          | 0                                                     | 0                                                   |

AESl=adverseeventofspecialinterest;Atezo=atezolizumab;CnP=carboplatin+nab-paclitaxel;imAE=immune-mediatedadverseevent;NE=notestimable.

Censored.

Hypophysitis occurred in 0.4% (2/473) of patients who received atezolizumab in combination with nab-paclitaxel and carboplatin. The median time to onset was 5.2 months (range: 5.1 to 5.3 months). Both patients required the use of corticosteroids.

<div style=\"page-break-after: always\"></div>

Important AESI for Atezolizumab  (Atezo+Chemo Combo)

Table 67: Summary of Safety Information for Important Adverse Events of Special Interest for Atezolizumab (Atezo+Chemo Combo, Safety-Evaluable Population) - pooled safety dataset

<!-- image -->

|                                              | No. of Patlents (Ss)   | No. of Patlents (Ss)   | No. of Patlents (Ss)   | No. of Patlents (Ss)    | Months (Ranoe)                    | Months (Ranoe)               | No. of Patlents ()                                | No. of Patlents ()                                |
|----------------------------------------------|------------------------|------------------------|------------------------|-------------------------|-----------------------------------|------------------------------|---------------------------------------------------|---------------------------------------------------|
|                                              | Severily               | Severily               | Severily               | Resolved (Mll Grades) * | Hedian Time to Onset (Mll Grades) | Medisn Duralion (Wll Grades) | AESIs Ledng to Alezolizumab Withdawal Mll Grades) | AESis Requiring Coricosleroids (lmAEa, NI Grmdes) |
| Important AESI N-1164 (48.15)                | Mll Grndes             | Gmda 3-4               | Grada5                 |                         |                                   |                              |                                                   |                                                   |
| Immune relaled:                              |                        |                        |                        |                         |                                   |                              |                                                   |                                                   |
| Hypothyroidiem                               | 277 (11.4%)            | 8(0.3%)                | 0                      | 109 (39.4%)             | 5.32 (0.1-24.9)                   | NE (0*26*)                   | 3 (0.1%6)                                         | 32 (1.346)                                        |
| Hepattis Idiognosis and Isborlory abromsliy! | 345 (14.3%)            | 100 (4.1%)             | 4(028)                 | 14280 012               | 145 (0.0-26.9)                    | 1.0 (0-24)                   | 33 (1.4%)                                         | 117 (4.8%)                                        |
| Hepalis (dingnosis)                          | 44 (1.85)              | 17 (0.7%)              | 3 (0.1%)               | 31 (70.5%8)             | 2.60 (03-16.9)                    | 1.9(0-239)                   | 16 (0.796)                                        | 24 [1.06]                                         |
| Hepalis (aboralory abnomalily)               | 315 (13.0%)            | 86 (2.64)              | 1(0.14)                | 246 (70.14)             | 1.41 (0.0-28.9)                   | 1.0 (0-24°)                  | 17 (0.746)                                        | 97 (4.096)                                        |
| Hyperhymldism                                | 91(3.894)              | 4 10.21                |                        | 67 (73.6%)              | 3.57 (0.0-22.8)                   | 28(0'-21\")                   | 2(.0.1%)                                          | 12 (0.561                                         |
| Infuslon-relaled reacllons                   | 70 (2.9951             | 12 10.541              | 0                      | 70 (10066)              | 0.74 (0.0-14.9)                   | 0.0(0-0)                     | 7 (0.36)                                          | 8 (0.396)                                         |
| Pneumonis                                    | 134 (5.59%)            | 33(1.44)               | 8 (0.2%)               | 85 (63.4%)              | 4.22 (0.3-27.4)                   | 22 (0-22)                    | 43 (1.86)                                         | 102 (4.26)                                        |
| Colls                                        | 38(1.64)               | 24 (1.04)              | 0                      | 29 (76.3%)              | 2.30(0.2-17.6)                    | 1.0 (023*                    | 6 (0.296)                                         | 26 (1.196]                                        |
| Gullaln Bame syndrome                        | 2(0.15)                | 1 (0.18)               | 1 (c0.1%)              | 1(50.04)                | 3.14 (2.6-3.6)                    | NE [1-49)                    | 1 (00.196)                                        | 1 (00.196)                                        |
| Pancrealilis                                 | 17 (0.74)              | 0 (0.3%)               | 0                      | 12 (7064)               | 4.37 (0.1-17.1)                   | 0.7 (0-219)                  | 1(40.1%6)                                         | 3(0.194)                                          |
| Dinbetes mellhus                             | 16 (0.74%)             | 1%E018                 | D                      | 2(12.54)                | 6.00 (0.8-17.9)                   | NE                           | 口                                                 | 5(0.296)                                          |
| Hypoph,slls                                  | 710.3%1                | 2 (.0.14)              |                        | 2(286%)                 | 6.37 (50-17.5)                    | NE (0'-18')                  | 21±0.1461                                         | 410 2461                                          |
| Nephriis                                     | 12(0.54)               | 810.3%1                |                        | 7 (59.341               | 6.16 (23-17.9)                    | 7210-239                     | 6(0.29)                                           | 9(0.41                                            |
| Adrenal Insumidency                          | 18(0.75)               | 310.1%)                |                        | 6 (33.3%)               | 6.90 (0.6-19.6)                   | NE (0-22\")                   | 1(40.156)                                         | 15 (0.6%)                                         |
| Meningoencephaliis                           | 10 (0.4%)              | 4 (0.2%)               | 0                      | 9 (90.04)               | 1.31 (0.5 6.2)                    | 1.5 (0-7)                    | 1 (c0.16)                                         | 4(0.26)                                           |
| Myocarditis                                  | 1 (-0.19)              | 1 (≤0.1%)              | 0                      | 0                       | 1.30 (1.4-1.4)                    | NE (1-1°)                    | 0                                                 | 1(-0.196)                                         |
| Myasheni qnws                                |                        |                        |                        |                         | NE                                | NE                           |                                                   | 口                                                 |

AESl-adversa event of speclal Interest; Atezo-atezolzumal, ImAE-Immune-medlaled adversa event; NE-not estimable

+Censomed.

Onh the firsti event withln each mportart AEsl medcal concent occuming for each callent is counted forresoluion

## Other AESI for Atezolizumab

Other AESIs include immune-related AEs (e.g., rash), potential risks, and class effects. These events are not considered important identified risks for atezolizumab as either the event is not considered severe (rash) or there is not enough evidence to confirm a causal relationship between the event and treatment with atezolizumab.

Table 68: Summary of Immune-Related skin reactions - Study IMpower130 and pooled safety datasets

<!-- image -->

|                                                              |                                                 | IMpower130          | IMpower130                                        |                                                     |                                    |                                                  |
|--------------------------------------------------------------|-------------------------------------------------|---------------------|---------------------------------------------------|-----------------------------------------------------|------------------------------------|--------------------------------------------------|
| AE of Special Interest Medical Concept MedDRA Preferred Term | Gradle                                          | CnP (N=232)         | Atezo+OnP (N=473)                                 | Atezo+Chemo Combo (N=2421)                          | Atezo Mono NSCIC (N=1636)          | Atezo Mono (N=3178)                              |
| IMMUNE-RELATED RASH                                          |                                                 |                     |                                                   |                                                     |                                    |                                                  |
| -Overall                                                     | Grade                                           | (15.18)             | (24.18)                                           | 616                                                 | 303 (18.58)                        | 620 (19.58)                                      |
|                                                              | 24                                              | (14.2%)             | (23.0%)                                           |                                                     | (17.68)                            | (18.4 4                                          |
|                                                              |                                                 | 0.98)               | (1.18)                                            |                                                     | 0.98)                              | 1号)                                              |
| RASH                                                         | Grade 24                                        | 6. 9%) 58)          | 64218171 (14.08) (13.5 5号 0. 4号) 6号               | 335 (13.8 8%) 13. 0.                                | 168 (10.3%) 161 9.8号) 7 0.4%)      | 358 (11. 3号)                                     |
| ERYTHEMA                                                     | —13—13—13—13—13—1—13—13—13—13—13— 24 2 Grade 24 | 1000000330220 0.4%) | 199 2.18) Z70770770661670#7550990 38) 1.38) 1.18) | 116165232912 <0.18) 2号) 2号) <0. 1号) 1. 08) 1. 0. 0. | 0.28) 1.8%) 1.8%) 0.8%)            | 344 14 0.4 48                                    |
|                                                              | Grade                                           |                     | 3.8号)                                             | 352                                                 | 329:32 2.0号) 1.8%)                 |                                                  |
| RASH MACULO-PAPULAR                                          | 24                                              | 3.0%)               | 2号                                                | 4号 8) 2. 78)                                        |                                    | 81586 1 6号 48                                    |
| RASH ERYTHEMATOUS                                            |                                                 |                     | 0.8%) 0.8%) 0.8%)                                 |                                                     | 0.8%) 0.48 0.4%                    | 0242477 0.88) 0.88)                              |
|                                                              | Grade 24                                        | 1.3%) 1.38)         | 0.6号) 0.28)                                       | 0.                                                  | 0.48) 0.4%) 0.98) 13 0.8%) (<0.18) | 0.58) 0.48) 281 (<0.18) 0.9% 0.8号) (<0.18)       |
|                                                              | Grade 24 Grade                                  | 0.4%)               | 0.6%)                                             | 0.78) <0.1号)                                        | 0.78) 0.78)                        | (40.v 0.8号) 0.88)                                |
| DERMATITISACNEIFORM ECZEMA SKIN ULCER RASH PRURITIC          | Grade 24                                        | 0.98) 0.98)         | 0.6%)                                             | 0. 1715 (<0.1%) 0. 7%)                              |                                    | 0亿记1966 2.2号) 2.18) (<0.18)                      |
| DERMATITIS ERYTHEMAMULTIFORME                                | Grade 24 Grade or 2                             | 110000 0.48) 0.48)  | 0.48) 0.48) 0.48) 0.48) 0.48)                     | gg 0.98) 0. 7号) 28 0.5号) 0.2 2号)                    | 0.8%) 12 0.7%) (<0.18) 0.2号)       | 2221 0.78) 0.6号 (<0.1%) 0.3号) 0.38 (<0.18) 0.4号) |
|                                                              | 24                                              | 0.48)               | 0.48)                                             | 0.2号) 0.53)                                         | 0.3号) 0.38)                        | 0.4%)                                            |
|                                                              |                                                 |                     |                                                   | 0.58)                                               | 143155 0.2%) (<0.18)               |                                                  |
| FOLLICULITIS                                                 |                                                 |                     |                                                   |                                                     |                                    |                                                  |
|                                                              |                                                 | 11 0.48)            |                                                   |                                                     | 000                                |                                                  |
|                                                              | Grade                                           |                     |                                                   |                                                     |                                    | 2                                                |
| TOXICEPIDERMALNECROLYSIS                                     |                                                 |                     |                                                   |                                                     |                                    |                                                  |
|                                                              | Any                                             |                     |                                                   |                                                     |                                    |                                                  |
|                                                              |                                                 |                     |                                                   |                                                     |                                    | (0.18)                                           |
|                                                              | ..的 'or 4                                       | opo                 | opo                                               |                                                     |                                    | (<0.18)                                          |
|                                                              |                                                 |                     |                                                   | 000                                                 |                                    | 1 (<0.18)                                        |

<div style=\"page-break-after: always\"></div>

<!-- image -->

## Laboratory findings

Table 69: Summary of clinically relevant shifts from baseline in laboratory parameters from Grade 0-2 at baseline to Grade 3-4 post-baseline (safety-evaluable population) - Study IMpower130

| Laboratory Test Category Laboratory Test                                | Grade Direction                                                         | CnP (Actual) (N=232)                                                    | Ateso+CnP (Actual) (N=473)                                              |
|-------------------------------------------------------------------------|-------------------------------------------------------------------------|-------------------------------------------------------------------------|-------------------------------------------------------------------------|
| Chemistry                                                               |                                                                         |                                                                         |                                                                         |
| Albumin (g/L)                                                           | Low                                                                     | 0/226                                                                   | 0/455                                                                   |
| Alkaline Phosphatase                                                    | (U/L) Righ                                                              | 2/227 (0.9*)                                                            | 11/461(2.4)                                                             |
| Bilirubin (umol/L)                                                      | High.                                                                   | 2/229(0.9)                                                              | 2/459(0.4)                                                              |
| Caleium (mmol/L)                                                        | High Low                                                                | 0/226 0/227                                                             | 0/458 0/458                                                             |
| Creatinine (umol/L)                                                     | High                                                                    | 1/229(0.4)                                                              | 14/463(3.0)                                                             |
| Glucose (mmo1/L)                                                        | Low                                                                     | 0/225                                                                   | 0/460                                                                   |
| Magmesium (mmol/L)                                                      | High LoW                                                                | 3/218(1.4) 0/218                                                        | 11/445.(2.54) 0/445                                                     |
| Fhosphorus (mmol/L)                                                     | Low                                                                     | 0/218                                                                   | 0/435                                                                   |
| Potassium (mmol/L)                                                      | High Low                                                                | 1/229(0.4) 0/229                                                        | 8/461(1.7) 0/461                                                        |
| SGOT/AST(U/L)                                                           | High                                                                    | 4/227 (1.8)                                                             | 9/458(2.0)                                                              |
| SGPT/ALT(U/L)                                                           | High                                                                    | 8/229 (3.5)                                                             | 11/462 (2.44)                                                           |
| Sodlium（mmol/L)                                                         | High Low                                                                | 0/229 0/221                                                             | 2/462(0.4) 0/457                                                        |
| Coagulation Activated IPartialThrcmboplastin Time (sec) High 0/78 0/106 | Coagulation Activated IPartialThrcmboplastin Time (sec) High 0/78 0/106 | Coagulation Activated IPartialThrcmboplastin Time (sec) High 0/78 0/106 | Coagulation Activated IPartialThrcmboplastin Time (sec) High 0/78 0/106 |
| International Nomaliged Ratio                                           | (ERACTION) High                                                         | 1/91 (1.1)                                                              | 3/148(2.04)                                                             |
| Hematolegy Hemogl6bin (g/L)                                             | High Low                                                                | 3/229(1.3) 0/229                                                        | 5/465.(1.1) 0/465                                                       |
| Lyuphoeytes Abs (l0~g/L)                                                | High Low                                                                | 0/228 0/220                                                             | 0/464 0/457                                                             |
| Neutrophils, Total,Abs (lo~g/L)                                         | Low                                                                     | 0/228                                                                   | 0/464                                                                   |
| Platelet (10~g/L)                                                       | Low                                                                     | 0/229                                                                   | 0/466                                                                   |
| White Blood Cell Count                                                  | (10~9/L) High LoW                                                       | 9                                                                       | 0/465 0/465                                                             |

Ateso-Atesolisumsb,CnP=Carboplatin+Neh-Paclitawel NCI-CicAE-National Cancer Institute Common Teminology Criteria for Adverse Events. Ehtended MCI-CICAEv4 waS used. For each laboratory 14624 244 01 P8pn13ug 81e1 4u90s6366e 8u5t36e4-460d 808 48991 4e 4474 64u214ed analyeis. For each cell, the denominator is the, mumber.of patients with baseline values of NcI-specified direction of: or with missing baseline values. Data Cutoff: 15MAR2018: RAVE Data Extractad: 18 May 2018l

<div style=\"page-break-after: always\"></div>

## Hy's Law Analysis

Hy's law cases were defined as elevated ALT or AST (&gt;3xULN) in combination with either an elevated total bilirubin (&gt;2XULN) or clinical jaundice in the absence of cholestasis or other causes of hyperbilirubinaemia. A total of 4 patients were identified as having at least one elevated total bilirubin (&gt;2xULN) within 7 days after the latest elevated ALT or AST (&gt;3xULN), including 5 patients in the Atezo-CnP arm and 1 patient in the CnP arm.

Of these 4 patients, two patients were diagnosed with immune mediated hepatitis; both patients recovered and their liver enzymes returned to within normal levels. One patient was reported to have not recovered. This patient had a confirmed tumoural obstruction of the biliary tract.  One patient was reported to have been recovering from the hepatic event, however this patient later died due to disease progression.

Table 70: Summary of clinically significant changes in electrocardiogram (safety-evaluable population) Study IMpower130

<!-- image -->

| Visit Name                                                                                       | CnP (Aetual) (N=232)                | Ateso+CnP (Actual) (N=473)              | All Patients (N=705)                        |
|--------------------------------------------------------------------------------------------------|-------------------------------------|-----------------------------------------|---------------------------------------------|
| Bereening                                                                                        |                                     |                                         |                                             |
| n Ahnoimal, :not clinically sigmificant Abnomal, clinieally sigmifieant Nomal Unsble to Bvaluate | 202 98 (48.54) 0 103 (51.08) (0.58) | 408 166(40.73) ( 1.08) 237(58.1) (0.28) | 610 264 [43.31) 4 (0.78) 340(55.74) 2 （0.3) |
| Post-baseline                                                                                    |                                     |                                         |                                             |
| n not clinieally signifiernt Abnormal,                                                           | 23 0 34 (59.61)                     | 83 27 (32.58) 3 [3.6] 53(63.98)         | 140 3 (2.18) 87(62.18)                      |
| clinically sigmifieant Nomal                                                                     | 57 (40.48)                          |                                         | 50(35.78)                                   |

Atero-Atenolieumeb, CnP-Carboplatin+Neb-Paclitawel

Deta Cutoff: 15MAR201B: RAVE bata Extractad: 18 May 2018.

Table 71: Summary of vital signs among subjects without abnormality at baseline (safety-evaluable population) - Study IMpower130

| Paremeter Deseription    | Direction of Abnomality   | CnP (Actual) (N=232)    | CnP (Actual) (N=232)    | Ateso+CnP (Actual) (N=473)   | Ateso+CnP (Actual) (N=473)   |
|--------------------------|---------------------------|-------------------------|-------------------------|------------------------------|------------------------------|
| Diegtolie Blood Pressure | Diegtolie Blood Pressure  |                         |                         |                              |                              |
|                          | High                      | 86/162                  | (53.18)                 | 181/337                      | 153.78)                      |
|                          | Lor                       | 50/162                  | (30.91)                 | 135/337                      | (40.18)                      |
| Pulse Rate               | Pulse Rate                |                         |                         |                              |                              |
|                          | High                      |                         | 59/194(30.48)           | 132/408(32.48)               |                              |
|                          | Low                       |                         | 30/194 (15.54)          |                              | 96/408(23.54)                |
| Respiratory Rate         | Respiratory Rate          | Respiratory Rate        | Respiratory Rate        | Respiratory Rate             | Respiratory Rate             |
|                          | High                      |                         | 61/169(36.1)            | 175/342                      | (51.28)                      |
|                          | Low                       | 2/169                   | (1.2)                   | 12/342                       | (3.58)                       |
| Syatolie Blood Pressure  | Syatolie Blood Pressure   | Syatolie Blood Pressure | Syatolie Blood Pressure | Syatolie Blood Pressure      | Syatolie Blood Pressure      |
|                          | High                      | 83/102                  | (81.4*)                 | 166/208                      | 168'6L1                      |
|                          | Lor                       | 11/102                  | (10.61)                 | 21/208                       | (10.18)                      |
| Temperature              | Temperature               | Temperature             | Temperature             | Temperature                  | Temperature                  |
|                          | High                      | 20/129                  | (15.51)                 | 49/262                       | (18.78)                      |
|                          |                           | 86/129                  | (66.74)                 | 206/262                      | (78.68)                      |

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Safety in special populations

## Intrinsic factors

Age

Table 72: Overview of safety by age (safety-evaluable population) - pooled safety dataset

|                                                                      | Ateso+Chemo Cembo (N=2421)   | Ateso+Chemo Cembo (N=2421)   | Ateso+Chemo Cembo (N=2421)   | Ateso+Chemo Cembo (N=2421)   | Ateso+Chemo Cembo (N=2421)   | Ateso+Chemo Cembo (N=2421)   | Ateso+Chemo Cembo (N=2421)   | Ateso+Chemo Cembo (N=2421)   |
|----------------------------------------------------------------------|------------------------------|------------------------------|------------------------------|------------------------------|------------------------------|------------------------------|------------------------------|------------------------------|
|                                                                      | <65 (W=1251)                 | <65 (W=1251)                 | =65 (N=1170)                 | =65 (N=1170)                 | 65 - 74 (N=927)              | 65 - 74 (N=927)              | 75 - 84 (N=234)              | >=65 (N=9)                   |
| Total number of patients with at least one AE Total number of Events | 1237 (98.94) 17852           | 1237 (98.94) 17852           | 1151(96.4) 17236             | 1151(96.4) 17236             | 909 (98.16) 13144            | 909 (98.16) 13144            | 233(99.6) 3977               | 9 （100] 115                  |
| Total number of patients with at least one                           |                              |                              |                              |                              |                              |                              |                              |                              |
| Treatment-related AE                                                 | 1169                         | (93.4*)                      | 1110                         | (94.91)                      | 875                          | (94.48)                      | 226 (96.64)                  | (100+)                       |
| Ateso-relatad AE                                                     | 668                          | (71.93)                      | 840                          | (71.84)                      | 650                          | (70.18)                      | 184 (78.63)                  | 6 (66.7*)                    |
| Grade3-4 AE                                                          | 802                          | 164.13)                      | 798                          | (68.21)                      | 617                          | 166.61]                      | 174 174.181                  | 7 177.831                    |
| Treatment-related Grade 3-4 AE                                       | 673                          | [53.8±)                      | 707                          | (60.4*)                      | 542                          | (58.54)                      | 159 (67.98)                  | 6 [66.7*]                    |
| Ateso-related Grade 3-4 HE                                           | 330                          | (26.43)                      | 328                          | (28.04)                      | 255                          | [27.51]                      | 70 129.93)                   | 3 (33.31)                    |
| Grade5 AE                                                            | 61                           | 4.94)                        | 83                           | 7.14)                        | 67                           | 7.28)                        | 14 6.04)                     | 2 (22.24)                    |
| Treatment-related Grade S AE                                         | 23                           | 1.831                        | 27                           | 2.31)                        | 23                           | 2.50                         | 3 1.31                       | (11.1#)                      |
| Ateso-related Grade 5 AE                                             | 16                           | 1.311                        | 15                           | 1.31)                        | 12                           | 1.3)                         | 3 1.31                       |                              |
| Serious AE                                                           | 507                          | [40.5]                       | 566                          | (48.4)                       | 439                          |                              | 122 (52.1#)                  | 5 (55.6*)                    |
| Treatment-related serious AE                                         | 281                          | (22.54)                      | 298                          | (25.54)                      | 238                          | 125.781                      | 57 (24.48)                   | 3 [33.34]                    |
| Ateso-relatad gerious AE                                             | 164                          | [14.7#]                      | 176                          | (15.0)                       | 141                          | [15.2]                       | (11.51)                      | [11.1#)                      |
| A2 leading to Treatment withdrawal                                   | 264                          | (21.13)                      | 324                          | (27.74)                      | 254                          | (27.48)                      | 67 [28.68)                   | 3 [33.38)                    |
| AE leading to Atero withdrawal                                       | 144                          | (11.5)                       | 175                          | (15.0)                       | 139                          | (15.04)                      | 33 (14.14)                   | 3 (33.3*)                    |
| AE leading to Treatnent modification/interruption                    | 806                          | (64.48)                      | 802                          | (68.54)                      | 623                          | (67.24)                      | 173 (73.98)                  | 6 (66.7*)                    |

<!-- image -->

Gender

|                                                                      | Atano+Chemo Combo (N=2421)   | Atano+Chemo Combo (N=2421)   | Atano+Chemo Combo (N=2421)   | Atano+Chemo Combo (N=2421)   |
|----------------------------------------------------------------------|------------------------------|------------------------------|------------------------------|------------------------------|
|                                                                      | Femele (N=812)               | Femele (N=812)               | Male (N=1609)                | Male (N=1609)                |
| Total nunber of patients with at lesut one AE Total nunber of Events |                              | 802(98.84) 13605             | 1586 (98.64) 21483           | 1586 (98.64) 21483           |
| Total nunber of patients with at least one                           |                              |                              |                              |                              |
| Treatment-releted AE                                                 | 779                          | 195.91)                      | 1500                         | 193.24)                      |
| Ateso-related AE                                                     | 603                          | [74.38)                      | 1136                         | (70.68)                      |
| Grade 3-4 AE                                                         | 573                          | (70.68)                      | 1027                         | (63.88)                      |
| Treatment-relatad Grede 3-4 AE                                       | 508                          | (62.61)                      | 872                          | (54.24)                      |
| Ateno-related Grade 3-4 AE                                           | 249                          | (30.74)                      | 409                          | (25.48)                      |
| Grade 5 AE                                                           | 33                           | 4.181                        | 111                          | 146'91                       |
| Treatment-nelatad Grade S AE                                         | 15                           | 1.811                        | 35                           | 12.28]                       |
| Ateso-related Grade 5 AE                                             | 10                           | (1.24)                       | 21                           | (1.38)                       |
| Berious AE                                                           | 378                          | (46.64)                      | 969                          | (43.24)                      |
| Treatment-related serious AE                                         | 208                          | [25.61)                      | 371                          | (23.18]                      |
| Ateso-related serious AE                                             | 128                          | (15.8*)                      | 232                          | (14.48)                      |
| AE leading to Treatment withdrawal                                   | 186                          | [22.98)                      | 402                          | (25.04)                      |
| HE leading to Ateso withdrawal                                       | 90                           | 11                           | 229                          | (14.28)                      |
| HE leading to Treatment modification/internuption                    | 582                          |                              | 1026                         | (63.88)                      |

Table 73: Overview of safety by gender (safety-evaluable population) - pooled safety dataset

<!-- image -->

Race

<div style=\"page-break-after: always\"></div>

Table 74: Overview of safety by race (safety-evaluable population) - pooled safety dataset

|                                                                      | Atero+Chemo Combo (N=2421)   | Atero+Chemo Combo (N=2421)   | Atero+Chemo Combo (N=2421)   | Atero+Chemo Combo (N=2421)   | Atero+Chemo Combo (N=2421)   | Atero+Chemo Combo (N=2421)   | Atero+Chemo Combo (N=2421)   |
|----------------------------------------------------------------------|------------------------------|------------------------------|------------------------------|------------------------------|------------------------------|------------------------------|------------------------------|
|                                                                      | White (N=1986)               | White (N=1986)               | Black (N=39)                 | Asian (N=293)                | Asian (N=293)                | Other. (N=103)               |                              |
| Total number of patients with at least one AE Total mumber of Events | 1956 (98.5) 28044            | 1956 (98.5) 28044            | 39(100#) 817                 | 291(99.3)                    | 291(99.3)                    | 102(99.0) 1533               |                              |
| Total number of patients with at least one                           |                              |                              |                              |                              |                              |                              |                              |
| Treatment-related AE                                                 | 1863                         | (93.81)                      | 37 (94.94)                   | 284                          | (96.94)                      | 95 (92.24)                   |                              |
| Ateno-relatad AE                                                     | 1385                         | (69.74)                      | 30 176.5 91                  | 248                          | (84.64)                      | 76 (73.84)                   |                              |
| Grade3-4 AE                                                          | 1271                         | (64.0)                       | 26 (66.73)                   | 232                          | 179.24)                      | 71 (68.94)                   |                              |
| Treatment-related Grade 3-4 AE                                       | 1081                         | (54.4)                       | 23 (59.08)                   | 218                          | (74.48)                      | 58 (56.34)                   |                              |
| Ateno-related Grade 3-4 AE                                           | 493                          | (24.81)                      | 11 (28.21)                   | 126                          | (43.04)                      | 28 [27.23)                   |                              |
| Grade 5 AE                                                           | 126                          | 6.31)                        | 3 7.741                      | 10                           | (3.4)                        | 5 (46*                       |                              |
| Treatment-related Grade 5 AE                                         | 40                           | 2.0±)                        | 1 1 2.61                     | 8                            | 2.731                        | 1 1.0)                       |                              |
| Ateso-related Grade 5 AE                                             | 23                           | 1.2+)                        | 2.631                        | 6                            | 2.0)                         | 1 1.04)                      |                              |
| Seriouu AE                                                           | 873                          | (44.0±)                      | 20 (51.3)                    | 136                          | (46.44)                      | 44 (42.73)                   |                              |
| Treatment-related serious AE                                         | 455                          | (22.94)                      | 10 (25.6)                    | 89                           | (30.44)                      | 25 (24.34) 17                |                              |
| Ateso-related gerious AE                                             | 266                          | (13.4#)                      | 7 (17.9#)                    | 70                           | (23.94)                      | (16.5)                       |                              |
|                                                                      | 474                          | (23.94)                      | 8 120.541                    | 81                           | 127.641                      | 25 (24.34)                   |                              |
| AE leading to Atezo withdrawal                                       | 253                          | (12.7)                       | 5 (12.8#)                    | 49                           | (16.7*)                      | 12 (11.7*)                   |                              |
| AE leading to Treatment modifieation/interruption                    | 1302                         | (65.6)                       | 28 (71.8#)                   | 211                          | (72.0*)                      | 67 (65.04)                   |                              |

<!-- image -->

## Extrinsic factors

Region

Table 75: Overview of safety by region (safety-evaluable population) - pooled safety dataset

<!-- image -->

|                                                   | Ateso+Chemo Combo (N=2421)   | Ateso+Chemo Combo (N=2421)   | Ateso+Chemo Combo (N=2421)                               | Ateso+Chemo Combo (N=2421)   | Ateso+Chemo Combo (N=2421)   |
|---------------------------------------------------|------------------------------|------------------------------|----------------------------------------------------------|------------------------------|------------------------------|
|                                                   | Asia-Pacific (N=264)         | Australia (N=102)            | Central and South America Europe and Middle East (N=118) | (N=1315)                     | North America (N=622)        |
| Total number of patients with at least oneAE      | 263 (99.6)                   | 101 (99.0)                   | 117 (99.24)                                              | 1288 (97.9)                  | 619(99.5)                    |
| Total number of Events                            | 4087                         | 1574                         | 1568                                                     | 16250                        | 11589                        |
| Total number of patients with at least ome        |                              |                              |                                                          |                              |                              |
| Treatment-related AE                              | 258 (97.74)                  | 96 (96.1#)                   | 110 (93.24)                                              | 1213 (92.24)                 | 600 (96.5)                   |
| Ateso-related AE                                  | 227 186.01)                  | 69 (67.61)                   | 70 (59.31)                                               | 687 (67.5)                   | 486 (78.18)                  |
| Grade3-4AE                                        | 209 [79.24]                  | 67 (65.74)                   | 65 (55.14)                                               | 808 (61.4*)                  | 451 (72.54)                  |
| Treatment-related Grade 3-4 AE                    | 199 175.41)                  | 55 (53.93)                   | 53 [44.93)                                               | 685 (52.1*)                  | 388 (62.43)                  |
| Ateso-related Grade 3-4 AE                        | 116 (66'81)                  | 21 [20.6+)                   | 17 [14.44]                                               | 336 (25.64)                  | 168 (27.04)                  |
| Grade5 AE                                         | 11 4.2)                      | 5 (4.9#)                     | 17 [14.43)                                               | 73 (5.6)                     | 38 6.1)                      |
| Treatment-related Grade 5 AE                      | 8 3.0+1                      | 0                            | 6 (5.1+)                                                 | 29 2.24)                     | 7 1.1+)                      |
| Ateso-related Grade 5 AE                          | 6 2.34)                      | 0                            | (3.43)                                                   | 17 [1.3]                     | 0.6)                         |
| Serious AE                                        | 116 [43.94]                  | 60 (58.8#)                   | 44 (37.3)                                                | 552 (42.04)                  | 301 (48.48)                  |
| Treatment-related serious AE                      | 81 (30.73)                   | 31 (30.43)                   | 21 (17.8)                                                | 331 (25.21)                  | 115 (18.58)                  |
| Ateso-related serious AE                          | 66 (25.0+)                   | 19 (18.6*)                   | 10 [8.5]                                                 | 205 (15.6)                   | 60 (9.6)                     |
| AE leading to Treatment withdrawal                | 73 (27.74)                   | 24 (23.54)                   | 24 (20.3)                                                | 312 (23.7)                   | 155 (24.9)                   |
| A leading to Ateso withdrawal                     | 45 (17.0#)                   | 13 (12.7)                    | 16 [13.6)                                                | 167 (12.74)                  | 78 (12.51)                   |
| AE leading to Treatment modification/interruption | 190 (72.04)                  | 69 (67.6*)                   | 70 (59.3)                                                | 825 (62.74)                  | 454 (73.04)                  |

<div style=\"page-break-after: always\"></div>

## Table 76: Overview of safety by tobacco use history (safety-evaluable population) - pooled safety dataset

|                                                                      | Ateso+Chemo Combo (N=2421)   | Ateso+Chemo Combo (N=2421)   | Ateso+Chemo Combo (N=2421)   | Ateso+Chemo Combo (N=2421)   | Ateso+Chemo Combo (N=2421)   | Ateso+Chemo Combo (N=2421)   |
|----------------------------------------------------------------------|------------------------------|------------------------------|------------------------------|------------------------------|------------------------------|------------------------------|
|                                                                      | Never (N=328)                | Never (N=328)                | Current (N=613)              | Current (N=613)              | Previous (N=1480)            | Previous (N=1480)            |
| Total number of patients with at leest one AE Total nunber of Bvents | 317(96.68) 4673              | 317(96.68) 4673              | 604(98.51) 8012              | 604(98.51) 8012              | 1467(99.18) 22403            | 1467(99.18) 22403            |
| Total nunber of patients with at leaut one                           |                              |                              |                              |                              |                              |                              |
| Treatment-related AE                                                 | 299                          | (91.28)                      | 572                          | (93.31)                      | 1408                         | (95.18)                      |
| Ateso-related AE                                                     | 233                          | (71.08)                      | 421                          | 168.741                      | 1085                         | (73.38]                      |
| Grade3-4AE                                                           | 197                          | (60.14)                      | 297                          | (64.84)                      | 1006                         | (68.04)                      |
| Treatment-related Grade 3-4 AE                                       | 171                          | (52.18)                      | 327                          | (53.31]                      | 882                          | 149'691                      |
| Ateno-related Grade 3-4 AE                                           | 73                           | (22.38)                      | 151                          | (24.68)                      | 434                          | (29.38)                      |
| GradeS AE                                                            | 11                           | 3.48)                        | 30                           | 4.981                        | 103                          | ( 7.08)                      |
| Treatment-related Grade 5 AE                                         | 3                            | 0.941                        | 12                           | 2.041                        | 35                           | 2.481                        |
| Ateno-related Grade S AE                                             | 3                            | 0.941                        | 3                            | 1.0.51)                      | 25                           | (.1.73)                      |
| Berious AE                                                           | 111                          | (33.80)                      | 255                          | (41.68]                      | 707                          |                              |
| Treatment-relatad serioug AE                                         | 63                           | (19.28)                      | 128                          | 120.981                      | 388                          | (26.28)                      |
| Ateno-related serious AE                                             | 42                           | (12.61)                      | 72                           | (11.78)                      | 246                          | (16.64)                      |
| AE leading to Treatment withdrawal                                   | 63                           | (19.24)                      | 134                          | (21.98)                      | 391                          | (26.48)                      |
| HE leading to Ateno withdrawal                                       | 26                           | 7.98]                        | 67                           | (10.98)                      | 226                          | (15.3)                       |
| AE leading to Treatment modification/interruption                    | 1.98                         | (60.48)                      | 80F                          | (65.74)                      | 1007                         | (68.04)                      |

e4p 4t N uo pe6eq eae 6e6raueaae8 *0'1zn 180PeA 6uten pepooue 6at 38g 4we4 soqe6g46enu1 column headings. Multiple oscurrences 6f the seme AE in one inaividual are counted only once eweept for \"Total number of events\" row in which multiple oecurrenees of the seme AE AteRo-Ate8oligumeb.Ate9o+Chemo Combo: G029537 (IMP0MER130) Am A + G029437 (IMP0MeR131) Am A+8 +G029436 (IMP0WER150) AmA+B +G029438 (1MP0MER132) Am A+G030081 (IMP0MER133) Am A. C1inical cut-off dates: G029436:22JAN2018, G029437:20APR2018, G029438:18MAY2018, G029537:15MAR2018.G030081:24APR2018.

## Safety related to drug-drug interactions and other interactions

No drug-drug interaction studies have been submitted with this application.

## Discontinuation due to adverse events

## AEs leading to withdrawal from study

Overall study period

<div style=\"page-break-after: always\"></div>

Table 77: Adverse events leading to treatment withdrawal in at least 1% of patients in any treatment arm by system organ class and preferred term (safety-evaluable population) - Study IMpower130

| MedDRA Sygtem Organ_Class MadDRA'Preferred Term           | CnP (Aetual) (N=232)   | Ateso+CnP_(Actual) (N=473)   |
|-----------------------------------------------------------|------------------------|------------------------------|
| Total nuuber of patients with at least one adverse event  | 51(22.04)              | 125(26.48)                   |
| Overalltotal mumber of events                             | 63                     | 172                          |
| BLOODANDLYMPHATICSYSTEMDISORDERS                          |                        |                              |
| Total_ nmber of patients with at least one adverse event  | 11 4.74)               | 33 7.031                     |
| IHROMBOCYTOPENIA                                          | 1.74)                  | 17 3.641                     |
| NEUTROPENIA                                               | 6 2.631                | 14 3.031                     |
| ANAEHTA                                                   | 2 0.941                | 71.74)                       |
| NERVOUS SYSTEM DISORDERS                                  |                        |                              |
| Total nwber_of.patients.with 1at least one adverse event  | (3.9)                  | 88162                        |
| PERIPHERALSENSORYNEUROPATHY                               | (1.7]                  |                              |
| GENERALDISORDERS AND ADMINISTRATION SITE CONDITIONS       |                        |                              |
| Total number of patients with at lesst one adverse event  | 6(2.6)                 | 20(4.24)                     |
| FATIGUE                                                   | 4( 1.7)                | 7(1.58)                      |
| INFECTIONS AND INFESTATIONS                               |                        |                              |
| Total number of patients with at lesst one adverse event  | 8(3.48)                | 13 ( 2.78)                   |
| FNEIMONLA                                                 | 3(1.38)                | 6(1.3)                       |
| RESPIRATORY,THORACIC AND MEDIASTINAL DISORDERS            |                        |                              |
| Total number of patients with at lenst one adverse event  | 5 [ 2.24)              | 15 [3.2)                     |
| DYSPNOEA                                                  | 0                      | 6 1.3)                       |
| INVESTIGATIONS                                            |                        |                              |
| Total oumber of patients with at least one adverse event. | 3 1.31)                | 16 (3.40)                    |
| NEUTROPHILCOUNTDECREASED                                  | 0.4)                   | 8 1.7$)                      |
| PLATELETCOUNTDECREASED                                    | 2 (0.98)               | 8(1.78)                      |

<!-- image -->

## Induction phase

| MedDRA System Organ Class WedlRA Preferred Tem           | CnP_(Actual) (N=232)   | Atezo+CnP (Actual) (N=473)   |
|----------------------------------------------------------|------------------------|------------------------------|
| Total nuber of patients with at least one adverse event  | 33(14.2)               | 83 (17.5)                    |
| Overall total number of events                           | 38                     | 106                          |
| BLOODANDLYMPHATICSYSTEMDISORDERS                         |                        |                              |
| Totel nuber_of patients with at least one adverse event  | 9 3.941                | 25 5.34)                     |
| THROMBOCYTOPENTA                                         | 3 1.311                | 11 2.3+)                     |
| NEUTROPENIA                                              | 1.73)                  | 10 2.1)                      |
| ANAEMTA                                                  | 0.4)                   | 1.54)                        |
| GENERAL DISORDERSAND AIMINISTRATION SITE CONDITIONS      |                        |                              |
| Total number of patients with at least one adverse event | 1.71                   | 11 (2.3)                     |
| FATIGUE                                                  | 1.3+)                  | (1.14)                       |
| INVESTIGATIONS                                           |                        |                              |
| Total number of patients with at least one adverse event | (0.4#)                 | 10 ( 2.1#)                   |
| PLATELET COUNTDECRPASED                                  | 1 (0.4#)               | 6 1.34)                      |
| NEUTROPHIL COUNT DECREASED                               | 口                      | (1.1+)                       |

Table 78: Adverse events leading to treatment withdrawal during the induction phase in at least 1% of patients in any treatment arm by system organ class and preferred term (safety-evaluable population) Study IMpower130

<!-- image -->

Maintenance phase

<div style=\"page-break-after: always\"></div>

## Adverse Events Leading to Withdrawal of Atezolizumab Treatment

A total of 24 patients (6.8%) in the Atezo-CnP arm experienced AEs leading to withdrawal of atezolizumab during the maintenance phase. The most common AE (&gt;2 patients) leading to atezolizumab treatment withdrawal during maintenance was dyspnoea.

## Adverse  Events  Leading  to  Withdrawal  of  Pemetrexed  Treatment  (Pemetrexed  Switch Maintenance Phase)

A total of 6 patients (12.2%) in the CnP arm experienced AEs leading to withdrawal of pemetrexed. The most common AEs (&gt;1% of patients) causing withdrawal from pemetrexed were fatigue, death (PT), pleural effusion, neutropenia, sepsis, creatine renal clearance increased, acute kidney injury, and drug eruption, each leading to pemetrexed withdrawal in 2.0% of patients in the CnP arm.

## AEs leading to dose modification/interruption

Table 79: Adverse events leading to dose modification/interruption in at least 2% of patients in any treatment arm (onset date before cross-over) by system organ class and preferred term (safety-evaluable population) Study IMpower130

| MedDRA Sygtem Orgen_ Class MedlRa'Preferred Tem          | CnP (Actual) [N=232)   | Ateso+CnP (Actual) (N=473)   |
|----------------------------------------------------------|------------------------|------------------------------|
| Total mumber of patients with at least one adverse event | 186(80.24)             | 402(85.04)                   |
| Duerall total number of events                           | 544                    | 1472                         |
| BLOOD AND LYMPHATIC SYSTEM DISORDERS                     |                        |                              |
| Total nuber of patients with at least one adverse event  | 128 (65.28)            | 255 153.911                  |
| NEUTROPENIA                                              | 83 (35.8)              | 182 138.581                  |
| THROHBOCYTOPENLA                                         | 46 (19.84)             | 93 (19.78)                   |
| ANAEHTA                                                  | 31 (13.48)             | 77 (16.38)                   |
| LEUNOPENIA                                               | 13 [5.61]              | 27 15.78]                    |
| FEBRTLE NEUTROFENIA                                      | 5 (2.24)               | 7 (1.58]                     |
| INVESTIGATIONS                                           |                        |                              |
| Total number of patients with at least one adverse event | 57 (24.64)             | 137 (29.08)                  |
| Total nimber of events                                   | 109                    | 285                          |
| PLATELETCOUNTDECREASED                                   | 26 [11.28)             | 71 (15.01)                   |
| NEUTROPHILCOUNT DECREASED                                | 31 (13.48]             | 68 (14.48)                   |
| WHTTEBLOODCELLCOUNTDECREASED                             | 9 (3.91)               | 37 15.701                    |
| BLOODCREATININETNCREASED                                 | 1 0.411                | 2.311                        |
| GENERALDISORDERSANDAIMINISTRATIONSTTECONDITIONS          |                        |                              |
| Total nimber of patients with at lesst one adverse event | 33 (14.28)             | 85 (18.01)                   |
| FATIGUE                                                  | 13 15.611              | 35 17.481                    |
| PYRERTA                                                  | 3 (1.38]               | 23 (4.98)                    |
| ASTHENIA                                                 | 11 ( 4.78)             | 10 1 2.18)                   |
| GASTROINTESTINALDISORDERS                                |                        |                              |
| Total number of patients with at least one adverse event | 24(10.38)              | 80(16.9)                     |
| Total number of events                                   | 38                     | 128                          |
| DIARRHOEA                                                | 13 ( 5.61)             | 43 ( 9.1)                    |
| NAUSEA                                                   | 4(1.74)                | 21 (4.48)                    |
| VOMITING                                                 | 3 (1.3)                | 15( 3.24)                    |
| INFECTIONS AND INEESTATIONS                              |                        |                              |
| Total number of patients with at lesst one adverse event | 30(12.94)              | 72(15.21)                    |
| FNEUMONIA                                                | 11 IHL'+1              | 18( 3.8)                     |
| RESPIRATORY,THORACIC AND MEDIASTINAL DISORDERS           |                        |                              |
| Total mimber of patients with at least one adverse event | 17 (7.38]              | 69(14.61)                    |
| DYSENOEA                                                 | 5 ( 2.24]              | 17(3.61)                     |
| FNEUHONITIS                                              | 1 (0.48)               | 13( 2.78)                    |
| METABOLISMANDNUTRTTIONDISORDERS                          |                        |                              |
| Total nuber of patients with at lerst one adverse event  | 10(4.38)               | 33 ( 7.04)                   |
| DEHYDRATION                                              | 1601                   | 1                            |
| DECREASED APPETITE                                       | 1.741                  | 12.8]                        |

Ateso-Atesolieumeb,CnP=Carboplatin+Neb-Paclitamel Inwestigator text for AEa encoded uuing KedDRA v2l.o. Percentages are based on N in the columm headings. For frequency coumts by preferred teim, multiple oceurrences of the same AE in an individual are counted only once. For freguency counts of \"lotal number of events\" rows, the mnltiple oeeurrenees of the game Ae in an individual are countad separately. AEs collected after first treatment dose are ineluded.

Deta Cutoff: 15MeR2018: RAVE Data Entraetad: 18 Hay 2018.

<div style=\"page-break-after: always\"></div>

## Immunogenicity

Table 80: Exposure to atezolizumab by atezolizumab ADA status (ADA-evaluable population) - Study IMpower130

<!-- image -->

|                          | ADA- (N=346)    | ADA+ (N=100)          | All AnA Evalusble Patients (N=446)   |
|--------------------------|-----------------|-----------------------|--------------------------------------|
| Treatment duration (M) n | 346             | 100                   | 446                                  |
| Mean (SD) Median         | 9.8 (7.2) 7.8   | 8.3 (6.5) 6.1         | 9.4 (7.1) 7.6                        |
| Min - Max                | 0-32            | 0-26                  | 0 - 32                               |
| Number of doses n        | 346             | 100                   |                                      |
| Mean (SD) Median         | 13.9 (9.9) 11.0 | 12.0 (8.9) 9.0 1 - 38 | 446 13.5 (9.7) 10.5                  |
| XEN- UTN                 | 1 - 45          |                       | 1 - 45                               |

Atezo=Atezolizumab,CnP=Carboplatin+Nab-Paclitaxel

ADA = Anti-Therapeutic Antibodies; ADA- = Without TX Enhanced/Incuced; ADA+ = With TX

Enhanced/Induced

M=Months. Ireatment duration is the date of the last dose of study medication minus the date of the first. dose plus one day.

Dose intensity is the mumber of doses actually received divided by the expected number of doses.

Data Cutoff: 15MAR20l8; RAVE Data Extracted: 18 May 2018.

Table 81: Overview of adverse events by atezolizumab ADA status (ADA-evaluable population) - Study IMpower130

| ____________________________________________________________________________________             | ADA- (N=346)   | ADA- (N=346)   | ADA+ (N=100)   | ADA+ (N=100)   |
|--------------------------------------------------------------------------------------------------|----------------|----------------|----------------|----------------|
| Total number of patients with at least one adverse event Total number of events one              | 346            | (100.0%) 6781  | 100            | (100.0%) 1760  |
| Total number of patients with at least                                                           |                |                |                |                |
| Treatment-related AE                                                                             | 334            | ( 96.5%)       | 100            | (100.0%)       |
| Grade 3-4 AE                                                                                     | 285            | ( 82.4%)       | 81             | ( 81.0%)       |
| Treatment-related Grade 3-4 AE                                                                   | 259            | ( 74.9%)       | 74             | ( 74.0%)       |
| Grade 5 AE                                                                                       | 15             | ( 4.3%)        | 3              | ( 3.0%)        |
| Treatment-related Grade 5 AE                                                                     | 4              | ( 1.2%)        | 1              | 1.0%)          |
| Serious Adverse Event                                                                            | 166            | ( 48.0%)       | 54             | ( ( 54.0%)     |
| Treatment-Related Serious Adverse Event                                                          | 78             | ( 22.5%)       | 23             | ( 23.0%)       |
| AE leading to withdrawal from any treatment                                                      | 83             | ( 24.0%)       | 31             | ( 31.0%)       |
| -MPDL3280A                                                                                       | 33             | ( 9.5%)        | 17             | ( 17.0%)       |
| -Nab-Paclitaxel                                                                                  | 64             | 18.5%)         | 22             | ( 22.0%)       |
| -Carboplatin                                                                                     | 57             | ( 16.5%)       | 17             | ( 17.0%)       |
| -Pemetrexed                                                                                      | 0              | (              | 1              | 1.0%)          |
| AE leading to any dose modification/interruption                                                 | 295            | ( 85.3%)       | 93             | ( ( 93.0%)     |
| -MPDL3280A                                                                                       | 215            | ( 62.1%)       | 72             | ( 72.0%)       |
| -Nab-Paclitaxel                                                                                  | 278            | 80.3%)         | 86             | ( 86.0%)       |
| -Carboplatin                                                                                     | 242            | ( ( 69.9%)     | 75             | ( 75.0%)       |
| -Pemetrexed ____________________________________________________________________________________ | 6              | ( 1.7%)        | 1              | ( 1.0%)        |

Atezo=Atezolizumab, CnP=Carboplatin+Nab-Paclitaxel.

Investigator  text  for  AEs  encoded  using  MedDRA  v21.0.  Percentages  are  based  on  N  in  the  column  headings.  Multiple occurrences of the same AE in one

ADA = Anti-Therapeutic Antibodies; ADA- = Without TX Enhanced/Induced; ADA+ = With TX Enhanced/Induced. Only events reported in the Adverse Events Form are included.

individual are counted only once except for \"Total number of events\" row in which multiple occurrences of the same AE are counted separately.

Data Cutoff: 15MAR2018; RAVE Data Extracted: 18 May 2018.

Counts in \"Grade 3-4 AE\" are number of patients whose highest grades of AE are 3 or 4.

<div style=\"page-break-after: always\"></div>

Table 82: Adverse events with at least 2% higher incidence in ADA-positive patients by preferred term and atezolizumab ADA status (ADA-evaluable population) - Study IMpower130

|                                                      |                           | Atezo+CnP, No. of Patients (%)   | Atezo+CnP, No. of Patients (%)   |
|------------------------------------------------------|---------------------------|----------------------------------|----------------------------------|
| System Organ Class                                   | Preferred Term            | Atezo ADA-Negative (N=346)       | Atezo ADA-Positive (N=100)       |
| Gastrointestinal Disorders                           | Nausea                    | 168 (48.6%)                      | 54 (54.0%)                       |
| Gastrointestinal Disorders                           | Dyspepsia                 | 19 (5.5%)                        | 10 (10.0%)                       |
| Gastrointestinal Disorders                           | Abdominal pain upper      | 12 (3.5%)                        | 9 (9.0%)                         |
| Gastrointestinal Disorders                           | Dry mouth                 | 15 (4.3%)                        | 6 (6.0%)                         |
| General Disorders and Administration Site Conditions | Asthenia                  | 59 (17.1%)                       | 23 (23.0%)                       |
| General Disorders and Administration Site Conditions | Pyrexia                   | 56 (16.2%)                       | 23 (23.0%)                       |
| General Disorders and Administration Site Conditions | Oedema peripheral         | 42 (12.1%)                       | 18 (18.0%)                       |
| General Disorders and Administration Site Conditions | Chills                    | 14 (4.0%)                        | 8 (8.0%)                         |
| General Disorders and Administration Site Conditions | Face oedema               | 2 (0.6%)                         | 3 (3.0%)                         |
| Blood and Lymphatic System Disorders                 | Neutropenia               | 162 (46.8%)                      | 54 (54.0%)                       |
| Blood and Lymphatic System Disorders                 | Thrombocytopenia          | 93 (26.9%)                       | 34 (34.0%)                       |
| Blood and Lymphatic System Disorders                 | Leukopenia                | 37 (10.7%)                       | 14 (14.0%)                       |
| Respiratory, Thoracic and Mediastinal Disorders      | Dyspnoea                  | 97 (28.0%)                       | 33 (33.0%)                       |
| Respiratory, Thoracic and Mediastinal Disorders      | Haemoptysis               | 18 (5.2%)                        | 10 (10.0%)                       |
| Respiratory, Thoracic and Mediastinal Disorders      | Pleural effusion          | 6 (1.7%)                         | 8 (8.0%)                         |
| Nervous System Disorders                             | Dysgeusia                 | 41 (11.8%)                       | 15 (15.0%)                       |
| Nervous System Disorders                             | Neurotoxicity             | 3 (0.9%)                         | 5 (5.0%)                         |
| Metabolism and Nutrition Disorders                   | Hypokalaemia              | 51 (14.7%)                       | 18 (18.0%)                       |
| Metabolism and Nutrition Disorders                   | Dehydration               | 35 (10.1%)                       | 12 (12.0%)                       |
| Metabolism and Nutrition Disorders                   | Hyponatraemia             | 20 (5.8%)                        | 8 (8.0%)                         |
| Metabolism and Nutrition Disorders                   | Hypoalbuminaemia          | 8 (2.3%)                         | 5 (5.0%)                         |
| Infections and Infestations                          | Bronchitis                | 21 (6.1%)                        | (%0'6) 6                         |
| Infections and Infestations                          | Herpes zoster             | 3 (0.9%)                         | 3 (3.0%)                         |
| Musculoskeletal and Connective Tissue Disorders      | Back pain                 | 60 (17.3%)                       | 22 (22.0%)                       |
| Musculoskeletal and Connective Tissue Disorders      | Pain in extremity         | 36 (10.4%)                       | 16 (16.0%)                       |
|                                                      | Bone pain                 | 15 (4.3%)                        | 7 (7.0%)                         |
| Cardiac Disorders                                    | Palpitations              | 7 (2.0%)                         | 4 (4.0%)                         |
| Injury, Poisoning and Procedural Complications       | Infusion-related reaction | 5 (1.4%)                         | 6 (6.0%)                         |

ADA=anti-drug antibody: AE=adverse event; Atezo=atezolizumab; CnP=carboplatin+nab-paclitaxel.

Note: Investigator text for AEs encoded using MedDRA v21.0. Percentages were based on N in the individual were counted only once. AEs collected after first treatment dose were included.

<div style=\"page-break-after: always\"></div>

Table 83: Adverse events of special interest with at least 2% difference between ADA-negative and ADA-positive patients by preferred term and atezolizumab ADA status (ADA-evaluable population) Study IMpower130

|                           | Atezo+CnP, No. of Patients (%)   | Atezo+CnP, No. of Patients (%)   |
|---------------------------|----------------------------------|----------------------------------|
| MedDRA Preferred Term     | Atezo ADA-Negative (N=346)       | Atezo ADA-Positive (N=100)       |
| Rash maculopapular        | 12 (3.5%)                        | 6 (6.0%)                         |
| Hypothyroidism            | 46 (13.3%)                       | 7 (7.0%)                         |
| Pneumonitis               | 20 (5.8%)                        | 3 (3.0%)                         |
| Hyperthyroidism           | 20 (5.8%)                        | 3 (3.0%)                         |
| Infusion-related reaction | 5 (1.4%)                         | 5 (5.0%)                         |

Table 84 : Safety by Treatment-Emergent ADA Status in Atezolizumab + Chemo Combination Population (Pooled Safety Population)

|                                                                      | Atezo+Chemo Combo (N=2267)   | Atezo+Chemo Combo (N=2267)   | Atezo+Chemo Combo (N=2267)   |
|----------------------------------------------------------------------|------------------------------|------------------------------|------------------------------|
|                                                                      | ADA- (N=1543)                | ADA- (N=1543)                | ADA+ (N=724)                 |
| Total number of patients with at least one AE Total number of Events | 1532 (99.3%) 23982           | 1532 (99.3%) 23982           | 718 (99.2%) 10204            |
| Total number of patients with at least one                           |                              |                              |                              |
| Treatment-related AE                                                 | 1476                         | (95.7%)                      | 696 (96.1%)                  |
| Atezo-related AE                                                     | 1125                         | (72.9%)                      | 547 (75.6%)                  |
| Grade 3-4 AE                                                         | 1051                         | (68.1%)                      | 476 (65.7%)                  |
| Treatment-related Grade 3-4 AE                                       | 905                          | (58.7%)                      | 414 (57.2%)                  |
| Atezo-related Grade 3-4 AE                                           | 418                          | (27.1%)                      | 207 (28.6%)                  |
| Grade 5 AE                                                           | 63                           | 4.1%)                        | 32 ( 4.4%)                   |
| Treatment-related Grade 5 AE                                         | 19                           | ( ( 1.2%)                    | 11 ( 1.5%)                   |
| Atezo-related Grade 5 AE                                             | 13                           | 0.8%)                        | 9 ( 1.2%)                    |
| Serious AE                                                           | 651                          | ( (42.2%)                    | 321 (44.3%)                  |
| Treatment-related serious AE                                         | 334                          | (21.6%)                      | 188 (26.0%)                  |
| Atezo-related serious AE                                             | 211                          | (13.7%)                      | 118 (16.3%)                  |
| AE leading to Treatment withdrawal                                   | 352                          | (22.8%)                      | 181 (25.0%)                  |
| AE leading to Atezo withdrawal                                       | 173                          | (11.2%)                      | 101 (14.0%)                  |
| AE leading to Treatment modification/interruption                    | 1067                         | (69.2%)                      | 496                          |

AE leading to Treatment modification/interruption  1067 (69.2%)  496 (68.5%)

Investigator text for AEs encoded using MedDRA v21.0. Percentages are based on N in the column headings. Multiple occurrences of the same AE in one individual are counted only once except for \"Total number of events\" row in which multiple occurrences of the same AE are counted separately. All treatment emergent AEs are included. Atezo=Atezolizumab.    Atezo+Chemo  Combo:  GO29537  (IMPOWER130)  Arm  A  +  GO29437  (IMPOWER131)  Arm  A+B  +  GO29436  (IMPOWER150) Arm A+B + GO29438 (IMPOWER132) Arm A + GO30081 (IMPOWER133) Arm A. Clinical cut-off dates: GO29436:22JAN2018, GO29437:20APR2018, GO29438:22MAY2018, GO29537:15MAR2018, GO30081:24APR2018.

## Post marketing experience

Since the international birth date (18 May 2016) through 17 May 2018, an estimated cumulative total of 20,783  patients  have  received  atezolizumab  from  marketing  experience  (United  States,  n=18,470; European Union,  n=987;  Japan,  n=181;  rest  of  the  world,  n=1145).  No  new  or  unexpected  safety findings were identified in the post-marketing setting for atezolizumab used as a monotherapy.

The combination regimen of atezolizumab with carboplatin and nab-paclitaxel administered in IMpower130 is not approved yet.

## 2.5.1. Discussion on clinical safety

Overall, Atezo+CnP caused more gastrointestinal (diarrhoea and vomiting), general disorders (pyrexia), respiratory disorders (dyspnoea and cough), nervous disorders (headache, dizziness), infections (urinary

<div style=\"page-break-after: always\"></div>

tract infection and pneumonia), skin disorders (rash and pruritus), decrease in platelet and neutrophil counts, musculoskeletal disorders (pain in muscles and joints) and hypothyroidism.

There were clearly more grade ≥3 AEs clearly reported in the Atezo+CnP arm vs the comparator arm, 85.8%  vs.  76.3%.  Main  differences  were  seen  with  regards  to  neutropenia,  thrombocytopenia  and anaemia.

There were also clearly more infections in the Atezo+CnP arm as a consequence of the more frequently observed neutropenia. There was almost a doubling in the rate of Grade ≥3 infections, 17.5% vs. 9.5%.

While dizziness was observed in 10.8% in the CnP arm and 16.1% in the Atezo+CnP (see Table 51) no syncope was observed in the CnP arm. However, 13 (2.7%) syncope were reported in the Atezo+CnP arm out  of  26  (1.1%)  in  the  Atezo+Chemo  combo,  in  other  words  half  of  the  reported  syncope  in  the Atezo+Chemo combo originated from the IMpower130. Syncope and Dizziness were added as ADRs in section 4.8 of the SmPC.

The proportion of patients experiencing SAEs was higher in the Atezo+CnP arm (50.7%) compared with the CnP arm (37.9%). Lung infection, neutropenia, diarrhoea were reported with ≥ 2% difference. Deaths as an AE (Table 64) were reported in 4 patients in the CnP arm (1.7%) and 1 patient (0.2%) in the Atezo+CnP arm.

Based  on  the  safety  data  submitted,  a  causal  relationship  with  atezolizumab  in  combination  with chemotherapy is established for the following ADRs which have been included in section 4.8 of the SmPC: lung infection, lymphocyte count decreased, vomiting, dysgueusia, AST/ALT increased, back pain and asthenia.

Looking  at  the  AEs  leading  to  death,  there  were  no  clinically  relevant  differences  between  the  two treatment arms.

Atezo in combination with chemotherapy seems to lead to an increase in AESI compared to the use of atezo as monotherapy, although the number of Grade 3-4 AESI was similar, when comparing the different arms including atezo. However the number of AESI leading to treatment modification/interruption or use of systemic use of corticosteroids was clearly higher in the atezo+chemo/CnP group compared to the monotherapy arms.

Looking at the individual AESIs, the main differences between atezo+CnP and the monotherapy arms, were seen with regards to rash, hypothyroidism, pneumonitis and hyperthyroidism. Important AESIs unique to patients in the Atezo+CnP arm included immune-related adrenal insufficiency, immune-related nephritis, immune-related meningoencephalitis, and immune-related hypophysitis. There were no cases of immune-related Guillain-Barre syndrome, immune-related myocarditis, or immune-related myasthenia gravis in either arm.

It is also noted that that there were 4 Grade 5 AESI (2 cases of hepatitis and 2 cases of pneumonitis).

With  regards  to  laboratory  parameters,  clinically  relevant  shifts  in  ALT,  creatinine,  magnesium  and potassium are observed in the atezo+CnP.  The majority resolved. Four patients met the criteria for Hy's Law. Two patients had immune related hepatitis. Their liver function returned to normal. One patient had a confirmed tumoural obstruction of the biliary tract. The last patient was recovering from the hepatitis event, but died due to PD.

Overall, there were slightly more AEs leading to withdrawal in the Atezo+CnP arm compared to the CnP arm, 26.4% vs. 22.0%. The main difference was in the 'blood and lymphatic system disorder' SOC. In general, the withdrawal rate is considered high, however, having in mind the clinical setting, it is acceptable.

<div style=\"page-break-after: always\"></div>

The majority of patients, 80.2% and 85.0% in the CnP and atezo+CnP arms respectively experienced an AE leading to a dose modification/interruption. There is no clear pattern, but merely a slightly higher number of AEs in all SOCs. Nonetheless, it seems that the majority of patients were kept on treatment with dose modifications/interruptions.

From the safety database all the adverse reactions reported in clinical trials have been included in the Summary of Product Characteristics. No changes to the RMP are needed as a result of the new safety data submitted as part of the application.

## 2.5.2. Conclusions on clinical safety

Overall, the safety profile of Atezo in combination with CnP is considered acceptable. However, there are more AEs and AESI in the Atezo+CnP arm, but no new safety concerns or major concerns were identified.

The current RMP is adequate to manage the risks associated with Tecentriq is this new indication.

## 2.5.3. PSUR cycle

The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

## 2.6. Risk management plan

The CHMP received the following PRAC Advice on the submitted Risk Management Plan:

The PRAC considered that the risk management plan version 9.1 is acceptable.

The CHMP endorsed the Risk Management Plan version 9.1 with the following content:

<div style=\"page-break-after: always\"></div>

## Safety concerns

| Summary of safety concerns   | Summary of safety concerns                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Important identified risks   | Immune-related hepatitis Immune-related pneumonitis Immune-related colitis Immune-related pancreatitis Immune-related endocrinopathies (diabetes mellitus, hypothyroidism, hyperthyroidism, adrenal insufficiency and hypophysitis) Immune-related neuropathies (Guillain-Barré syndrome, and myasthenic syndrome / myasthenia gravis) Immune-related meningoencephalitis Infusion-related reactions Immune-related myocarditis Immune-related nephritis Immune-related myositis |
| Important potential risks    | Anti-drug antibodies Embryo-fetal toxicity                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| Missing information          | Concomitant use with other immuno-modulatory drugs Long term use Concomitant or sequential use of atezolizumab with intra-vesical Bacillus Calmette-Guérin vaccine for the treatment of urothelial carcinoma                                                                                                                                                                                                                                                                     |

No changes to the list of safety concerns were made as a result of this extension of indication.

## Pharmacovigilance plan

<div style=\"page-break-after: always\"></div>

| Study Status                                                                                                                                                                                                                                                                      | Summary of Objectives                                                                                                                                                                                                                                                                                                                        | Safety concerns addressed                                                                                                                                                                                                  | Milestones                                                                                                                                                                                                                 | Due dates                                                                                                                                                                                                                  |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorization                                                                                                                                                        | Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorization                                                                                                                                                                                                                   | Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorization                                                                                                 | Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorization                                                                                                 | Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorization                                                                                                 |
| There are no Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorization                                                                                                                                                        | There are no Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorization                                                                                                                                                                                                                   | There are no Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorization                                                                                                 | There are no Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorization                                                                                                 | There are no Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorization                                                                                                 |
| Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorization or a marketing authorization under exceptional circumstances                                                        | Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorization or a marketing authorization under exceptional circumstances                                                                                                                   | Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorization or a marketing authorization under exceptional circumstances | Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorization or a marketing authorization under exceptional circumstances | Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorization or a marketing authorization under exceptional circumstances |
| There are no Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorization or a marketing authorization under exceptional circumstances                                                        | There are no Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorization or a marketing authorization under exceptional circumstances                                                                                                                   | There are no Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorization or a marketing authorization under exceptional circumstances | There are no Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorization or a marketing authorization under exceptional circumstances | There are no Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorization or a marketing authorization under exceptional circumstances |
| Category 3 - Required additional pharmacovigilance activities                                                                                                                                                                                                                     | Category 3 - Required additional pharmacovigilance activities                                                                                                                                                                                                                                                                                | Category 3 - Required additional pharmacovigilance activities                                                                                                                                                              | Category 3 - Required additional pharmacovigilance activities                                                                                                                                                              | Category 3 - Required additional pharmacovigilance activities                                                                                                                                                              |
| GO28915 (OAK) A Phase III, Open-Label, Multicenter, Randomized Study to Investigate the Efficacy and Safety of Atezolizumab (Anti-PD-L1 Antibody) Compared with Docetaxel in Patients with Non-Small Cell Lung Cancer After Failure with Platinum-Containing Chemotherapy Ongoing | To determine if atezolizumab treatment results in an improved OS compared with docetaxel To evaluate safety and tolerability of atezolizumab compared with docetaxel To evaluate incidence of ADAs against atezolizumab and to explore the potential relationship of the immunogenicity response with pharmacokinetics, safety, and efficacy | Anti-drug antibodies                                                                                                                                                                                                       | Final CSR                                                                                                                                                                                                                  | December 2019                                                                                                                                                                                                              |
| GO29322: A Phase IB Study of the Safety and Pharmacology of atezolizumab Administered with Ipilimumab or Interferon-Alpha in Patients with Locally Advanced or Metastatic Solid Tumors Ongoing                                                                                    | To evaluate the safety and tolerability of atezolizumab and ipilimumab in combination in patients with advanced or metastatic NSCLC or melanoma. To evaluate the safety and tolerability of atezolizumab and interferon alfa-2b in combination in patients with advanced or metastatic RCC or                                                | Concomitant use with other immunomodulatory drugs                                                                                                                                                                          | Final CSR                                                                                                                                                                                                                  | March 2020                                                                                                                                                                                                                 |
| WO29635: A Phase IB/II, Open-Label Study of the Safety and Pharmacology of Atezolizumab Administered with or without Bacille Calmette-Guérin in Patients with High Risk Non Muscle-Invasive Bladder Cancer                                                                        | melanoma To evaluate the safety and tolerability of atezolizumab as a single agent and in combination with BCG. To identify the DLTs and to determine the MTD or tolerability at the MAD of BCG in combination with atezolizumab                                                                                                             | Concomitant or sequential use of atezolizumab with intra-vesical BCG vaccine for the treatment of urothelial carcinoma                                                                                                     | Final CSR                                                                                                                                                                                                                  | June 2022                                                                                                                                                                                                                  |

<div style=\"page-break-after: always\"></div>

| Ongoing                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                                                                                                                                                                                                                                                                   |                                                                                                                                                                                                                                                                                                                                                                                                                                                           |                                                 |                                           |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------|-------------------------------------------|
| MO39171 (TAIL): Single-Arm Long-Term Safety and Efficacy Study of atezolizumab in previously treated NSCLC Patients Ongoing                                                                                                                                                                                                                                                | To evaluate the long-term safety of atezolizumab on the bases of the following endpoints: The incidence of all serious adverse events (SAEs) related to atezolizumab treatment and the incidence of immune-related adverse events (irAEs) related to atezolizumab treatment                                                                                       | Long-term use                                                                                                                                                                                                                                                                                                                                                                                                                                             | Final CSR                                       | May 2022                                  |
| MO29983: An Open-Label, Single Arm, Multicenter, Safety Study of atezolizumab in Locally Advanced or Metastatic Urothelial or Non-Urothelial Carcinoma of the Urinary Tract Ongoing                                                                                                                                                                                        | To evaluate the safety of atezolizumab based on the following endpoints: Nature, severity, duration, frequency and timing of adverse events (AEs) and changes in vital signs, physical findings, and clinical laboratory results during and following atezolizumab administration.                                                                                | Long-term use                                                                                                                                                                                                                                                                                                                                                                                                                                             | Final CSR                                       | Q1 2023                                   |
| WO40486 (Observational Study) Evaluation of the effectiveness of HCP educational materials which aims to facilitate early recognition and intervention of the following important immune-related risks: Pneumonitis, hepatitis, colitis, pancreatitis, endocrinopathies, neuropathies, meningoencephalitis, myocarditis, nephritis, and infusion-related reactions Ongoing | The overall objective is to evaluate the effectiveness of the HCP brochure designed to mitigate important immune-related risks in patients receiving atezolizumab in the European Union. Data from HCP surveys and reporting rates for the important identified immune related risks will be collected and analyzed to evaluate effectiveness of the HCP brochure | Immune-related hepatitis Immune-related pneumonitis Immune-related colitis Immune-related pancreatitis Immune-related endocrinopathies (diabetes mellitus, hypothyroidism, hyperthyroidism, adrenal insufficiency, and hypophysitis) Immune-related neuropathies (Guillain-Barré syndrome, and myasthenic syndrome / myasthenia gravis) Immune related meningoencephalitis Infusion-related reactions Immune-related myocarditis Immune-related nephritis | Protocol submission Interim report Final Report | February 2018 December 2020 December 2022 |

No new studies were added to the pharmacovigilance plan as a result of this extension of indication.

## Risk minimisation measures

<div style=\"page-break-after: always\"></div>

| Safety concern             | Risk minimization measures                                                                                                                                                                                                                                                                                                                              | Pharmacovigilance activities                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|----------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Immune-Related Hepatitis   | Routine risk minimization measures: Proposed measures are described in the E.U. SmPC under the following sections: Section 4.2 Posology and method of administration Section 4.4 Special Warnings and Precautions for Use Section 4.8 Undesirable effects Additional risk minimization measures: • Educational materials for HCPs • Patient alert cards | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: None Additional pharmacovigilance activities: WO40486 (Observational Study) Evaluation of the effectiveness of HCP educational materials which aims to facilitate early recognition and intervention of the following important immune-related risks: Pneumonitis, hepatitis, colitis, pancreatitis, endocrinopathies, neuropathies, meningoencephalitis, myocarditis, nephritis, and                             |
| Immune-Related Pneumonitis | Routine risk minimization measures: Proposed measures are described in the E.U. SmPC under the following sections: Section 4.2 Posology and method of administration Section 4.4 Special Warnings and Precautions for Use Section 4.8 Undesirable effects Additional risk minimization measures: • Educational materials for HCPs • Patient alert cards | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: None Additional pharmacovigilance activities: WO40486 (Observational Study) Evaluation of the effectiveness of HCP educational materials which aims to facilitate early recognition and intervention of the following important immune-related risks: Pneumonitis, hepatitis, colitis, pancreatitis, endocrinopathies, neuropathies, meningoencephalitis, myocarditis, nephritis, and infusion-related reactions. |

<div style=\"page-break-after: always\"></div>

| Safety concern              | Risk minimization measures                                                                                                                                                                                                                                                                                                                              | Pharmacovigilance activities                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|-----------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Immune-Related Colitis      | Routine risk minimization measures: Proposed measures are described in the E.U. SmPC under the following sections: Section 4.2 Posology and method of administration Section 4.4 Special Warnings and Precautions for Use Section 4.8 Undesirable effects Additional risk minimization measures: • Educational materials for HCPs • Patient alert cards | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: None Additional pharmacovigilance activities: WO40486 (Observational Study) Evaluation of the effectiveness of HCP educational materials which aims to facilitate early recognition and intervention of the following important immune-related risks: Pneumonitis, hepatitis, colitis, pancreatitis, endocrinopathies, neuropathies, meningoencephalitis, myocarditis, nephritis, and                             |
| Immune-Related Pancreatitis | Routine risk minimization measures: Proposed measures are described in the E.U. SmPC under the following sections: Section 4.2 Posology and method of administration Section 4.4 Special Warnings and Precautions for Use Section 4.8 Undesirable effects Additional risk minimization measures: • Educational materials for HCPs • Patient alert cards | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: None Additional pharmacovigilance activities: WO40486 (Observational Study) Evaluation of the effectiveness of HCP educational materials which aims to facilitate early recognition and intervention of the following important immune-related risks: Pneumonitis, hepatitis, colitis, pancreatitis, endocrinopathies, neuropathies, meningoencephalitis, myocarditis, nephritis, and infusion-related reactions. |

<div style=\"page-break-after: always\"></div>

| Safety concern                                                                                                                 | Risk minimization measures                                                                                                                                                                                                                                                                                                                              | Pharmacovigilance activities                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|--------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Immune-Related Endocrinopathies (Diabetes Mellitus, Hypothyroidism, Hyperthryroidism, Adrenal Insufficiency, and Hypophysitis) | Routine risk minimization measures: Proposed measures are described in the E.U. SmPC under the following sections: Section 4.2 Posology and method of administration Section 4.4 Special Warnings and Precautions for Use Section 4.8 Undesirable effects Additional risk minimization measures: • Educational materials for HCPs • Patient alert cards | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: None Additional pharmacovigilance activities: WO40486 (Observational Study) Evaluation of the effectiveness of HCP educational materials which aims to facilitate early recognition and intervention of the following important immune-related risks: Pneumonitis, hepatitis, colitis, pancreatitis, endocrinopathies, neuropathies, meningoencephalitis, myocarditis, nephritis and                              |
| Immune-Related Neuropathies (Guillain-Barre Syndrome and Myasthenia Gravis)                                                    | Routine risk minimization measures: Proposed measures are described in the E.U. SmPC under the following sections: Section 4.2 Posology and method of administration Section 4.4 Special Warnings and Precautions for Use Section 4.8 Undesirable effects Additional risk minimization measures: • Educational materials for HCPs • Patient alert cards | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: None Additional pharmacovigilance activities: WO40486 (Observational Study) Evaluation of the effectiveness of HCP educational materials which aims to facilitate early recognition and intervention of the following important immune-related risks: Pneumonitis, hepatitis, colitis, pancreatitis, endocrinopathies, neuropathies, meningoencephalitis, myocarditis, nephritis, and infusion-related reactions. |

<div style=\"page-break-after: always\"></div>

| Safety concern                     | Risk minimization measures                                                                                                                                                                                                                                                                                                                              | Pharmacovigilance activities                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Immune-Related Meningoencephalitis | Routine risk minimization measures: Proposed measures are described in the E.U. SmPC under the following sections: Section 4.2 Posology and method of administration Section 4.4 Special Warnings and Precautions for Use Section 4.8 Undesirable effects Additional risk minimization measures: • Educational materials for HCPs • Patient alert cards | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: None Additional pharmacovigilance activities: WO40486 (Observational Study) Evaluation of the effectiveness of HCP educational materials which aims to facilitate early recognition and intervention of the following important immune-related risks: Pneumonitis, hepatitis, colitis, pancreatitis, endocrinopathies, neuropathies, meningoencephalitis, myocarditis, nephritis and                              |
| Infusion-Related Reactions         | Routine risk minimization measures: Proposed measures are described in the E.U. SmPC under the following sections: Section 4.2 Posology and method of administration Section 4.4 Special Warnings and Precautions for Use Section 4.8 Undesirable effects Additional risk minimization measures: • Educational materials for HCPs • Patient alert cards | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: None Additional pharmacovigilance activities: WO40486 (Observational Study) Evaluation of the effectiveness of HCP educational materials which aims to facilitate early recognition and intervention of the following important immune-related risks: Pneumonitis, hepatitis, colitis, pancreatitis, endocrinopathies, neuropathies, meningoencephalitis, myocarditis, nephritis, and infusion-related reactions. |

<div style=\"page-break-after: always\"></div>

| Safety concern             | Risk minimization measures                                                                                                                                                                                                                                                                                                                              | Pharmacovigilance activities                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|----------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Immune-Related Myocarditis | Routine risk minimization measures: Proposed measures are described in the E.U. SmPC under the following sections: Section 4.2 Posology and method of administration Section 4.4 Special Warnings and Precautions for Use Section 4.8 Undesirable effects Additional risk minimization measures: • Educational materials for HCPs • Patient alert cards | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: None Additional pharmacovigilance activities: WO40486 (Observational Study) Evaluation of the effectiveness of HCP educational materials which aims to facilitate early recognition of and intervention in the following important immune-related risks: Pneumonitis, hepatitis, colitis, pancreatitis, endocrinopathies, neuropathies, meningoencephalitis, myocarditis, nephritis, and                             |
| Immune-related nephritis   | Routine risk minimization measures: Proposed measures are described in the E.U. SmPC under the following sections: Section 4.2 Posology and method of administration Section 4.4 Special Warnings and Precautions for Use Section 4.8 -Undesirable effects Additional risk minimization measures: • Educational materials for HCPs Patient alert cards  | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: None Additional pharmacovigilance activities: WO40486 (Observational Study) Evaluation of the effectiveness of HCP educational materials which aims to facilitate early recognition of and intervention in the following important immune-related risks: Pneumonitis, hepatitis, colitis, pancreatitis, endocrinopathies, neuropathies, meningoencephalitis, myocarditis, nephritis, and infusion-related reactions. |

<div style=\"page-break-after: always\"></div>

| Safety concern          | Risk minimization measures                                                                                                                                                                                                                                                                                                        | Pharmacovigilance activities                                                                                                                                    |
|-------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Immune-related myositis | Routine risk minimization measures: Proposed measures are described in the E.U. SmPC under the following sections: Section 4.2 Posology and method of administration Section 4.4 Special Warnings and Precautions for Use Section 4.8 Undesirable effects Additional risk minimization measures: • Educational materials for HCPs | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: None Additional pharmacovigilance activities: None                |
| Anti-drug Antibodies    | Routine risk minimization measures: Proposed measures are described in the E.U. SmPC under the following sections: Section 4.8 Undesirable effects No additional risk minimization measures                                                                                                                                       | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: None Additional pharmacovigilance activities: Study GO28915 (OAK) |
| Embryo-fetal toxicity   | Routine risk minimization measures: Proposed measures are described in the E.U. SmPC under the following sections: Section 4.6 Fertility, pregnancy and lactation Section 5.3 Preclinical safety data No additional risk minimization measures                                                                                    | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: None Additional pharmacovigilance activities: None                |

<div style=\"page-break-after: always\"></div>

| Safety concern                                                                                                                               | Risk minimization measures                                                                                                                                                                                                                                                                                                                                           | Pharmacovigilance activities                                                                                                                                             |
|----------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Concomitant use with other immuno-modulatory agents                                                                                          | Routine risk minimization measures: This safety concern considered as missing information is mentioned as one of the exclusion criteria within the Warnings and Precautions and description of studies included in the E.U. SmPC. No Additional risk minimization measures                                                                                           | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: None Additional pharmacovigilance activities: Study GO29322                |
| Long-term use                                                                                                                                | Routine risk minimization measures: Proposed text in E.U. SmPC: None No Additional risk minimization measures                                                                                                                                                                                                                                                        | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: None Additional pharmacovigilance activities: Studies: • MO29983 • MO39171 |
| Concomitant or sequential use of atezolizumab with intra-vesical Bacillus Calmette-Guérin vaccine for the treatment of urothelial carcinoma. | Routine risk minimization measures: Proposed measures are described in the E.U. SmPC under the following sections: Section 4.4 Special Warnings and Precautions for Use: Includes language that patients who were administered a live attenuated vaccine with 28 days prior to enrolment were excluded from clinical trials No Additional risk minimization measures | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: None Additional pharmacovigilance activities: Study WO29635                |

The risk minimisations measures remain unchanged as a result of this extension of indication.

<div style=\"page-break-after: always\"></div>

## 2.7. Update of the Product information

As a consequence of this new indication, sections 4.1, 4.2, 4.4, 4.8 and 5.1 of the SmPC have been updated. The Package Leaflet has been updated accordingly.

The new indication has only been reflected in the SmPC for the 1,200 mg strength, however the safety sections have been aligned between the 840 mg and 1,200 mg strengths.

## 2.7.1. User consultation

A justification for not performing a full user consultation with target patient groups on the package leaflet has been submitted by the MAH and has been found acceptable for the following reasons:

- No significant changes impacting the readability of the package leaflet are made. The new additions follow the same structure and use similar descriptions and terminology as used in the approved package leaflet.
- The target group of users will be similar between the approved indication (locally advanced or metastatic NSCLC previously treated with chemotherapy) and the applied indication (first-line treatment of metastatic non-squamous NSCLC), with no significant age difference.
- The posology proposed in this application is the same as for the currently approved indication.

## 3. Benefit-Risk Balance

## 3.1. Therapeutic Context

## 3.1.1. Disease or condition

The proposed new therapeutic indication is for atezolizumab in combination with nab paclitaxel and carboplatin, for the first line treatment of adult patients with metastatic non-squamous NSCLC who do not have EGFR mutant or ALK positive NSCLC.

Lung cancer remains the leading cause of cancer death worldwide, estimated to be responsible for nearly one in five cancer deaths globally (1.76 million deaths, 18.4% of the total; Globocan 2018). There were estimated to be 2.1 million new cases in 2018 (11.6% of the total), 58% of which occurred in less developed regions. This disease is the most common cancer in men worldwide (1.4 million [15% of cancers in men]) and accounts for the highest absolute number of cancer deaths globally (1.2 million deaths [24% of cancer deaths in men]; Fitzmaurice et al. 2015). NSCLC is the predominant subtype, accounting for approximately 85% of all cases (Molina et al. 2008; Howlader et al. 2014).

NSCLC can be divided into two major histologic types: non-squamous and squamous cell carcinoma (Travis et al. 2011). Non-squamous histology accounts for more than half of all NSCLC, whereas squamous histology accounts for approximately 30% (Langer et al. 2010).

Genetic changes that have prognostic and/or predictive significance in NSCLC include EGFR mutations in exons 18 through 21 and rearrangements in the ALK gene. EGFR mutations are rare in squamous NSCLC but are seen in 10%-40% of patients with non-squamous NSCLC (Herbst et al. 2008). ALK rearrangements have been reported in 2%-6% of NSCLC patients, predominantly in non-squamous NSCLC (Kwak et al. 2010; Crinò et al. 2011).

<div style=\"page-break-after: always\"></div>

## 3.1.2. Available therapies and unmet medical need

For patients who have metastatic non-squamous NSCLC without an oncogenic driver mutation (such as EGFR mutations  or ALK translocations),  the  standard-of-care  options  in  first-line  are  anti-PD-1 monotherapy (only for high PD-L1 expression) or platinum-based chemotherapy in combination with anti-PD-1/PD-L1 agents.

## 3.1.3. Main clinical studies

The MAH has provided results from the IMpower 130 study, which is a relatively large  (&gt; 700 patients) phase III, open label, randomised study conducted to evaluate the efficacy and safety of atezolizumab in combination with nab paclitaxel and carboplatin, in chemotherapy naïve patients with metastatic non-squamous NSCLC.

## 3.2. Favourable effects

The  primary  analysis  was  conducted  in  all  patients,  excluding  those  with  EGFR  mutations  or  ALK rearrangements, defined as ITT-WT population (n=679). Patients had a median survival follow up time of 18.6 months. The study met one of its co-primary endpoints, PFS in ITT-WT. Results showed a HR of 0.64 (95%CI: 0.54, 0.77; p&lt;0.0001). The median duration of PFS was 7.0 months in the atezo+CnP arm. With regards  to  OS  in  ITT-WT,  median  OS  was  18.6  months  in  the  atezo+CnP  vs  13.9  months  in  the comparator arm (HR=0.79 (95%CI 0.64, 0.98).

Updated OS data with median follow-up of 24.1 months showed a HR = 0.82 (95% CI: 0.67, 1.01) and the p-value = 0.057. As OS data has matured, the difference between the two treatment arms is no longer statistically significant, but the study is considered positive as at least one of the co-primary endpoints is statistically significant. The updated results are clearly reflected in section 5.1.

Concerning the secondary endpoints, results were overall in line with the primary analyses in the ITT-WT population.

Finally, the secondary analyses of OS and PFS in the ITT population show similar results to the ITT-WT population. Breaking down the treatment effect per PD-L1 expression, it is clearly seen that the majority of patients are TC0/IC0, however, a similar treatment effect is observed across all the different PD-L1 subgroups. These results are in line with the primary estimate.

## 3.3. Uncertainties and limitations about favourable effects

There are no uncertainties regarding the favourable effects of the Atezo+CnP combination.

## 3.4. Unfavourable effects

Overall incidences of treatment-related AEs are numerically higher in the Atezo+CnP arm (96.2 % vs 92.7% in the CnP arm).

Incidence of Grade 3-4 adverse events was higher in the Atezo+CnP arm, especially grade 4 AEs (27.7% vs 15.9%) were reported numerically higher in the Atezo+CnP (85.0%) than in the CnP arm (74.6%).

The proportion of patients experiencing SAEs was higher in the Atezo+CnP arm (50.7%) compared with the CnP arm (37.9%).

Lung infection, neutropenia, diarrhoea were reported with ≥ 2% difference.

<div style=\"page-break-after: always\"></div>

Deaths due to AEs were reported in 4 patients in the CnP arm (1.7%) and 1 patient (0.2%) in the Atezo+CnP arm.

## 3.5. Uncertainties and limitations about unfavourable effects

There are no uncertainties or limitations about the unfavourable effects.

## 3.6. Effects Table

Table 85: Effects Table for atezolizumab in combination with nab paclitaxel and carboplatin, in 1L metastatic non-squamous NSCLC (data cut-off: 15 March 2018)

| Effect                                | Short description         | Unit                 | Treatment            | Control              | Uncertainties / Strength of evidence    | References           |
|---------------------------------------|---------------------------|----------------------|----------------------|----------------------|-----------------------------------------|----------------------|
| Favourable Effects                    | Favourable Effects        | Favourable Effects   | Favourable Effects   | Favourable Effects   | Favourable Effects                      | Favourable Effects   |
| PFS ITT-WT                            | Progression free survival | mont hs              | 7.0                  | 5.5                  | HR=0.64 (95%CI: 0.54, 0.77; p<0.0001)   |                      |
| OS ITT-WT                             | Overall survival          | mont hs              | 18.6                 | 13.9                 | HR=0.79 (95%CI; 0.64, 0.98) , p = 0.033 |                      |
| Unfavourable Effects                  | Unfavourable Effects      | Unfavourable Effects | Unfavourable Effects | Unfavourable Effects | Unfavourable Effects                    | Unfavourable Effects |
| Grade 3/4 infections and infestations |                           | %                    | 17.5                 | 9.5                  |                                         |                      |
| Grade 3/4 neutropenia                 |                           | %                    | 32.3                 | 28.4                 |                                         |                      |
| AESI                                  |                           | %                    | 45                   | 25.0                 |                                         |                      |
| Grade 3-5 AEs                         |                           | %                    | 80.5                 | 70.7                 |                                         |                      |
| Discontinuation                       |                           | %                    | 26.4                 | 22.0                 |                                         |                      |
| SAE                                   |                           | %                    | 50.7                 | 37.9                 |                                         |                      |

Abbreviations: PFS: progression free survival; OS: overall survival; AESI: adverse events of special interest; AEs: Adverse events;

SAEs: serious adverse events. HR: hazard ratio

## 3.7. Benefit-risk assessment and discussion

## 3.7.1. Importance of favourable and unfavourable effects

In the intended indication, there is a need for further treatment options, especially for patients with PD-L1 negative tumours or with low PD-L1 expression. Study IMpower130 shows clinically meaningful results in both PD-L1 positive and PD-L1 negative patients. In the ITT-WT population the median OS was 18.6 months vs 13.9 months in the atezo+CnP and CnP arms respectively, an improvement of median OS by 4.7 months, which is considered clinically encouraging in this patient population with a dismal prognosis. Updated OS results no longer show a statistically significant result. PFS results in the ITT-WT population, showed a HR of 0.64 (95% CI: 0.54, 0.77; p&lt;0.0001). The median duration of PFS was 7.0 months in the atezo+CnP arm. Overall, study IMpower130 is considered positive, since it met both of its co-primary endpoints in the ITT-WT population at the primary analysis.

There are more AEs, Grade 3/4 AEs, AESI and discontinuation in the atezo+CnP arm, but overall the safety profile of Atezo in combination with CnP is considered acceptable. The majority of AEs are clinically manageable with supportive therapy and/or dose reduction/interruptions.

The addition of atezolizumab to CnP is in the interest of the patient as shown by the difference in OS and PFS compared to the control arm.

<div style=\"page-break-after: always\"></div>

## 3.7.2. Balance of benefits and risks

The B/R balance of Tecentriq in combination with nab paclitaxel and carboplatin, for the first line treatment of adult patients with metastatic non-squamous NSCLC who do not have EGFR mutant or ALK positive NSCLC is positive.

## 3.7.3. Additional considerations on the benefit-risk balance

N/A

## 3.8. Conclusions

The overall B/R of Tecentriq is positive.

## 4. Recommendations

## Outcome

Based on the review of the submitted data, the CHMP considers the following variation acceptable and therefore recommends by consensus the variation to the terms of the Marketing Authorisation, concerning the following change:

| Variation accepted   | Variation accepted                                                                                                             | Type    | Annexes affected   |
|----------------------|--------------------------------------------------------------------------------------------------------------------------------|---------|--------------------|
| C.I.6.a              | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | Type II | I and IIIB         |

Extension of Indication to include Tecentriq, in combination with nab-paclitaxel and carboplatin, indicated for the first-line treatment of adult patients with metastatic non-squamous non-small cell lung cancer (NSCLC) who do not have EGFR mutant or ALK-positive NSCLC; as a consequence, sections 4.1, 4.2, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. RMP version 9.1 has been accepted.

The variation leads to amendments to the Summary of Product Characteristics and Package Leaflet and to the Risk Management Plan (RMP).

## 5. EPAR changes

The EPAR will be updated following Commission Decision for this variation. In particular the EPAR module \" steps after the authorisation \" will be updated as follows:

## Scope

Extension of Indication to include Tecentriq, in combination with nab-paclitaxel and carboplatin, indicated for the first-line treatment of adult patients with metastatic non-squamous non-small cell lung cancer (NSCLC) who do not have EGFR mutant or ALK-positive NSCLC; as a consequence, sections 4.1, 4.2, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. RMP version 9.1 has been accepted.

## Summary

Please refer to the Scientific Discussion Tecentriq-H-C-4143-II-19.